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Assessing interventions applied during clinically-encounterable 
extreme scenarios is vital to enhance the quality of care. However, the 
studies that examine these situations are rare, ethically and clinically 
challenging. Computational modelling offers a reliable, efficient and 
almost ethical-free approach to investigate high-risk scenarios. This 
thesis evaluated interventions applied during (i) prolonged apnoea in 
obesity, (ii) airway obstruction in emergency crises, and (iii) 
hyperbaric oxygen therapy in severe hypoxaemic respiratory failure 
patients through a series of high-fidelity computational modelling 
studies. 
Worldwide, there are more than 650 million obese individuals 
and anticipated to increase. In the context of anaesthesia and critical 
care, obese subjects are at increased risks during general 
anaesthesia, such as airway difficulties and apnoea intolerance (rapid 
occurrence of hypoxaemia). Developing and quantifying methods to 
extend the safe (non-hypoxaemic) apnoea time would increase their 
safety remarkably during this procedure. The thesis showed that the 
use of high-flow nasal oxygen significantly delayed the safe apnoea 
time in a bank of obese virtual subjects. 
Persistent airway obstruction is not common in anaesthesia 
practice, but it could lead to catastrophic outcomes. Complete 
blockage of the upper airway was simulated until life-threatening 
hypoxaemia occurred, followed by relieving the obstruction and 
delivery of multiple patterns of tidal ventilation. Larger tidal volume did 
not achieve faster re-oxygenation compared to lower tidal volume.  
Globally, up to 20 million acute respiratory failure patients 
receive mechanical ventilation annually. The mortality of acute 
respiratory distress syndrome (ARDS) remains considerably high 
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despite the implementation of the lung-protective ventilation strategy. 
A bank of severe ARDS virtual patients was configured and underwent 
maximum lung-protective ventilation strategy at atmospheric pressure 
(with high positive end-expiratory pressure [PEEP]) and hyperbaric 
pressure (with low PEEP). The hyperbaric oxygen significantly 
increased the oxygen delivery to tissues even with a low fraction of 
inspired oxygen.  
The thesis’s original contributions to knowledge are: first, it 
quantified the impact of airway obstruction and patency, high oxygen 
concentration and high-flow nasal oxygen, applied during apnoea, on 
the safe apnoea time in obesity. Second, it demonstrated that larger 
tidal ventilation during airway rescue is not necessary. Finally, it 
highlighted that hyperbaric oxygen therapy could provide adequate 
tissue oxygen delivery and may be considered as a rescue option for 
severe ARDS patients who remain hypoxaemic despite maximum 
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Chapter 1: Overview 
1.1 Thesis outline 
Chapter 1 encompasses the thesis potential beneficiaries and 
stakeholders, the importance of the investigated research area, and 
the original contributions to knowledge. Additionally, it states the 
overall aims of the thesis. Chapter 2 provides an introduction to the 
respiratory gas exchange, respiratory failure, pre-oxygenation, and 
apnoeic oxygenation. Moreover, this chapter briefly covers the ARDS, 
hyperbaric oxygen therapy (HBOT) and extracorporeal membrane 
oxygenation (ECMO). 
Chapter 3 offers a comprehensive literature review of the 
scholarly articles that investigated the pulmonary pathophysiology of 
obesity and ARDS and state of the art underpinning apnoeic 
oxygenation. Further, the chapter highlights gaps in the literature as 
well as limitations to implement apnoeic oxygenation and HBOT in 
clinical practice. Chapter 4 presents the methodology used, i.e. 
computational modelling. It covers its background, common 
terminologies, strengths, and limitations. Additionally, the 
Interdisciplinary Collaboration in Systems Medicine (ICSM) model is 
described, which is used to conduct a series of computational 
modelling studies reported in the thesis. 
Chapter 5 examines gas exchange during apnoea while 
undergoing several scenarios pertaining to the patency of the upper 
airway and various apnoeic oxygenation strategies. Chapter 6 
compares gas exchange during three interventions (i) high-flow nasal 
oxygen (HFNO), (ii) classical (low-flow non-heated) apnoeic 
oxygenation, and (iii) no provision of oxygen during patent-airway 
apnoea. This study was conducted on a bank (n=90) of virtual subjects 
with multiple obesity severity levels. 
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Chapter 7 investigates various patterns of tidal ventilation, 
following the opening of an obstructed airway, on the re-oxygenation 
period to a safe level in obese virtual subjects. Chapter 8 evaluates 
the use of HBOT in virtual patients suffering from severe ARDS who 
remain hypoxaemic despite maximum lung-protective ventilation 
strategy. Chapter 9 summarises (i) the main findings obtained from 
the thesis studies, (ii) the thesis original contributions to the scientific 
and clinical fields, and (iii) the limitations, recommendations and the 
proposed future research.  
1.2 Who might benefit from the thesis? 
Professionals that might be interested in the thesis are 
researchers, healthcare practitioners and medical equipment 
manufacturers who are involved in airway management and ARDS 
treatment. These include anaesthetists, intensivists, respiratory 
therapists, ED physicians, and critical care nurses. Additional 
beneficiaries include hospital quality and safety officers, upper 
management and policymaker personnel. 
1.3 Why is this area of research important? 
It may be helpful to offer a perspective of the scale and the 
sensitivity of the issues involved. First, obesity is common, harmful and 
costly. Universally, according to the world health organization (WHO) 
[1], there are approximately two billions overweight adults and more 
than half a billion obese individuals. Moreover, the prevalence of 
obesity has almost tripled since 1975 [1]. In the UK, about a third of 
the adult population is obese [2] and, by 2030, an additional 11 million 
subjects are projected to become obese, which is estimated to add 




Therefore, obesity is expected to be managed more frequently 
in settings where anaesthesia is administered. In 2011, it was 
estimated that approximately three million patients undergo general 
anaesthesia annually in the UK [4], and hypoxia has been identified as 
the mechanism responsible for the leading cause of anaesthesia-
related mortality [4]. 
Secondly, obesity increases two serious risks during 
anaesthesia. Firstly, anaesthetised obese subjects are at an increased 
risk for rapid oxygen desaturation. Secondly, obesity is associated 
with increased complexity in airway management that may require a 
longer time to secure an airway. Therefore, developing methods to 
extend the non-hypoxaemic apnoea time in obese patients would be 
very useful to increase their safety. This would positively impact a 
large portion of the community as well as save an excessive amount 
of financial capital. 
Worldwide, it has been estimated that up to 20 million acute 
respiratory failure patients receive mechanical ventilation per year [5]. 
The mortality of ARDS remains considerably high despite the 
implementation of the lung-protective ventilation strategy [6]. It is 
urgently imperative to research how can we improve the survival and 
the quality-of-life of ARDS patients. 
1.4 How does the thesis contribute to the relevant field? 
The first two modelling investigations (Chapter 5 and 6) provided 
quantitative insights into the gas exchange during apnoea. Diverse 
scenarios (e.g. airway obstruction) and treatments (e.g. HFNO) in a 
spectrum of obesity severity levels were simulated. The findings 
revealed informative data such as the safe apnoea time and the 
hypoxaemia progression rate until life-threatening degrees in a bank 
of obese virtual subjects. The implication of the knowledge generated 
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by these studies underlines the efficacity of multiple apnoeic 
oxygenation strategies and recommend HFNO to airway managers, 
as it showed to provide longer safe apnoea time in obesity, respect to 
classical apnoeic oxygenation. 
The third investigation (Chapter 7) provided evidence that 
during the rescue of airway obstruction, the delivery of larger tidal 
volume does not lead to a faster re-oxygenation rate compared to 
smaller tidal volume. The implication of this finding could inform 
clinicians that massive tidal ventilation in this scenario is not necessary 
and might risk patients for undesirable complications; instead, the 
emphasis on delivering a high concentration of oxygen is much more 
crucial. 
The last study (Chapter 8) answered a question that was 
previously unknown that pertains to the capability of the hyperbaric 
oxygen therapy to rescue severely hypoxaemic respiratory failure 
patients who failed maximum lung-protective mechanical ventilation. 
The implication of this finding may encourage researchers to consider 
HBOT in ARDS future trials. 
1.5 Aims of the thesis 
The overall aims of the thesis are to develop new rescue 
strategies in order to evaluate and quantify oxygenation and 
ventilation in banks of in-silico (virtual) patients suffering from obesity 
and critical respiratory illness. 
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Chapter 2: Introduction 
2.1 Gas exchange 
The primary function of the respiratory system is gas exchange, 
i.e. oxygen (O2) and carbon dioxide (CO2). Alveoli are the terminal 
functional units that are responsible for this process. They unload 
oxygen to the pulmonary capillaries as well as load CO2 from the 
pulmonary capillaries by diffusion. Then, oxygen-rich blood is 
eventually circulated to the tissues and CO2, on the other hand, is 
expelled outside the body [7]. 
2.1.1 Oxygenation 
Oxygen is a vital requirement for the 37.2 trillion cells in a human 
body [8]. The precise structure of the pulmonary system was designed 
to not only fulfil but exceed the oxygen demand of these many cells. 
There are about 500 million alveoli surrounded by 620 miles length of 
pulmonary capillaries resulting in a large surface area available for gas 
exchange of about 75 m2 [9]. The lungs supply one litre of oxygen 
every minute while the total O2 demand is only a quarter of it (i.e. 0.25 
L·min-1) in healthy adults during rest. 
Tissue oxygen delivery (DO2) is the cardiac output (CO) 
multiplied by the arterial oxygen content (CaO2). The three most 
influential factors that affect tissue oxygenation at atmospheric 
pressure are cardiac output, haemoglobin concentration, and oxygen 
saturation in arterial haemoglobin.  
2.1.2 Respiratory failure 
Respiratory failure refers to the inability to maintain either 
adequate tissue oxygenation (hypoxaemic respiratory failure) or 
carbon dioxide elimination (hypercapnic respiratory failure) [10]. It is 
diagnosed via the arterial blood gas (i.e. PaO2 and PaCO2). Campbell 
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[11] has established the values associated with each failure type. 
Respiratory failure could present as acutely or chronically. 
2.1.2.1 Hypoxaemic respiratory failure 
Hypoxaemia refers to the low oxygen content in the arterial 
blood below normal values. Hypoxaemic failure is defined as PaO2 of 
less than 8 kPa while breathing room air at atmospheric pressure. 
Hypoxaemia is the most commonly encountered complication during 
endotracheal intubation [12-15]. It is considered the highest risk factor 
for cardiac arrest and death during emergency intubation [16]. 
Scenarios that can cause hypoxaemia are (i) upper airway obstruction 
leading to delayed/failed intubation, (ii) oesophageal intubation, and 
(iii) aspiration. 
During anaesthesia and apnoea (cessation of breathing), 
maintaining an adequate level of oxygen is crucial and is, unarguably, 
among the top priorities (if not the top priority) of the airway manager. 
Emergency airway management that takes place outside the 
operating theatre has been identified to be associated with a higher 
rate of airway complications, including hypoxia, failed intubation, 
oesophageal intubation and cricothyroidotomy, than elective 
intubation [4]. Moreover, it was reported that hypoxia was not only 
common, but it also led to significant untoward outcomes, i.e. brain 
damage and death (61% in ICU and 33% in emergency departments) 
[4]. This may be due to the deranged physiology of this population as 
well as the unavailability of trained staff and appropriate equipment. 
More than 50% of claims in anaesthesia-related deaths were 
found to be related to hypoxia [17]. There are four physiological 
derangements that can cause hypoxaemia: (i) ventilation/perfusion 




 Ventilation to perfusion mismatch 
The normal ventilation to perfusion (V/Q) ratio is 0.8, which is the 
alveolar minute ventilation of 4 L·min-1, divided by the cardiac output 
of 5 L·min-1 [7]. V/Q inequality has been identified as the most common 
cause of hypoxaemia [19]. The V/Q mismatch lays between two 
extreme physiological abnormalities, dead space (ventilation with no 
perfusion) and shunt (perfusion with no ventilation), as depicted in 
Figure 2.1. 
 
Figure 2.1. Illustration of the shunt-dead space continuum. Redrawn from [7]. 
 Shunt 
The shunt of the blood can be classified as anatomical shunt and 
pathophysiological shunt. Anatomical shunted blood accounts for 
about 2-3% of the cardiac output and is resulted from the shunted 
blood through the bronchial and thebesian veins that supply the lungs 
and heart [20]. Pathophysiological shunt presents either as an intra-
cardiac or intra-pulmonary shunt that could be caused by pulmonary 
oedema, atelectasis and alveolar consolidation [18]. An absolute intra-
pulmonary shunt is called an alveolar shunt. The merge of anatomical 
and alveolar shunted blood, with the oxygenated blood, on the left side 
of the heart is called venous admixture [20]. The total amount of intra-
pulmonary shunted blood is called physiological shunt [20]. The 
anatomical shunt is responsible for the three-fourths of the difference 
between alveolar oxygen pressure and arterial oxygen pressure, that 
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is present in healthy young subjects, while the remaining difference is 
due to normal V/Q inequality [20]. 
2.1.2.2 Hypercapnic respiratory failure 
Hypercapnic failure is defined as a PaCO2 of more than 6.6 kPa 
[20]. Some conditions that could cause this failure include inadequate 
ventilation manifested by abnormal neural drive or muscular strength 
and abnormal pulmonary or thoracic mechanics [11]. 
2.2 Pre-oxygenation  
2.2.1 Definition & purpose 
Pre-oxygenation refers to the brief administration of a high 
concentration of oxygen before anaesthesia induction. The purpose 
of pre-oxygenation is to maximise the time of non-hypoxaemic apnoea 
to enable successful placement of invasive artificial airway. Difficult 
Airway Society has recommended pre-oxygenation not only before 
the induction of anaesthesia but also before endotracheal extubation 
[21, 22]. 
2.2.2 Physiological background 
Oxygen can be stored in several places in the human body, such 
as blood, tissues, and lungs. Nitrogen occupies about 79% of the 
lungs' volume. Table 2.1 demonstrates the powerful impact of pre-
oxygenation with 100% oxygen. The oxygen depletion time would be 
increased significantly, from 1.3 to 9.0 min, when 100% O2 is breathed 
compared to room air. 
A healthy subject breathing 100% O2 would have a non-
hypoxaemic apnoea time (i.e. SpO2 = 90%) of about 6.9 min as 
compared with 5.1 min when breathing 80% O2, 3.6 min when 
breathing 60% O2 and less than 1 min when breathing room air [23]. 
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Morbidly obese patients were found to have a non-hypoxaemic 
apnoea time of only 2.7 minutes despite receiving appropriate pre-
oxygenation [24, 25]. The absence of pre-oxygenation is the main 
predictor of intubation-related cardiac arrest [26]. 
Table 2.1. A comparison of oxygen content in FRC in a healthy adult male, 
when breathing room air (21%) and 100% oxygen, using the alveolar gas 
equation. 
 




 breathing 21 % O2 breathing 100 % O2 




PAO2 = 13.3 kPa 




PAO2 = 88.5 kPa 
O2 in FRC 
(%) 
13.3 / 101.3 
0.13 
88.5 / 101.3 
0.87 
O2 in FRC 
(ml) 
0.13 * 2,400 
312 




312 / 230 
1.3 
2,088 / 230 
9.0 
PAO2: the alveolar partial pressure of oxygen, FiO2: the fraction of inspired oxygen, PATM: the 
atmospheric pressure at the sea level, PH2O: the water vapour pressure when relative humidity 
is 100% at normal body temperature, PaCO2: the arterial partial pressure of carbon dioxide, 
RER: the respiratory exchange ratio, 230 ml oxygen consumption [27]; 2,400 ml FRC[28]. 
2.2.3 Pre-oxygenation optimisation 
The efficacy of the pre-oxygenation (i.e. denitrogenation) is 
assessed by the concentration of the expired O2 (FETO2 > 90%), 
nitrogen (FETN2 < 5%)  [25], where SaO2 during apnoea reflect the pre-
oxygenation efficiency [27]. The SpO2 is not an appropriate measure 
to evaluate the pre-oxygenation efficacy. For instance, Rudlof and 
Hohenhorst [29] reported a COPD case with diffusion limitation. 
Although the patient had a SpO2 of only 94% after proper 
denitrogenation, but tolerated 45 minutes of non-hypoxaemic apnoea 
(with 0.5 L·min-1 of O2 insufflation at the carina), indicating an effective 
pre-oxygenation despite the initial low SpO2. Increasing the FRC and 
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filling it with high O2 concentration via a leak-free interface are 
essential factors for optimal pre-oxygenation [30]. 
2.2.3.1 The role of body position in pre-oxygenation 
When lying flat, FRC is decreased by 20-25% (about 0.8 L) [31]. 
The highest and lowest FRC values were observed during sitting and 
supine position, respectively [32]. Moreover, Lane and co-workers 
[33] found a safe apnoea time of about 100 seconds longer in the 
head-up elevation than the supine position. Two other studies [34, 35] 
were in agreement with this finding. 
Despite proper positioning and O2 supplementation, some 
critically ill patients may remain hypoxaemic during the pre-
oxygenation phase. This may be due to the pulmonary shunt 
physiology, which could be improved by augmenting the mean airway 
pressure [36]. 
2.2.3.2 The role of positive airway pressure in pre-oxygenation 
Positive airway pressure (PAP), e.g. continuous positive airway 
pressure (CPAP), bilevel positive airway pressure (BPAP), and 
positive end-expiratory pressure (PEEP), have been shown to improve 
the efficacy of pre-oxygenation. BPAP demonstrated to increase FRC 
in morbid obesity [37]. BPAP was associated with higher SpO2 and a 
lower incidence of critical hypoxaemia than bag valve mask (BVM) in 
hypoxaemic respiratory failure patients [38]. CPAP of 7.5 cm H2O was 
linked with a longer safe apnoea time by approximately 35 seconds in 
20 morbidly obese women [39]. A substantially (3.7 minutes) longer 
safe apnoea time was observed in non-obesity while receiving CPAP 
of 5 cm H2O [40]. 
Appropriate pre-oxygenation has been described as the main 
method to extend the safe apnoea time [27]. However, another 
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technique could significantly prolong the safe apnoea time, which is 
called apnoeic oxygenation. 
2.3 Apnoeic oxygenation 
2.3.1 History and definition 
Apnoeic oxygenation is an interesting phenomenon that was first 
observed by Hook in 1666 [41] when he blew air into an apnoeic dog's 
airway. The dog remained alive for over an hour, and as soon as the 
air ceases, the dog fell in convulsive fits. Two and a half centuries later, 
Volhard [42] provided a mechanistic explanation of apnoeic 
oxygenation. In curarized dogs and rabbits with patent airway, he 
noticed a significate sub-atmospheric intrapulmonary pressure (-20 
cm H2O) [43]. The early experiments of apnoeic oxygenation were 
conducted by Hirsch in 1905 [44] and by Volhard in 1908 [42]. On 
rabbits, the authors observed a continued O2 saturation during 1 to 2 
hours of apnoea. The rabbits received atmospheric 100% O2 via a 
tracheal catheter, and when the supplemental O2 was replaced by air, 
rabbits died rapidly within a few minutes. 
Many other researchers, since the early 20th century, have 
investigated this occurrence [45, 46]. It was termed differently over 
time, "diffusion respiration" [47], "apnoeic diffusion oxygenation" [48], 
"aventilatory mass flow" [43] and finally "apnoeic oxygenation" [46]. 
Apnoeic oxygenation is the mass inflow of O2 that occurs during 
apnoea if there are an open airway and a continuous O2 supply [49]. 
Apnoeic oxygenation is performed after the induction of anaesthetic 
and paralytic agents that cause hypoventilation and/or apnoea in 
patients undergoing invasive interventions such as endotracheal 
intubation, endoscopy, or laryngeal surgeries [29, 50, 51]. 
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2.3.2 Physiological mechanism and application 
Oxygen moves from alveoli to blood capillaries by passive 
diffusion, which is driven by the pressure gradient of the O2 available 
between the alveoli and the pulmonary capillaries. In order to achieve 
and maintain apnoeic oxygenation, three conditions are required: (i) 
airway patency, (ii) alveolar PO2 that is higher than pulmonary 
capillaries PO2, which can be achieved by the continuous provision of 
oxygen-rich gas, and (iii) the presence of the negative alveolar 
pressure that drives the airflow 'en masse' from the upper airway to 
the alveoli [48]. 
The transairway pressure (PTA) is the pressure gradient between 
the airway opening and the alveoli that drives the air in and out of the 
respiratory system. PTA determines the direction and intensity of the 
gas flow. If PTA is positive, the gas will flow from the upper to the lower 
airways and vice versa. The higher the PTA value, the higher the flow 
rate enter or exit the respiratory system [20]. 
Figure 2.2 illustrates some of the differences in pulmonary 
mechanics and gas exchange during spontaneous breathing and 
apnoea. The pressure at the airway opening (e.g. mouth) is relatively 
constant at atmospheric pressure, while the alveolar pressure value 
varies during inspiration and expiration. In a healthy individual, the 
active contraction of the diaphragm during inspiration generates an 
alveolar pressure of about 1 cm H2O below the atmospheric pressure 
[52]. However, during apnoea, the loss of the pressure gradient 
between alveolar and pulmonary capillary PCO2 causes an extreme 
limitation for CO2 to diffuse to the alveoli. The amount of CO2 diffused 
to the alveoli become only 4% or 8 ml·min-1 of its normal amount of 
200 ml·min-1, while the majority of the produced CO2 (i.e. 96%) 
dissolves in tissue water that can contain 20 times more CO2 as the 
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FRC can hold [53]. As a result of this dramatic gaseous net imbalance, 
alveolar pressure may reach up to 20 cm H2O below the atmospheric 
pressure (i.e. 20 times more negative than normal inspiration), which 
plays the paramount role in establishing the underlining force that 
drives the gas (e.g. O2) inflow downwards that maintains oxygenation 
during apnoea [42]. 
During apnoea, O2 uptake continues to diffuse approximately at 
a rate of 228 ml·min-1 [53], which is derived as the following (i) the 
gas inflow equals the O2 uptake minus the CO2 excretion, so if O2 
uptake is assumed to be 250 ml·min-1 and CO2 excretion 8 ml·min-1, 
then the net difference is 242 ml·min-1. Then if 100% O2 is delivered 
and water vapour is considered, O2 uptake equals gas inflow minus 
water vapour (approximately 6% of the inhaled gas pressure, 14 ml). 
So, 242 ml·min-1 minus 14 ml gives an O2 uptake of 228 ml·min-1.  
If we assume that an individual consumes a total of 250 ml·min-1 
of O2, then the amount of the O2 uptake during apnoea would fulfil 
about 91% of the total O2 demand, which will delay hypoxaemia, 
especially if the subject has been appropriately pre-oxygenated. 
  
Figure 2.2. Schematic illustration of the gas exchange during spontaneous breathing 
and apnoea. 
Accumulation of gases other than O2 (e.g. CO2 or N2) in the 
alveoli decreases the space for O2 to occupy, hence limit the 
continuous O2 uptake, which eventually diminishes the negative 
alveolar pressure that drives the apnoeic oxygenation inflow [54]. 
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Ultimately CO2 will build up in the alveoli, which will cause the PAO2 
to be less than the O2 tension in the pulmonary capillaries, which will 
prevent O2 diffusion to the blood, resulting in hypoxaemia. 
2.4 Acute Respiratory Distress Syndrome  
2.4.1 Definition, history, and epidemiology 
According to the Berlin definition [55], Acute Respiratory 
Distress Syndrome (ARDS) is defined as (i) an acute insult, (ii) bilateral 
pulmonary opacities that are caused by neither cardiac failure nor 
fluid overload, and (iii) significant arterial hypoxaemia. The ARDS 
severity has been classified as mild, moderate and severe, based on 
the magnitude of hypoxaemia in relation to the O2 requirement, which 
is objectively represented as the ratio of the partial pressure of O2 in 
arterial blood to the fraction of inspired O2 (PaO2/FiO2, or PF ratio) 
measured while a minimum of 5 cm H2O of positive airway pressure 
is being applied. The PF ratios for mild, moderate and severe ARDS 
are listed in Table 2.2. The ARDS was first described by Ashbaugh 
and colleagues in 1967 [56]. 
Table 2.2. The classification of the Acute Respiratory Distress 
Syndrome severity according to the Berlin definition [55]. 
Mild 26.6 kPa < PaO2/FiO2 ≤ 39.9 kPa 
Moderate 13.3 kPa < PaO2/FiO2 ≤ 26.6 kPa 
Severe 13.3 kPa ≥ PaO2/FiO2  
PaO2, the partial pressure of oxygen in arterial blood; FiO2, the fraction of inspired oxygen 
Note: all PF values must be obtained while receiving a minimum of 5 cm H2O of positive 
airway pressure. 
A large observational study that collected data from 50 countries 
has shown that the prevalence of ARDS accounts for 10% of all ICU 
admission and 23% of those receiving mechanical ventilation. Hospital 
mortalities were 35%, 40% and 46%, in mild, moderate and severe 
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ARDS patients, respectively [57].  Factors that are likely to affect 
survival from ARDS include age, the severity of lung injury, intensity 
of inflammatory response, degree of vital organs' dysfunction, 
comorbidity, and the quality of supportive care [58-60]. 
2.4.2 Aetiology and pathophysiology 
ARDS is a syndrome rather than a disease entity. It can originate 
from either a pulmonary or non-pulmonary insult. Pulmonary insults 
include pneumonia, aspiration of gastric content, pulmonary 
contusion, toxic and smoke inhalation, and near-drowning. Non-
pulmonary insults include sepsis, major trauma, massive blood 
transfusion, and acute pancreatitis [7].  
The current understanding suggests that the main 
pathophysiological manifestation in ARDS is the increased 
permeability of the pulmonary capillaries. A subsequent leakage of 
protein-rich fluid (e.g. oedema) enters the pulmonary interstitium then 
the alveoli. This often initiates a release of inflammatory mediators' 
cascade (e.g. prostaglandins, endotoxins, and cytokines) that activate 
neutrophils and attract them in. Neutrophils release toxic substances 
that further increase the permeability of the capillaries as well as 
destroy tissues [7]. The flooding in the airspaces results in (i) 
deactivation of the surfactant (that plays a crucial role in preventing 
lung collapse during expiration), (ii) disruption of the ventilation to 
perfusion matching (low V/Q ratio), causing a shunt-like effect in lung 
areas that are under-aerated, but not collapsed, (iii) hyperinflation of 
the healthy regions of the lung leading to excessive ventilation relative 
to perfusion (high V/Q ratio), causing an increase in alveolar 
deadspace.  
The intrapulmonary shunt is the result of the alveolar filling and 
the considerable atelectasis that causes a reduction in the lung 
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compliance (thus require higher work of breathing), refractory 
hypoxaemia, while the increased alveolar deadspace may induce 
hypercapnia if alveolar minute ventilation is not increased for 
compensation [61]. The magnitude of pulmonary shunting (i.e. 
hypoxaemia) is further worsened by the diminished hypoxic 
pulmonary vasoconstriction (HPV) that is likely present in ARDS [62]. 
HPV is an astonishing physiological mechanism of the pulmonary 
capillaries that decreases the blood flow to the poorly aerated regions 
of the lungs. HPV is activated when the alveolar PO2 is less than 9.3 
kPa [7]. Moreover, acidemia is an independent factor to increase 
pulmonary vascular resistance (even at normal PAO2) irrespective of 
PAO2 value [63]. A shunt fraction of more than 30% is considered life-
threatening and require immediate mechanical ventilatory support [7]. 
2.5 Hyperbaric oxygen therapy 
2.5.1 Definition and history 
The Undersea and Hyperbaric Medical Society (UHMS) defines 
hyperbaric oxygen as "an intervention in which an individual breathes 
near 100% O2 intermittently while inside a hyperbaric chamber that is 
pressurized to greater than sea level pressure (1 atmosphere 
absolute, or ATA)". According to the UHMS, the therapeutic pressure 
level must be at least 1.4 ATA while breathing near 100% O2. The 
British Hyperbaric Association categories hyperbaric chambers into 
four classes. Class I is defined as a hyperbaric facility capable of 
supporting ICU patients and offers Advanced Life Support in or out of 
the chamber (if needed). 
Paul Bert thoroughly described the physiological changes 
caused by the elevation and reduction of ambient pressure [64]. The 
cardiac surgeon Boerema and co-workers [65] demonstrated that 
dogs tolerated longer durations of cardiac arrest when they were 
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cooled and exposed to 3 ATA O2. In 1959, Boerema and co-workers 
[66] performed cardiac surgeries using a hyperbaric operating theatre 
with an ischemic clamp time of 14 minutes was successfully achieved 
on humans. Many similar operating chambers were soon built across 
the world. Gradually, these hyperbaric operating theatres became 
obsolete due to the development of extracorporeal cardiovascular 
circulation machines. 
2.5.2 Mechanism and relevant physical laws  
There are several consequences of increasing the ambient 
pressure governed by physical laws. For instance, Boyle's law 
describes that, at a constant temperature, the volume is inversely 
related to pressure. Increasing ambient pressure reduces the cavities 
that are filled with air like the lungs, middle ear, and sinuses. 
Additionally, hyperbaric pressure compresses the particles, thus 
decreasing their diameters, which is the reason HBOT is 
recommended in treating conditions like decompression sickness and 
gas embolism. Henry's law explains that the amount of dissolved gas 
in a defined volume is proportional to the gas partial pressure. As 
ambient pressure increases, the partial pressure of the inhaled gases 
(e.g. O2) increase as well, which increases the pressure gradient 
across the alveolar-capillary membrane, thus enables higher diffusion 
rates. 
Normally, the overwhelming majority of O2 is transported via 
bonding to haemoglobin, and a negligible amount of O2 is transported 
by dissolving in plasma. Once haemoglobin is fully saturated with O2, 
it cannot carry any further O2 molecules despite increasing PO2 in 
alveoli. Nevertheless, PO2 will continue to diffuse into the plasma as 
long as the PO2 gradient between alveoli and plasma is positive.  
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Table 2.3 illustrates the influence of increased barometric 
pressure and FiO2 on the amount of O2 dissolved in the plasma in a 
healthy subject and a subject with diseased lungs. If we assume that 
a healthy subject is exposed to a 3 ATA of hyperbaric O2 and has a 
cardiac output of 5 L·min-1, then the amount of the O2 dissolved in the 
plasma (excluding those bond with haemoglobin) would fulfil and 
exceed the average resting O2 demand. This has been confirmed by 
animal model experiments [67]. 
Table 2.3. The estimated impact of the ambient pressure and 
inspired oxygen concentration on the amount of dissolved oxygen 
in plasma in a healthy subject and a subject with diseased lungs.  
 
PB FiO2 PAO2 PaO2 
O2 in 
plasma* 
 (ATA)  (kPa) (kPa) (mL·L-1) 
Healthy 
1 0.21 14 12 2.8 
1 1.0 90 82 18.9 
2 1.0 185 177 40.8 





1 1.0 90 45 10.1 
2 1.0 185 92 21.2 
3 1.0 280 140 32.2 
PB, barometric pressure; FiO2, the fraction of inspired oxygen; PAO2, the alveolar partial 
pressure of oxygen; PaO2, the arterial partial pressure of oxygen; QS/QT, shunt fraction. 
* The solubility coefficient used to determine the amount of oxygen in plasma is 0.023 
(mL·dL-1·kPa-1) [68]. 
2.5.3 Potential benefits and risks of HBOT 
When hyperbaric oxygen therapy is conducted correctly, the 
severe untoward effects are rare [69], and if they occur, they are 
almost always reversible [70]. There is no doubt that HBOT could 
cause hyperoxia, and hyperoxia is thought to cause benefits and carry 
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some risks. Some advantages of hyperoxia include (i) enhanced 
wound healing induced by the high amount of O2 at the tissue level as 
well as angiogenesis (i.e. forming new blood vessels), (ii) reduces 
tissue inflammation [71], and (iii) kills and/or inhibits the growth of 
some anaerobic bacteria [72] and suppresses the release of their 
toxins [73]. 
On the other hand, risks of hyperoxia include (i) O2 toxicity 
affecting several organ systems like the central nervous and the 
pulmonary systems, (ii) barotrauma of the middle ear, sinus, teeth, or 
lungs, and (iii) myopia (i.e. short-sightedness). An additional extremely 
important hazard of HBOT is the high potential of fire, which many 
individuals have sadly lost their lives in terrifying catastrophic 
incidences around the world [74]. Moreover, in the event of an 
emergency, it is likely that rapid decompression will be needed, 
risking decompression sickness, which would be extremely risky in 
critically ill, severely hypoxaemic patients considering their poor 
oxygenation reservoir. However, the use of mechanical ventilation per 
se has been deemed safe in hyperbaric chambers [75]. 
2.5.3.1 Oxygen toxicity 
Two factors determine the likelihood of developing O2 toxicity, 
(i) the partial pressure of O2 in the inhaled gas, which is determined 
by (and proportional to), the ambient pressure as well as the FiO2, and 
(ii) the duration of exposure. The higher the values of these two 
factors, the more likely O2 toxicity will occur. However, the exact upper 
threshold could not be precisely defined due to the high degree of 
variability of O2 tolerance not only among different subjects but also 
within the same subject at different times [76]. Nonetheless, in order 




The most common manifestation of CNS O2 toxicity (i.e. the Bert 
effect) is nausea followed by seizures [77]. Sometimes, seizures that 
occur during an HBOT session are caused by HBOT-induced 
hypoglycaemia rather than O2 toxicity. Therefore, to minimise CNS O2 
toxicity, one should consider thorough patient assessment pre and 
post-treatment, close monitoring during treatment, vitamin E, air 
breaks, and appropriate selection of PO2 and exposure time. 
Hypercapnia has been reported to accelerate the occurrence of 
CNS O2 toxicity [78]. A proposed mechanism responsible was the 
hypercapnia-induced cerebral vasodilation which enabled higher O2 
tension delivery to the brain [79]. Additional factors that foster O2 
toxicity include premature birth, viral pneumonia, humidity, fever, and 
vitamin E deficiency. On the other hand, some factors that protect 
against O2 toxicity include lower FiO2 or intermittent 100% O2, chronic 
hypoxia, young age, surfactant and nitric oxide [64]. 
Pulmonary O2 toxicity has been first described by James Lorrain 
Smith in 1899 when he exposed mice to FiO2 of 0.4 at an ambient 
pressure of 4.5 atmospheres. He notices lung inflammation and 
massive lung congestion at the postmortem examination [80]. 
Subsequently, other studies on humans revealed that prolonged 
exposure to O2 caused tracheobronchitis, nausea, and alteration in 
pulmonary parameters such as a reduction in vital capacity and in the 
diffusing capacity of the lungs for carbon monoxide (DlCO) [80].  
Oxygen is quite reactive, and it is most stable when it is bond 
with hydrogen to produce water. In this cellular respiration chemical 
process, reactive (or sometimes referred to as radical) oxygen 
species (ROS), i.e. superoxide (O2−), hydrogen peroxide (H2O2), and 
hydroxyl radical (OH−), are produced. During normoxia, the cells are 
capable of neutralizing ROS, while in hyperoxic states, ROS 
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overwhelm the antioxidant defence. ROS targets and damage various 
biological sites such as cell membranes, proteins, nucleic acid, and 
enzymes [81]. A natural protective mechanism is that the lungs are 
equipped with an increased concentration of antioxidants to endure a 
higher concentration of O2 [82]. 
Lambertsen and colleagues [83] developed a means to quantify 
the O2 toxicity, which is called the Unit Pulmonary Toxic Dose (UPTD). 
Basically, one UPTD is equal to breathing 100% O2 at 1 ATA for 1 
minute. An upper cut-off of the UPTD has been determined based on 
the reversible 10% reduction of vital capacity that occurs when 
receiving 1440 UPTD, which equals breathing pure O2 for 24 hours at 
sea level. To minimise the occurrence of the CNS O2 toxicity, 
international organisations recommend that the PO2 level does not 
exceed 2.8 bar absolute. 
2.6 Extracorporeal membrane oxygenation  
Extracorporeal membrane oxygenation (ECMO) became 
available in 1972 to support patients suffering from severe acute 
hypoxemic respiratory failure. ECMO can be set up to support either 
haemodynamic and gas exchange (veno-arterial abbreviated as VA 
ECMO) or only gas exchange (veno-venous abbreviated as VV 
ECMO) [20]. ECMO requires invasive vascular cannulation as well as 
administration of systematic anticoagulation, and bleeding is 
considered the predominant complication of ECMO with an incidence 
rate of 4-8%, 13%, and 17%, intracranial haemorrhage, surgical site 
bleeding, and cannulation site bleeding, respectively [84]. Other 
complications include clotting disorders like platelet dysfunction [85] 
and others. 
On the other hand, some features of ECMO are being portable, 
no risk or discomfort for staff, and predisposes lower risk for O2 
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toxicity as well as lung injury as the intensity of the ventilator support 
will be decreased, allowing the lungs to rest. 
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Chapter 3: Literature review 
3.1 Aims of the literature review 
The literature review chapter is intended to enhance my 
understanding of the physiological processes underpinning apnoeic 
oxygenation, pulmonary alterations in obesity, and the use of HBOT in 
ARDS. Additionally, identify what is not yet known and recognise what 
is urgent to be investigated. 
3.2 Literature search technique 
I conducted a thorough, non-systematic, electronic review of 
scholarly journal articles on search databases including, but not 
limited to, EMBASE, MEDLINE, Web of Science and Ovid Journals. 
Examples of search keywords were apnoeic oxygenation, pre-
oxygenation, obesity, ARDS, airway management, intubation, safe 
apnoea time, HFNO, THRIVE, and HBOT. The search was limited to 
neither a particular time nor a language. The literature review aimed 
to cover the very first experiments in humans and animals up to the 
era of modern and sophisticated methods of apnoeic oxygenation. 
3.3 Respiratory alterations in obesity 
Obesity is a condition characterised by an excessive amount of 
total body fat [86]. Obesity severity is commonly classified via the 
Body Mass Index (BMI). A BMI is calculated as the weight in kg divided 
by the height in meter2. A BMI of ≥ 30, ≥ 35, and ≥ 40 kg∙m-2 are 
classified as obese class I, class II, and class III, respectively [87].  
The effects of obesity on the respiratory functions seem to be 
heterogeneous and incompletely explained, but the most consistent 
alterations appear to be a reduction in the total respiratory system 
compliance [18, 88-90] and the functional residual capacity (FRC), 
which is prominently due to a decrease in the expiratory reserve 
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volume (ERV) [90-93]. The severity of the respiratory abnormalities 
caused by obesity tend to be associated with the excessiveness of 
tissue adiposity, its distribution in the body and obesity-
hypoventilation syndrome (OHS) [18, 94].  
3.3.1 Lung volumes 
The lungs consist of several volumes and capacities. Capacity is 
defined as a sum of two lung volumes or more. A schematic illustration 
of the lung volumes and capacities for a normal subject is presented 
in Figure 3.1. 
 
Figure 3.1. Lung volumes and capacities: TLC, total lung capacity; VC, vital capacity; RV, 
residual volume; FRC, functional residual capacity; IC, inspiratory capacity; VT tidal 
volume; IRV, inspiratory reserve volume; ERV, expiratory reserve volume. 
There is sufficient evidence indicating that as obesity increases, 
expiratory reserve volume (ERV) and functional residual capacity 
(FRC) continue to decrease [90-93]. Jones and Nzekwu [91] evaluated 
pulmonary function tests (PFT) of various awake obese subjects using 
BMI. They found a negative exponential relationship between BMI and 
FRC and ERV. The ERV values (% of predicted) for BMI 20-25, 25-30, 
30-35, 35-40 and >40 kg·m-2 were 95.6%, 72.3%, 42.4%, 29.3% and 
24.6%, respectively. Furthermore, another study by Biring and co-
workers [92] supported the previous study's finding by showing that 
patients with BMI ≥ 62 kg·m-2 had an ERV of only 17.8 - 22 % of 
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predicted. Three factors independently contribute to the reduction of 
FRC, obesity, general anaesthesia, and supine position. 
3.3.2 Closing capacity 
Figure 3.2 illustrates the closing capacity (CC) with the FRC in 
non-obese, obese subjects and during anaesthesia. The CC is the 
sum of closing volume (CV) and RV, where CV is the amount of vital 
capacity (VC) that can be exhaled after airway closure begins. 
When FRC drops below the CC, patients may develop distal 
absorption atelectasis, thus resulting in ventilation-perfusion 
mismatch and pulmonary shunt, leading to hypoxaemia. In such 
conditions, patients may require PAP to increase the FRC above the 
CC. Factors that increase CV and CC are advanced age, smoking, 
congestive heart failure and obesity [95]. In contrast, factors that 
decrease FRC include anaesthesia, supine position and any restrictive 
pulmonary disease, e.g. obesity, [28, 32, 96]. 
 
Figure 3.2. Illustration of functional residual capacity (FRC) and closing capacity (CC). 
Increasing obesity, supine position and anaesthesia induction are independent factors 
that decrease the FRC. 
3.3.3 Fat distribution 
Central obesity, where fat is stored mainly in the abdominal and 
chest walls, is believed to impact the respiratory mechanics more than 
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peripheral obesity. The excessive adipose tissue stored in the 
abdomen and chest decreases the respiratory compliance and 
increase the intra-abdominal pressure [97]. Canoy and co-workers 
[98] evaluated PFTs of a large UK cohort of more than 21,000 
subjects. They found that abdominal obesity had an inverse relation 
with forced expiratory volume in 1 second (FEV1) and forced vital 
capacity (FVC) across the entire cohort. Similarly, Chen and co-
workers [99] found that waist circumference had a consistent negative 
correlation with FEV1 and FVC. 
3.3.4 Obesity-Hypoventilation Syndrome 
Obesity-hypoventilation syndrome (OHS) is characterised by 
morbid obesity (BMI >40 kg·m-2) and chronic hypercapnia (PaCO2 > 6 
kPa) during wakefulness. The overall effects of obesity on respiratory 
mechanics appear to be worse in OHS than in those with similar 
obesity but without chronic CO2 retention, as reported in Table 3.1. 
Table 3.1. Respiratory Mechanics in Simple Obesity (SO) and 
Obesity Hypoventilation Syndrome (OHS) [18] 
 Non-obese SO OHS 
BMI (kg·m-2) 24 45 46 
TLC (% predicted) 100 95 83 
CRS (L·cm H2O-1) 0.11 0.05 0.06 
RRS (cm H2O·L-1·sec-1) 1.2 4.0 7.8 
Work (J·L-1) 0.43 0.74 1.64 
MVV (L·min-1) 159 129 89 
PImax (cm H2O) 100 95 60 
CRS = compliance of the respiratory system; RRS = respiratory system resistance; PImax 
= maximal inspiratory pressure; MVV = maximum voluntary ventilation. 
3.3.5 Respiratory mechanics 
It is well known that obesity decreases total respiratory system 
compliance (CRS) [18, 88-90]. Naimark and Cherniack [100] found 
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that the CRS of obese subjects was almost entirely due to a reduction 
in chest wall compliance and was further decreased in the supine 
position. On the other hand, Sharp and co-workers [89] found, in SO 
subjects, that lung compliance (0.16 L·cm H2O-1) is more 
pronouncedly reduced as compared to thoracic compliance (0.20 
L·cm H2O-1), wheres in OHS patients, thoracic compliance (0.08 L·cm 
H2O-1) was more declined than lung compliance (0.12 L·cm H2O-1). 
3.3.6 Control of breathing 
In eucapnic morbidly obese patients, Burki and Baker [90] found 
a significant increase in minute ventilation at rest due to increased 
inspiratory neuromuscular drive and high respiratory rate without a 
large difference in tidal volume. Also, another study [101] found a 
strong positive relationship between obesity and neuromuscular 
respiratory drive. The hypercapnic ventilatory response was reported 
to be reduced by 40% in SO and by 65% in OHS, while SO could have 
a normal or higher ventilatory response to hypoxaemia than non-
obese subjects [102]. 
3.3.7 Oxygen consumption 
Obese subjects consume approximately 25% higher O2 content 
at rest than non-obese individuals [94]. Compared to non-obese 
subjects, the O2 demand required for the increased work of breathing 
is about 60% higher in SO subjects and up to 250% higher in OHS 
patients. Additionally, the O2 cost of breathing at rest increases to 
approximately five folds in SO and close to 10 folds in OHS [18]. 
Hypoxaemia is a manifestation of OHS patients but is not present in 
SO subjects except in severe SO or during supine position [18].  
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3.3.8 Anaesthesia effects on respiratory function 
The induction of anaesthesia was observed to reduce the FRC 
by approximately 20% in non-obese subjects [103] and 50% in obese 
patients with BMI > 40 kg·m-1 [96]. A possible explanation for the 
anaesthesia-induced FRC reduction is the loss of the tonic activity 
present in the inspiratory muscles, allowing the diaphragm cephalad 
displacement into the thoracic cavity and further restricting the lung 
volume, as illustrated in Figure 3.3. Ketamine was documented to be 
the only anaesthetic that does not affect the muscular tone, thus 
preserve FRC and prevent subsequent atelectasis [103]. 
 
Figure 3.3. Progressive cephalad displacement of the diaphragm; Pab abdominal 
pressure, FRC functional residual capacity. Redrawn from Hagberg and Benumof's 
airway management, Chapter 5, Page 138 
In anaesthetised obese patients, the intra-pulmonary shunt 
found to be 10% - 25%, as compared to 2% - 5% in lean subjects 
[104], which explain why obese patients are at high risk for rapid 




3.3.9 Body position 
Dixon and co-workers [106] found, in severely obese patients, 
that the inclined position had about 50 seconds longer safe apnoea 
time and 11 kPa higher PaO2 than the supine position group. 
Additionally, ramped position significantly improved the 
laryngeal view in morbidly obese patients as compared to the sniffing 
position [107]. Another study [108] showed a more than 50% 
reduction of intubation-related complications in the 30° back-up head-
elevated (BUHE) group than the supine group. Furthermore, Turner 
and co-workers [109] found a 65.8%, 77.9% and 85.6% first intubation 
attempt success in the supine, inclined and upright positions, 
respectively. 
3.3.10 Airway difficulty in obesity  
Face mask and laryngeal mask ventilation, tracheal intubation 
and emergency surgical airway have been identified to be more 
difficult when obesity is accompanied by obstructive sleep apnoea 
(OSA) [4, 110]. Obesity, particularly around the neck, is a significant 
risk factor for OSA and strongly correlates with increasing BMI [111, 
112]. A 10% increase in body weight risks for devolving moderate to 
severe OSA by six-fold [113]. A study found that the prevalence of 
OSA in obese subjects undergoing bariatric surgery is between 73% 
to 83 % [114]. 
Obesity has been identified as an independent risk factor for 
airway complications. The 4th National Audit Project of the Royal 
College of Anaesthetists and the Difficult Airway Society (NAP4) have 
found that approximately 50% of the severe airway complications 
occurred to obese patients [115]. 
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Table 3.2. Summary of the anatomical, cardiopulmonary and 
metabolic alterations imposed by obesity 
Parameter Effect Ref 
CRS decreased [89] 
RS increased [89] 
WOB increased [89] 
P0.1 increased [116] 
PIMAX decreased [116] 
VT decreased [116] 
RR increased [116] 
VE increased [117] 
FRC decreases as BMI increases [91] 
FVC decreases as BMI increases [98] 
FEV1 decreases as BMI increases [98] 
CC increased [95] 
QS/QT increased [104] 
PaO2 decreases as BMI increases [93] 
VO2 increases as BMI increases [118] 
CO increased [119] 
SV increased [119] 
HR normal [119] 
Airway - Difficult FMV and ESA 
- SGA failure 
[120] 
CRS, respiratory system compliance; RS, respiratory resistance;  WOB, work of 
breathing; P0.1 occlusion pressure (represent respiratory drive); PIMAX, maximal inspiratory 
pressure; VT tidal volume; RR, respiratory rate; VE, minute ventilation; FRC, functional 
residual capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; 
CC, closing capacity; QS/QT, shunt fraction; PaO2, partial pressure of oxygen in arterial 
blood; VO2, oxygen consumption; CO, cardiac output; SV, stroke volume; HR, heart rate; 
FMV, face mask ventilation; LMA, laryngeal mask airway; ESA, emergency surgical 




3.4 Apnoeic oxygenation  
3.4.1 Safe apnoea time 
Safe apnoea time refers to the time between the onset of apnoea 
and up until a certain O2 desaturation level is reached, e.g. SpO2 = 90-
92%. 
3.4.1.1 Apnoeic oxygenation during elective procedures 
The first apnoeic oxygenation experiment that was conducted 
on humans was performed by Enghoff and co-workers [121] in 1951. 
The subjects were sedated and paralysed, then a cuffed endotracheal 
tube (ETT) was inserted in the trachea followed by a 10 min of 100% 
O2 inhalation (i.e. denitrogenation) via the anaesthetic machine. Next, 
the ETT was disconnected from the anaesthetic machine and 
connected to a spirometry expiratory hose that provided 100% O2 with 
no artificial respirations nor positive pressure. The subjects tolerated 
a period of 5 to 7 minutes of apnoea with no hypoxaemia.  
Similarly, Frumin and co-workers [46] have investigated apnoeic 
oxygenation, but for extended periods of apnoea, with a mean apnoea 
time of 40 min and a range of 18 to 55 min. First, the eight healthy 
patients received a 100% O2 via facemask for 5 minutes. Next, they 
were sedated and paralysed, and then ETT was inserted. Then, 
manual breathing started, which consisted of airflow ≥ 8 L·min-1 of 
100% O2 for a period of ≥ 30 min. After that, manual compression 
stopped, and apnoea was allowed to persist while the ETT is 
connected to the circular anaesthesia apparatus. The reservoir bag 
was filled with approximately 2-3 litres of O2 every 15 minutes (i.e. 
133-200 ml·min-1). All participants had a non-hypoxaemic apnoea time 
≥ 30 min except for one subject. All subjects had a SaO2 ≥ 98% 
throughout the study. No cardiac arrhythmia was observed except in 
two subjects that had ventricular extrasystole. Moderate to severe 
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hypertension occurred during apnoea and followed by mild 
hypotension after the commencement of artificial respiration. 
Rudlof and Hohenhorst [29] observed a SpO2 of ≥ 98% for up to 
45 minutes of apnoea in 47 subjects who received 0.5 L·min-1 of O2 
via an intra-tracheal catheter. Three subjects had O2 desaturation, 
which was due to obesity, inadequate pre-oxygenation and 
spontaneous breathing. In 12 healthy individuals, Teller and co-
workers [122] examined less invasively apnoeic oxygenation 
delivered via pharyngeal insufflation. They found that all the subjects 
that received 3 L·min-1 of O2  during apnoea had completed the full 
allocated apnoea duration (10 min) with SpO2 ≥ 97%, as compared to 
a mean safe apnoea time of 6.8 min in the control group. Lee [123] 
investigated non-invasive apnoeic oxygenation via nasal prongs. He 
reported that the PaO2 had dropped less sharply in the patients that 
received 5 L·min-1 O2 (from 65±6 kPa at baseline to 46±10 kPa at 3ed 
minute of apnoea) than the control group (from 64±8 kPa at baseline 
to 35±11 kPa at 3rd minute of apnoea). 
Finally, Rajan and co-workers [124] studied the effects of CPAP 
applied during the pre-oxygenation phase and apnoea. The CPAP 
group received 20 cm H2O with O2 supplement during the pre-
oxygenation and the apnoeic periods, while the control group 
received only 6 L·min-1 of 100% O2 during the pre-oxygenation and 
the apnoeic periods. The CPAP group had a significantly longer safe 
apnoea time (SpO2 = 90%) of 816±30 sec as compared to 348±122 
sec in the control group. A summary of the studies that investigated 
apnoeic oxygenation during elective procedures is presented in Table 




 THRIVE during elective procedures 
THRIVE is an acronym for “Transnasal Humidified Rapid-
Insufflation Ventilatory Exchange”, which refers to the use of HFNO 
during apnoea. Gustafsson and co-workers [51] conducted a 
physiological case series of 30 subjects planned for minor surgeries. 
The majority of the subjects were non-obese (i.e. BMI < 25 kg·m-2), 
while several were overweight, and a few were mildly obese. The 
subjects were pre-oxygenated using HFNO 40 L·min-1 of 100% O2 for 
at least 3 minutes. Next, the subjects were sedated and paralysed, 
and the HFNO flow was increased to 70 L·min-1 of 100% O2. The 
apnoea duration ranged from 11 to 33 min, with a mean of 22.5 min. 
All the subjects completed their procedures while maintaining 
adequate oxygenation throughout the apnoeic period except in one 
subject, which was due to hypercapnia. 
Similarly, Lyons and Callaghan [125] performed a case series of 
28 patients undergoing elective laryngeal or tracheal surgeries. All the 
subjects were pre-oxygenated for 3 minutes using 80 L·min-1 via 
HFNO. During apnoea, the same set up remained unchanged. The 
median apnoea time was 19 min, with a range of 9-37 min. All patients 
had a SpO2 of ≥ 92% except for four patients that had mild 
hypoxaemia with the lowest SpO2 of 85%. The subject that had the 
longest apnoea duration (i.e. 37 min) was an overweight subject and 
had a SpO2 of 87%. 
Joseph and co-workers [126] compared the efficiency of CPAP 
and HFNO, delivered during apnoea, in 20 non-obese patients 
undergoing general anaesthesia. The subjects in the CPAP group 
received a CPAP of 15 cm H2O with O2 supplementation, while the 
subjects in the HFNO group received 30 L·min-1 of 100% O2 for 3 min. 
After induction and neuromuscular blockade, the O2 flow rate was 
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increased to 10 L·min-1 with the same CPAP level in the CPAP group, 
while the O2 flow was increased to 60 L·min-1 in the HFNO group. Both 
groups have completed the full allocated apnoea time of 12 min 
without hypoxaemia. However, the CPAP group had a significantly 
higher PaO2 at the end of apnoea, 54 kPa, as compared to 28 kPa in 
the HFNO group. However, it is questionable how these two studies 
[124, 126] found the same PaO2 rate of decrease (i.e. 1.0 kPa·min-1) in 
the CPAP group despite using two different levels of CPAP (i.e. 15 
and 20 cmH2O). A summary of the studies that investigated THRIVE 
during elective procedures is presented in Table 0.2 in the appendix. 
3.4.1.2  Apnoeic oxygenation during emergency intubation 
Dyett and co-workers [15] conducted a prospective 
observational study to evaluate apnoeic oxygenation in 129 critically 
ill patients. Respiratory failure was the most common indication for 
intubation. Strategies of pre-oxygenation and apnoeic oxygenation 
were quite varied. Their findings showed that the hypoxaemia 
incidence in the non-respiratory failure patients who received apnoeic 
oxygenation via NC 15 L·min-1 was 0.0% as compared to 16.7% in 
those who did not receive it. Apnoeic oxygenation did not prevent 
hypoxaemia in respiratory failure patients. There was indeed 
considerable variability in the strategies used in both phases (i.e. pre-
oxygenation and apnoeic oxygenation), so it is difficult to conclude as 
to which device offers a higher efficacy during each phase. However, 
the overall effect of apnoeic oxygenation in the non-respiratory failure 
patients was significantly positive. 
The effectiveness of apnoeic oxygenation is supported by 
Wimalasena and co-workers [127], who evaluated 728 patients in the 
pre-hospital setting, mainly due to trauma. The cohort that received 
apnoeic oxygenation via NC 15 L·min-1 of O2 had a hypoxaemia 
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incidence of 16.5%, while it was 22.6% in the cohort that did not 
receive apnoeic oxygenation.  
Moreover, Sakles and co-workers [128] found that 82.1% of the 
patients that received apnoeic oxygenation had a first-attempt 
intubation success without hypoxaemia, as compared to 69.0% in the 
cohort that did not receive apnoeic oxygenation. In this study, the 
observed benefit is evident even though the patients in the apnoeic 
oxygenation group had more risk factors for hypoxaemia, such as 
respiratory failure (17% vs 12%) and obesity (57% vs 49%). 
Further, Sakles and co-workers [129] showed that the incidence 
of mild (SpO2 < 90%), moderate (SpO2 < 80%) and severe (SpO2 < 
70%) hypoxaemia was remarkably lower in the patients that received 
apnoeic oxygenation, 7% vs 29% in mild, 4% vs 18% in moderate and 
3% vs 9% in the severe hypoxaemia. An essential limitation of this 
study is that the study data were entered by the clinicians and were 
not extracted directly from the monitors, which may have caused 
inaccurate data reporting or recall bias. A summary of the studies that 
investigated apnoeic oxygenation during emergency intubation is 
presented in Table 0.3 in the appendix. 
 THRIVE during emergency procedures 
Miguel-Montanes and co-workers [130] examined two methods 
of apnoeic oxygenation, 60 L·min-1 O2 via HFNO and 6 L·min-1 via a 
nasopharyngeal catheter. The investigators found a median SpO2 of 
100%, while it was 94% in the HFNO and the other group, 
respectively. The incidence of critical hypoxaemia (SpO2 < 80%) was 
2% in the HFNO group and 14% in the other group. The study failed 
to properly examine the efficacy of the two devices used for pre-
oxygenation, as end-tidal O2 concentration was not used. It is worth 
noting that these results may have been affected by the uneven 
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distribution of the patient population, in particular, respiratory failure. 
It is unknown whether the increased SpO2 was related to the pre-
oxygenation or the apnoeic oxygenation techniques since the 
investigators implemented two different pre-oxygenation and apnoeic 
oxygenation strategies. 
Furthermore, Semler and co-workers [131] randomised 150 ICU 
patients, mainly due to respiratory failure, to either receive 15 L·min-1 
of 100% O2 via HFNO or receives nothing during laryngoscopy. They 
found no difference in the median lowest SpO2 between the two 
groups. However, there are a few concerns regarding the study’s 
methods. First, the researchers did not prohibit manual ventilation 
after the onset of apnoea in all patients, which can affect the primary 
outcome (lowest SpO2). Secondly, the prescribed flow rate was not 
high enough. It is well known that many of the physiological benefits 
of using HFNO are originated from its ability to deliver high flow (e.g. 
70 L·min-1). Some benefits are flow-dependent, like the dead space 
flushing and the positive airway pressure, which is proportionally 
correlated with flow rate, reaching up to 16 cm H2O with 100 L·min-1 
[132]. I postulate that the increased positive airway pressure may have 
positively affected this patient population (i.e. respiratory failure) by 
increasing the FRC and improving the V/Q matching hence delay the 
hypoxaemia onset. 
Finally, Jaber and co-workers [133] conducted an interesting 
proof-of-concept RCT in severely hypoxaemic respiratory failure 
patients. The researchers randomised patients to receive either 60 
L·min-1 of 100% O2 via HFNO, combined with PS of 10 cm H2O and 
PEEP of 5 cm H2O and FiO2 1.0 for 4 min, or receive the same NIV 
settings but without HFNO. During apnoea, the NIV mask was 
removed, and HFNO kept in place in the interventional arm, where the 
reference group received no O2 during apnoea. Although the median 
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apnoea time in the interventional group was double as compared with 
the reference group, the interventional group had a significantly 
higher lowest SpO2 of 100% vs 96% in the reference group. 
To sum up, both techniques of apnoeic oxygenation, i.e. 
classical and HFNO, appear to be effective in improving the 
oxygenation during the laryngoscopy period. However, both 
techniques seem not to be effective in respiratory failure patients. 
However, I would argue that HFNO may still offer clinical benefits, 
even in this population, but with the addition of PAP as demonstrated 
by Jaber and co-workers [133]. The benefit may be attributed to the 
partial restoration of the FRC that may have been profoundly reduced 
due to the intrapulmonary shunt induced by the disease process and 
by the induction of general anaesthesia. 
The superior efficiency of HFNO over classical apnoeic 
oxygenation appears more clearly in the anaesthesia literature than in 
the ICU and ED literature. This inconsistency may be due to (i) the 
deranged physiology, (ii) sub-optimal pre-oxygenation, and (iii) the 
relatively short apnoea duration that may conceal the benefits of 
apnoeic oxygenation. A summary of the studies that investigated 
THRIVE during emergency procedures is presented in Table 0.4 in 
the appendix. 
3.4.1.3 Apnoeic oxygenation in obese patients 
The effect of obesity on safe apnoea time has been well 
demonstrated by Jense and co-workers [24]. The researchers 
examined normal-weight, obese, and morbidly obese. All the patients 
were properly pre-oxygenated. After induction of anaesthesia and 
paralytic agent administration, the patients left apnoeic to room air. 
The safe apnoea time (i.e. SpO2 of 90%) were 6.0, 4.1 and 2.7 min in 
the normal, obese and morbidly obese groups, respectively. This 
38 
 
finding reveals a significant inverse relationship between the severity 
of obesity and the safe apnoea time. 
Numerous apnoeic oxygenation methods have been evaluated 
in various obesity severities. For instance, Ramachandran and co-
workers [134] conducted an RCT in mild obesity (i.e. 30 kg·m-2 < BMI 
< 35 kg·m-2). The authors assigned the patients to receive either 5 
L·min-1 O2 via nasal prongs or not receive O2. They found that apnoeic 
oxygenation significantly increased the time to reach SpO2 of 95%, 
5.29 min in the interventional arm, where it was 3.49 min in the control 
group. 
Heard and co-workers [135] performed an RCT of 40 mildly to 
moderately obese individuals. The patients received either 10 L·min-1 
O2 via a modified 3.5 ETT placed in the buccal area or received no O2. 
The researchers found a clinically important and statistically 
significant increase in the safe apnoea time in the group that received 
apnoeic oxygenation. The median apnoea time with SpO2 ≥ 95% was 
12.5 min in the interventional arm, while it was 4.9 min in the control 
group. To date, this finding is considered the longest safe apnoea time 
for both groups, interventional and control, reported in a randomised 
control trial in the obese population.  
I believe this method of apnoeic oxygenation is novel and 
overcomes a number of challenges faced during apnoeic 
oxygenation. First, nasopharyngeal insufflation may provide O2-rich 
gas in the supra-laryngeal region, but it may not allow an adequate 
route for exhalation, which could cause barotrauma even at a low flow 
rate (e.g. 4 L·min-1) [136]. Nasal cannulae may not be effective in 
obese patients who may develop retropalatal obstruction after 
anaesthesia induction. However, as the HFNO generates positive 
pressure, it may be reasonable to anticipate partial or complete relief 
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of the airway obstruction that occurs in the retropalatal area. The 
buccal apnoeic oxygenation method also allows the insertion of 
various airways such as Guedel, nasopharyngeal, and laryngeal mask 
airways without affecting the O2 delivery. 
In morbidly obese apnoeic patients, Baraka and co-workers 
[137] assigned patients to receive either 5 L·min-1 O2 via a 
nasopharyngeal catheter or no O2. The subjects in the apnoeic 
oxygenation group completed the entire allocated apnoea time (i.e. 4 
min) with SpO2 of 100%, while the control group had a mean safe 
apnoea time of 2.4 min. 
Moon and co-workers [138] randomised 135 obese patients to 
receive either, (i) control group (not receive any intervention), (ii) 
received 15 L·min-1 O2 during apnoea, and (iii) received 15 L·min-1 of 
air during apnoea using a nasal cannulae via a nasopharyngeal airway. 
The authors found a median safe apnoea time (SpO2 95%) of 4.4, 2.5, 
and 2.7 min in the subjects that received O2, air, and the control group, 
respectively. It is worth noting that ten subjects in the O2 group have 
completed the entire allocated apnoea time (8 minutes) with SpO2 
values higher than 95 %. The finding of this study confirms the 
paramount importance of the provision of a high concentration of O2 
as well as the patency of airway to successfully extend the safe 
apnoea time in obesity. A Summary of apnoeic oxygenation studies 
during elective procedures on obese patients is presented in Table 
0.5 in the appendix. 
 THRIVE in obesity 
There are currently a few clinical studies that evaluated the use 
of HFNO during apnoea in obesity. For instance, Patel and Nouraei 
[50] conducted a landmark observational study, which revealed that 
the use of HFNO prevented the hypoxaemia onset up to 65 min of 
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apnoea without signs of CO2 toxicity. The researchers observed 25 
patients with a median BMI of 30 kg.m-2 who were deemed difficult 
airway. The patients were scheduled for hypopharyngeal or 
laryngotracheal surgeries. They received 70 L·min-1 with FiO2 1.0 via 
HFNO for 10 minutes during the pre-oxygenation phase and remained 
unchanged during apnoea. The authors termed this technique 
Transnasal Humidified Rapid-Insufflation Ventilatory Exchange 
(THRIVE). After anaesthesia induction and neuromuscular blockade, 
jaw thrust was maintained throughout the procedure to ensure airway 
patency. All the patients had a safe apnoea time (i.e. SpO2 ≥ 90%) 
between 5 to 35 min, except one patient who had a 65 min of apnoea 
with an O2 saturation of 95%. O2 desaturation, but not hypoxaemia, 
was encountered in two cases who suffered from severe obesity and 
severe tracheobronchomalacia and obesity. 
Further, Gustafsson and co-workers [51]  case series included 
four subjects with mild obesity. Table 3.3 highlights the SpO2 at the 
end of apnoea of the four obese patients reported by Gustafsson and 
co-workers [51] and Lyons and Callaghan [125]. These data provide 
evidence that the use of HFNO during apnoea in mild obesity does 
delay the onset of hypoxaemia for ≥19 minutes. Regarding the 
occurrence of hypoxaemia that occurred to subject # 3, the authors 
mentioned that the desaturation was reversed by opening the airway 
and increasing the flow rate from 80 to 120 L·min-1. This desaturation 
could be caused by some degree of airway obstruction rather than 
the inefficiency of the HFNO. These data are in agreement and 
support the claim that HFNO can provide long non-hypoxaemic 




Table 3.3. SpO2 at the end of apnoea of the obese patients 
reported by Gustafsson et al. and Lyons and Callaghan during 
apnoeic HFNO. 
Author Subject 
BMI Apnoea duration Lowest SpO2 
(kg·m-2) (min) (%) 
Gustafsson 
et al. [51] 
1 30.5 25 99 
2 32.2 21 91 
3 30.3 23 98 




1 31.1 24 99 
2 30.2 19 92 
3 32.8 13 87 
4 32.7 30 93 
BMI, body mass index; SpO2, pulse oximetry 
Finally, Lee and Quek [139] reported a morbidly obese case that 
successfully maintained the SpO2 above 98% during the entire 
procedure, which lasted 14 min of apnoea. They implemented HFNO 
of 60 L·min-1 and FiO2 of 1.0. Although this is only a case report, it adds 
to the available evidence that HFNO does extend the time of non-
hypoxaemic apnoea, even in severe obesity. 
3.4.1.4 Apnoeic oxygenation in computational modelling 
In 1996, Farmery and Roe [140] constructed a computational 
model that consisted of three compartments that represented 
deadspace, shunt and ideal alveoli. They examined the rate of O2 
desaturation during apnoea. The authors simulated multiple values of 
pre-oxygenation, FRC, O2 consumption, shunt fraction, cardiac 
output, and haemoglobin concentration. The importance of FRC and 
pre-oxygenation in delaying hypoxaemia was highlighted. The 
researchers quantified that pre-oxygenation increased the time to 
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reach SaO2 85% from 1.4 to 8.4 minutes in the non-obese subject and 
from 0.8 to 2.9 minutes in the obese (i.e. low FRC) subject. 
Benumof and co-workers [141] have criticised the difficult airway 
algorithm issued by the American Society of Anesthetists, which 
recommend “consider the advisability of awakening the patient” if the 
initial intubation attempt is unsuccessful. In this article, the authors 
demonstrated, using the data from Farmery and Roe [140], that critical 
hypoxaemia will occur before patients return to the unparalysed state. 
The author concluded that applying the awakening element is not a 
safe option. Nevertheless, apnoeic oxygenation has not been 
evaluated nor considered in these studies. 
In 2000, Hardman and co-workers [142] examined apnoeic 
oxygenation and several physiological factors that influence the 
hypoxaemia occurrence during apnoea, using high-fidelity multi-
compartmental computational modelling. The authors found that 
when apnoeic oxygenation was not applied (i.e. FiO2 0.21), the time 
taken to reach SaO2 50% was 11 min 37 sec in the patent-airway 
virtual subject, while it was 8 min 13 sec when the airway was 
obstructed. Patent-airway apnoeic oxygenation with 100% O2 resulted 
in a significant increase (66 min 20 sec) in the time taken to reach 
SaO2 50%. Apnoeic oxygenation, FRC, O2 consumption and airway 
patency were identified as the most potent factors in determining 
hypoxaemia onset during apnoea. 
Moreover, McNamara and Hardman  [143] revealed an 
interesting finding of the pivotal role of high FiO2 during apnoea. They 
found that increasing the FiO2 from 0.9 to 1.0 causes a remarkable 
delay in hypoxaemia occurrence (more than double) as compared to 
the FiO2 increase from 0.21 to 0.9. They numerically explained why 
and how this benefit is established. An additional finding was, as the 
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FiO2 increases, the hypoxaemia is delayed, regardless of the shunt 
fraction. 
Pillai and co-workers [49] modelled different virtual clinical 
scenarios for in-silico patients. They found that the conditions that had 
the longest time to 90% desaturation were average parturient, 
anaemia, twin pregnancy, obesity, sepsis, morbid obesity and average 
parturient in labour, respectively. Increasing FiO2 from 0.8 to 1.0 
significantly prolonged the time to 40% O2 desaturation (from ~23 min 
to ~75 min) during apnoea with an open airway. Even though much 
research has underpinned the benefits of apnoeic oxygenation, but 
there is still a significant element that hinders its use for an extended 
period of time, hypercapnia. 
3.5 Apnoeic ventilation 
Apnoea-induced hypercapnia and its clinical consequences 
(e.g. respiratory acidemia) play a significant role in limiting the wide 
use of apnoeic oxygenation in clinical practice, especially for a long 
duration of apnoea. Apnoeic ventilation refers to the increased 
clearance of CO2 during the apnoeic period with no artificial 
ventilation. The efficiency of apnoeic ventilation could be affected by 
anatomical (airway patency), physiological (cardiogenic oscillations), 
and interventional factors (method of apnoeic oxygenation). 
3.5.1 Physiological background 
Gas diffusion is inversely proportional to its molecular weight, 
and directly proportional to its solubility, and to the pressure gradient 
available across the diffusion area. Even though oxygen’s molecular 
weight (32 g·mol-1) is lighter than CO2 (44 g·mol-1) [144], making O2 
1.17 times faster to diffuse but, on the other hand, CO2 is about 24 
times more soluble than O2. By considering the combined properties, 
44 
 
weight and solubility, the overall rate of CO2 diffusion is about 20 times 
faster than O2 [7], making it a much easier gas to diffuse than O2. 
However, the diffusion pressure gradient for O2 (8 kPa) is substantially 
(10 times) higher than CO2 (0.8 kPa) [7]. 
During apnoea, few mechanisms are thought to prevent CO2 
elimination, thus cause hypercapnia. Shortly after the onset of 
apnoea, the CO2 pressure gradient that drives CO2 from pulmonary 
capillaries to alveoli is lost. Therefore, a small amount of CO2 is 
diffused to the lungs (8-20 ml out of 200 ml·min-1) [145]. The second 
mechanism was described by Holmdahl [48], which claims that the 
alveolar sub-atmospheric pressure that occurs during apnoea create 
a unidirectional (from upper airway towards alveoli) convective gas 
stream that is strong enough to not allow the CO2 to move against. 
3.5.2 The CO2 rate of increase 
There are several factors that may affect the CO2 rate of increase 
and its clearance during apnoea, such as airway patency, pre-apnoea 
hyperventilation, metabolic statues (e.g. hypothermia, pregnancy), 
and apnoeic oxygenation delivery method [45, 47, 145-147]. The CO2 
values are also affected by the measurement method of CO2 obtained 
via arterial or venous blood gas, capnography and transcutaneous 
CO2 [51]. 
3.5.2.1 The CO2 rate of increase during apnoeic oxygenation 
Holmdahl and co-workers [48] studied apnoeic oxygenation in 
ten dogs and found an almost linear increase at an approximate rate 
of 0.9 kPa·min-1 during the first 40 min of apnoea. Afterwards, during 
the next 20 minutes, the rate of rise has decreased. The same 
research group [48] investigated the PaCO2 rate of rise in humans and 
found a rate of 0.68 kPa·min-1 during 6 min of apnoea. Frumin and co-
workers [46] conducted one of the most extended apnoeic 
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oxygenation studies on human up to 55 minutes of apnoea. They 
delivered, via an ETT, approximately 133-200 ml·min-1 of O2 on eight 
subjects. The authors found an average CO2 rate of rise of 0.45 
kPa·min-1, with a range of 0.35 to 0.65 kPa·min-1, and the highest 
recorded value of CO2 was 33.3 kPa corresponding with an arterial 
pH of 6.72. Lee [123] has examined the effect of low-flow apnoeic 
oxygenation using 5 L·min-1 via nasal prongs. He found a significant 
reduction in the mean PaCO2 rate of rise in the apnoeic oxygenation 
group, 0.5 as compared to 0.8 kPa·min-1. The duration of apnoea 
lasted between 3-4 min. 
3.5.2.2 The CO2 rate of increase during HFNO 
Patel and Nouraei [50] found even a lower end-tidal CO2 rate of 
rise of 0.15 kPa·min-1, but with an O2 flow rate of 70 L·min-1 delivered 
nasally. Gustafsson and co-workers [51] found a similar rate of rise of 
end-tidal CO2 of 0.12 kPa·min-1, while the arterial CO2 rate of rise was 
0.24 kPa·min-1. However, capnography was identified, by the authors, 
to underestimate the actual value of CO2 during apnoeic oxygenation, 
unlike transcutaneous CO2, as it showed a good correlation to arterial 
CO2. 
3.5.2.3 The CO2 rate of increase during CPAP 
Joseph and co-workers [126] found the arterial CO2 rate of rise 
in lean subjects was lower when using a CPAP of 15 cm H2O, as 
compared with HFNC of 60 L·min-1, during the 12 min of apnoea. The 
CPAP group had a mean PaCO2 rate of 0.3 kPa·min-1, while it was 0.5 
kPa·min-1 in the HFNC group. Nevertheless, their finding is not in 
agreement with the previous study [51]. 
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3.5.2.4 The CO2 rate of increase during intra-tracheal insufflation 
Rudlof and Hohenhorst [29] found a median end-tidal CO2 rate 
of rise of 0.24 kPa·min-1 while delivering 0.5 L·min-1 O2 at the carina. 
The non-invasive HFNO produced higher CO2 clearance than this 
strategy. 
3.5.2.5 The CO2 rate of increase during endo-bronchial 
insufflation 
The lowest levels of CO2 rate of increase, during apnoea, have 
been achieved via endobronchial insufflation. Babinski and co-
workers [148] investigated five non-obese women. Two catheters 
were placed 2 cm below the carina, one catheter in each main 
bronchus. Heated and humidified O2 was delivered at a flow rate of 
24-28 L·min-1. The PaCO2 rate of rise was 0.08 kPa·min-1. Interestingly, 
one patient’s PaCO2 remained within the normal range after 30 min of 
apnoea. 
Watson and co-workers [146] have used the same technique but 
with a higher O2 flow rate (i.e. 45 L·min-1). They revealed that the 
PaCO2 had increased significantly during the first 5 min of 
endobronchial insufflation, from 4.2 to 5.8 kPa, and then remained 
relatively unchanged. The arterial pH was 7.3±0.02, and PvCO2 was 
6.8±0.4 kPa, after 20 min of apnoea. Moreover, three patients had a 
PaCO2 of less than 5.0 kPa, throughout the entire 25 min of apnoea. 
Mackenzie and co-workers [149] studied the required flow rate of 
room air (not O2) to achieve near acceptable gas exchange on six 
dogs. They found the average flow rate required maintaining a PaO2 
above 6 kPa and a PaCO2 below 8.6 kPa was 2.5 L·min-1 (0.25 L·kg-
1·min-1). All dogs survived, with no neurologic dysfunction, for the two 
hours of apnoea, using these flow rates of room air. 
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3.5.2.6 The CO2 rate of increase during airway obstruction 
Stock and co-workers [150] analysed the CO2 rate of rise, during 
apnoea, in 14 patients while their airway was completely obstructed. 
They found that the PaCO2 rate of rise during the first minute of 
apnoea was 1.6 kPa·min-1 and 0.45 kPa·min-1 thereafter. They 
concluded that the PaCO2 raises in a logarithmic manner. Similarly, 
Cheun and Choi [147] examined the PaCO2 rate of rise during apnoea 
and total airway blockage and found a mean rate of 0.37 kPa·min-1 in 
the non-pregnant group and 0.90 kPa·min-1 in the parturient group. 
They concluded that this finding is due to the increased O2 
consumption induced by pregnancy, thus increasing the production 
of CO2. 
3.5.2.7 The role of hyperventilation and hypothermia on the CO2 
rate of increase  
Eger and Severinghaus [145] investigated pre-apnoeic 
hyperventilation (average initial end-tidal CO2 1.8 kPa) and 
hypothermia (31.7°C) on the CO2 rate of rise during apnoea on five 
healthy subjects. They found that the CO2 rate of rise during the first 
minute of apnoea is significantly higher (more than triple) than the 
subsequent apnoea duration. Hyperventilation did reduce the CO2 
rate of rise during the initial and the subsequent apnoea duration. Its 
overall rate was 0.40 kPa·min-1 as compared to 0.55 kPa·min-1 in the 
normal ventilation. Hypothermia has further decreased the rate of rise, 
from 2.3 kPa·min-1 at a core body temperature of 35.5° C to 0.8 
kPa·min-1 at 31.7° C. After the first minute of apnoea, at normal 
temperature, the rate of rise was 0.6 kPa·min-1 compared to 0.3 
kPa·min-1 when hypothermia was applied. A summary of the studies 
that investigated the CO2 rate of increase during apnoea is presented 
in Table 0.6 in the appendix. 
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3.6 Acute Respiratory Distress Syndrome 
3.6.1 Management and evidence-based practice 
Since the hypoxaemia in ARDS responds poorly to conventional 
O2 therapy, the obvious next level of respiratory support is mechanical 
ventilation. Compared to negative pressure ventilation, positive 
pressure mechanical ventilation has shown to decrease mortality from 
87% to 40% in non-ARDS patients with respiratory insufficiency 
during the Copenhagen poliomyelitis epidemic [151]. Nevertheless, 
positive pressure ventilation can induce serious lung injury that 
increases mortality if the ventilator parameters’ settings (e.g. tidal 
volume, plateau and driving pressure) are not set in accordance with 
the lung-protective ventilation strategy. 
3.6.1.1 Lung injuries 
Ventilator-induced lung injury (VILI), as the name implies, is an 
insult caused by the forces applied by the mechanical ventilator to the 
lungs, which can be as harmful as the syndrome itself. Abundant 
literature underpins the basis of VILI [152]. Generally, the current 
understanding suggests that VILI is categorised into three main 
mechanisms (i) alveolar stretch beyond its anatomical capability (i.e. 
overdistension), which can be caused by either excessive lung 
volume or excessive pressure (volutrauma/barotrauma) respectively, 
(ii) repetitive cyclic inflation (during inspiration) and collapsing (during 
expiration) of the diseased alveolar units (atelectrauma), which could 
be caused by a positive airway pressure level that is not high enough 
to prevent lung collapse during expiration, and not low enough to 
prevent inflation of the affected lung regions during inspiration, and 
(iii) toxic substances released by the inflammatory mediators 
(biotrauma), that might be aggravated by the alveolar overdistention, 
which will cause a vicious cycle.  
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Increased airway pressure in itself may not cause lung injury 
(trumpet players can normally endure an expiratory airway pressure 
of 150 cm H2O [153]), but rather the increased alveolar 
transpulmonary (distending) pressure. 
3.6.1.2 Lung-protective ventilation strategy  
ARDS is a complex syndrome and is challenging to manage due 
to its heterogeneity [154]. Even though through basic, animal and 
clinical research, scientists now know few interventions that increase 
survival, such as using lower tidal volume [155], lower plateau 
pressure [155], lower driving pressure [156], and prone positioning 
[157]. However, the optimal safe thresholds for these interventions are 
to be determined. 
The ARMA trial [155] compared the effects of ventilating ARDS 
patients using a tidal volume of 6 ml·kg-1 of predicted body weight 
(PBW) limited to a plateau pressure of 30 cm H2O versus 12 ml·kg-1 of 
PBW limited to a plateau pressure of 50 cm H2O. The mortality rate in 
the group that received lower tidal volume was 31% as compared with 
40% in the group that received higher tidal volume.  
It is commonly referred to the delivery of a tidal volume of 6 
ml·kg-1 of PBW as a “low” tidal volume strategy, while in fact, the 
normal tidal volume in mammals (including in healthy human) is 6.3 
ml·kg-1 [158]. However, in ARDS, a significant portion of the lung units 
are not available to accept volume (termed as baby lung) due to either 
alveolar collapsed or filled with fluids. Therefore, I would argue that 
even 6 ml·kg-1 of PBW may still be injurious in some ARDS patients in 
which the received tidal volume exceeds its maximal stretch capability 
since the vast majority of the delivered tidal volume will be received 
by the remaining “functional” lung units [159].  
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Consequently, Amato and co-workers [156] retrospectively 
analysed data of 3,562 patients extracted from 9 major ARDS clinical 
trials. They concluded that the driving pressure (i.e. plateau pressure 
– total PEEP) is a better predictor of mortality (and maybe a better 
indicator of lung protection) than tidal volume and respiratory 
compliance. The driving pressure positively correlated with mortality 
rate irrespective of plateau pressure levels. An exponential increase 
in mortality was depicted at driving pressure higher than 15 cm H2O. 
The driving pressure is the ratio of tidal volume to the static respiratory 
system compliance (which roughly represent the amount of 
“functional” lung unites) rather than predicted body weight.  
3.6.1.3 What is the evidence of the ECMO outcomes in severe 
ARDS?  
In the past four decades, only four randomised trials [160-163] 
have been conducted to assess the efficacy of ECMO in severe ARDS 
patients. The first two trials were performed before the publication of 
the ARMA trial in 2000 that demonstrated a survival benefit in the 
lower VT and Pplat group. The CESAR trial [162] concluded that the 
mortality and severe disability at six months were significantly lower 
in the patients transferred to an ECMO centre than those who were 
not transferred to an ECMO centre. However, it is not clear if the 
patients in the control group received a lung-protective ventilation 
strategy and not all the patients assigned to the ECMO group received 
ECMO. In the EOLIA trial [163], the 60-day mortality was lower in the 
ECMO group. However, it was not statistically significant (p=0.09). 
Nevertheless, the trial was underpowered due to futility after the 
enrolment of 249 patients, as supposed to the planned 331 patients. 
A more recent systematic review and meta-analysis [164] 
assessed the outcomes of severe ARDS patients undergoing ECMO. 
The authors synthesised the results obtained from the CESAR and 
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EOLIA trials as well as three observational studies, and they have 
demonstrated that ECMO was linked with a decreased risk of 30-day 
mortality (RR 0·69 [95% CI 0·50–0·95), and moderate risk of 
substantial bleeding. However, this systematic review is limited by the 
inclusion of only two randomised trials as well as the potential bias 
that may have originated from the lack of patients’ randomisation for 
ECMO in the observational studies. 
3.6.1.4 What is the optimal target for oxygen in ARDS? 
Hypoxia and hyperoxia are harmful. The optimal target for O2 
level in ARDS remains unknown. However, two large meta-analyses 
suggested slightly different ranges of SpO2 in critically ill patients. The 
first recommended that the SpO2 value should not exceed 94%-96% 
[165], and the second indicated that the SpO2 optimal range is 
between 94% 98% [166]. 
Nevertheless, Marn and co-workers [167] reported that in 
sepsis-induced ARDS, a DO2 < 640 ml·min·m2 was associated with 
100% mortality, while a DO2 > 686 ml·min·m2 was linked with a 70% 
survival rate. On the other hand, Girardis and co-workers [168] found 
a mortality reduction by roughly 50% in patients who had a PaO2 of 
11.6 kPa, compared to a PaO2 of 13.6 kPa. The highest mortality was 
observed in patients who had, on average, a PaO2 ≥ 14.26 kPa. 
3.7 The literature gap  
Currently, there is no consensus for the optimal method to 
perform apnoeic oxygenation for all patient populations. Although 
apnoeic oxygenation has been shown to prolong the safe apnoea time 
during elective procedures [29, 46] even in mild [134], mild-to-
moderate [135] and severe obesity [137], the effects of HFNO has not 
been extensively quantified in obesity. Further, it is unknown whether 
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HFNO provides additional benefits as compared to the classical 
apnoeic oxygenation, i.e. low-flow non-humidified. 
The clinical implementation of prolonged apnoeic oxygenation 
may be limited by the significant rise in PaCO2 and its subsequent falls 
in pH that may or may not jeopardise the patients’ health conditions 
[46, 50, 51, 145]. Other limitations to using HFNO during apnoea 
include its high cost and unavailability at the clinical bedside. 
An additional gap in the literature is the lack of studies that 
investigated the role of HBOT in ARDS. Reasons that may have 
prevented the use of the HBOT in ARDS include the fact that 
international HBOT societies have not classified ARDS as an approved 
indication for HBOT. Other factors include the cumbersome to use of 
HBOT, its high cost, lack of expertise, bulky, requires special 
equipment that is compatible with high pressure (e.g. ventilator, 
infusion pump) and the scarcity of Class I (i.e. that can support ICU 
patients) hyperbaric chambers. Additional factors are related to the 
severity of the targeted population for investigation, i.e. severe ARDS. 
This is a very sick population, and establishing acceptable (or 
near acceptable) oxygenation in severe ARDS can be a challenging 
clinical task. Once achieved, clinicians would want to preserve it and 
minimise any interruption. I would argue that transporting severe 
ARDS patients and placing them on a different ventilator (HBOT-
compatible ventilator) is a risky procedure that may hinder a trial of an 
HBOT session. HBOT is mainly limited by the O2 toxicity affecting CNS 
and the pulmonary system. Even a slight elevation of pressure during 
prolonged sessions may produce a poisonous effect induced by O2. 
The conducted studies reported in Chapter 5 and 6 filled the gap 
pertaining to the efficacy of various apnoeic oxygenation strategies in 
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obesity. Chapter 8 addressed the gap related to the potential role of 
HBOT in ARDS with refractory hypoxaemia. 
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Chapter 4: Methodology 
For the PhD thesis, I used the Interdisciplinary Collaboration in 
Systems Medicine (ICSM) simulation suite, created and developed by 
the principal supervisor Prof Jonathan Hardman and his research 
group. It is a computational model of the pulmonary and 
cardiovascular systems, which details are reported in the second 




A model is the final product that is believed to represent a 
particular system or phenomenon, subject to various levels of 
approximation [169]. Some types of models are physical, 
mathematical and conceptional models. Few examples are cadavers, 
research animals, physical manikins, and computer models. A 
computer model is a set of ideas that are expressed mathematically 
using a series of equations in a particular order/fashion (e.g. iteration) 
to simulate the studied system or phenomenon. The accuracy of any 
given model is dependent on the knowledge base of the studied 
system or phenomenon, as well as the ability to precisely incorporate 
that knowledge in the model. 
4.1.1.2 Modelling 
Modelling refers to the construction process of a model [169]. In 
the case of a computer model, modelling involves a complete or near-
complete understanding of the studied system or phenomenon as well 
as translating that understating to mathematical equations that best 
represent the process. This is particularly challenging when modelling 
constantly dynamic systems (e.g. human being), especially during 
55 
 
abnormal physiology that has predicted and unpredicted methods of 
compensatory mechanisms. 
4.1.1.3 Simulation 
Simulation is the process of performing the mathematical 
equations and running the pre-defined algorithms as set by the 
assigned researcher [169]. Simulation of complex systems is usually 
performed via computer software. The software may also output 
graphical illustration of different variables that interest the researcher.   
4.1.2 Introduction 
Modelling is as old as the civilizations of human. Historically, 
physical models were made for different reasons. For instance, 
architects used demo designs as models to illustrate and/or market 
their ideas. Ancient scholars used physical models to understand and 
portray the world. Computational modelling is a stand-alone research 
methodology [170]. Its purposes include investigating, predicting, and 
optimising certain behaviours of a system or phenomenon.  
The first general-purpose computer was developed in 1946. It 
was able to execute 14 ten-digit multiplications in only 1 sec [171]. 
The increasing computing power, as well as the capacity to store a 
large amount of digital data, have played a critical role in advancing 
the use of computational modelling in diverse scientific fields like 
astrophysics, engineering, biology, and weather forecasting. In the 
modern era of technology, modelling and simulation have been 
expanded beyond research. It is widely used for training purposes in 
industries such as aviation and healthcare.  
Simulation-based learning (SBL) is effective in hazardous 
industries such as aviation. It led to a 50% reduction in aircrafts 
accidents [172]. In healthcare, the third top cause of deaths in the 
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United States is preventable medical errors, resulting in more than 
400,000 deaths annually [173]. A recent review highlighted that team 
training that included simulation has been shown to decrease 
mortality by 13% [174]. SBL offers a safe and controlled setting that is 
analogous to the real targeted environment. SBL could develop and 
enhance certain technical and non-technical skills by exposing 
trainees and allowing them to respond to challenging scenarios that 
are relevant to their work duties. Debriefing, feedback and reflection 
are vital to achieving learning [172]. 
Lung models have contributed to advance our understanding of 
the pulmonary system. For instance, West [175] lung model provided 
detailed quantification of the regional gas exchange (e.g. ventilation to 
perfusion match). Nine horizontal zones were identified with their 
associated regional parameters such as minute ventilation, perfusion, 
the pressure tension of O2 and CO2, which exhibited considerable 
variation. Hahn and Farmery [176] informed and critiqued the different 
types of lung models, along with their features and pitfalls. They 
advocated developing non-linear tidal-ventilation lung models rather 
than continuous-ventilation and steady-state models, as tidal-
ventilation lung models reflect our natural way of breathing. 
In the context of anaesthesia and critical care, comprehensive 
research work has been conducted using a computational model of 
the pulmonary and cardiovascular systems. In particular, Hardman 
and co-workers [142] examined hypoxaemia behaviour during several 
simulated conditions that may be encountered clinically. Examples of 
the factors that the authors studied include airway patency and 
obstruction, length of denitrogenation, FRC, and O2 consumption. 
They individually quantified the impact of these factors on 
hypoxaemia. Moreover, McNamara and Hardman [143] evaluated the 
role of the O2 concentration when applied during apnoea while 
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maintaining a patent airway. Interestingly, they observed a profound 
delay to reach life-threatening hypoxaemia when the O2 concentration 
was increased from 90% to 100%. This finding has enriched the field's 
understanding of apnoeic oxygenation. 
4.1.2.1 Strengths and limitations of computational modelling 
There are many powerful features that distinct computational 
modelling methodology from other methodology types (e.g. 
laboratory and clinical investigation). First, computational modelling 
provides a safe research environment, as there are no real human nor 
animals involved in the investigations. Second, it enables high 
degrees of configurability of variables that may be of interest to 
researchers. The configurability of variables is performed 
independently hence controlling confounding and non-confounding 
factors, which leads to the homogeneity of subjects. Third, 
computational modelling offers a time-efficient and cost-effective 
method to conduct research as compared to clinical trials. Fourth, 
some models are highly integrated and incorporate important 
complex reactions that will improve the model outputs' accuracy, such 
as considering the effects of pH on the O2 association dissociation 
curve and the hypoxic pulmonary vasoconstriction. Last but certainly 
not least, computational modelling can investigate conditions that are 
not ethically nor clinically possible due to its lethality, such as 
prolonged duration of apnoea or life-threatening hypoxaemia [170]. 
Despite these advantages, it is essential to recognise its shortcoming. 
Just like any other methodologies, computational modelling 
presents some limitations. In biological research, where dynamic 
actions constantly exist, it is impossible to fully model a system due to 
the incomplete knowledge of human physiology or extreme scenarios. 
Therefore, computational modelling is based on an approximation of 
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the relevant physiological processes; thus, all the inherent complexity 
of the underlying pathophysiology cannot be represented. 
Furthermore, the human being has different compensatory 
mechanisms to maintain normal body status. For example, during 
vigorous exercise, alteration in the breathing pattern and the 
cardiovascular system helps cope with the increased metabolic 
demand induced by exercise. Similarly, pathologies such as 
pulmonary oedema, pneumonia and metabolic acidosis can stimulate 
compensatory reactions, including increasing the minute ventilation 
and pulmonary vasoconstriction in hypoxic lung regions. However, not 
all compensatory mechanisms are completely understood, thus not 
incorporated in the computational models. Our model was configured 
to attenuate the confounding effects assuming that virtual subjects are 
fully sedated and paralysed; therefore, autonomic reflex modules 
were not utilised. Another limitation is that mathematical modelling 
relies on numerical data input; some of the required data may not be 
available in the literature. The researchers may enter data based on 
their knowledge that the entered values approximate the true values, 
according to their expertise. 
4.2 The Interdisciplinary Collaboration in Systems 
Medicine 
The Interdisciplinary Collaboration in Systems Medicine (ICSM) 
simulation suite is a computational model, and it is the newer version 
of the model Nottingham Physiology Simulator (NPS). NPS was 
established more than two decades ago by Professor Jonathan 
Hardman at the University of Nottingham. The ICSM has been 
advanced remarkably throughout the years by Professor Hardman 
and his research group (ICSM), producing a world-renowned high-
fidelity computational model of a number of organ systems, including 
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the heart, blood vessels (and blood) and the lungs. The ICSM is a 
dynamic model in which the outputs of the system will be fed back as 
inputs in an iterative fashion. Equilibrium in this context refers to the 
output variables being unchanged overtime. 
The ICSM simulation suite has been widely validated in 
numerous research areas, including hypoxaemia during apnoea [142], 
pre-oxygenation [177] and apnoeic oxygenation in adults [143], 
children [178], obese [177, 179] and pregnant virtual (in-silico) 
subjects [49, 179-181], as well as in ARDS [182], and in chronic 
obstructive pulmonary disease (COPD) [183]. Recently, it has been 
utilised to investigate research areas such as the emergency rescue 
of airway obstruction  [184], ventilator [185] and blast lung injuries 
[186]. The model integrates numerous complex physiological 
phenomena, such as the shift of the O2 association dissociation curve 
and hypoxic pulmonary vasoconstriction. 
As illustrated in Figure 4.1, the cardiopulmonary model contains 
a series deadspace (SD), 100 alveolar compartments and 19 in-series 
cardiovascular compartments that are independently configurable. 
The SD is located between the airway and the alveolar compartments. 
In the model, the SD is simulated as a series of stacked, rigid laminae 
(𝑁𝑙𝑎𝑚 = 50) of equal volume. The static total volume of the SD is set 
by the user and each lamina, 𝑗, has a known fraction (𝑓_((𝑆𝐷, 𝑗))^𝑥) 
of gas 𝑥. These gases comprise O2, nitrogen, CO2, water vapour and 
a 5th gas used to model additives. During each computational iteration 
of the model, the gases shift up or down the stacked laminae, driven 




Figure 4.1. Schematic illustration of the cardiopulmonary system of the ICSM model. 
The pressure of each alveolar compartment is described by a cubic 
function: 
Equation 4.1 
𝑝𝑖 = 𝑆𝑖((10 ∙ 𝑣𝑖 − 300)
3/6600) − 𝑃𝑒𝑥𝑡,𝑖  𝑣𝑖 > 0 𝑓𝑜𝑟 𝑖 = 0, … , 𝑁𝑎𝑙𝑣 
𝑝𝑖 = 0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
where 
𝑆𝑖 =  𝑘𝑠𝑡𝑖𝑓𝑓  · 𝑁𝑎𝑙𝑣
2 /200000 
𝑝𝑖 = 𝑆𝑖((10 ∙ 𝑣𝑖 − 300)
3/6600) − 𝑃𝑒𝑥𝑡,𝑖  𝑣𝑖 > 0 𝑓𝑜𝑟 𝑖 =
0, … , 𝑁𝑎𝑙𝑣 determines the alveolar pressure 𝑝𝑖 (as the pressure above 
atmospheric pressure in cm H2O) for the 𝑖𝑡ℎ of 𝑁𝑎𝑙𝑣 alveolar 
compartments for the given volume of the alveolar compartment, 𝑣𝑖, 
in millilitres. 𝑃𝑒𝑥𝑡,𝑖 (per alveolar unit, in cm H2O) represents the 
effective net pressure generated by the sum of the effects of factors 
outside each alveolus [187]. The parameter 𝑆𝑖 is a scalar that 
determines the intra-alveolar pressure for a given volume and is 
dependent on the parameter 𝐾𝑠𝑡𝑖𝑓𝑓 (stiffness coefficient that represent 
the stiffness of the alveolar compartments). The units of 𝑆𝑖 are cm H2O 
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ml-2. Further details of the physiological principles and mathematical 
equations underpinning the model are described in [187, 188]. 
4.2.1 Apnoea Modules 
Four modules have been recently developed and validated [189] 
to address known and hypothesised physiological mechanisms that 
influence gas exchange during apnoea. These mechanisms include 
cardiogenic oscillations of intrapulmonary gas, gas-mixing of the 
anatomical deadspace, and micro-ventilation induced by pharyngeal 
pressure oscillation during HFNO [189-192]. 
4.2.1.1 Cardiogenic oscillations module 
The cardiogenic oscillations have been shown to influence the 
CO2 clearance during breathing and apnoea [190, 191]. Other 
researchers suggested that the change in the gas flow is rather due 
to the change in the pulmonary blood flow [192]. Therefore, this 
module was established to incorporate the effects of the cardiogenic 
oscillations on the gas exchange during apnoea. The following 
equation describes their effect on alveolar compartments: 
Equation 4.2 
Posc,i = Kosc ∙ φ for i = 0, … , Nosc where Nosc ≤ Nalv 
𝑃𝑜𝑠𝑐,𝑖 represents the total pressure applied by the heart that acts 
on the alveolar compartment 𝑖. 𝐾𝑜𝑠𝑐,𝑖 is a constant, representing the 
strength of the effect of cardiogenic oscillations on alveolar ventilation 
due to the alveoli being physically compressed in a biphasic basis 
induced by, and synchronous with, the heartbeats and/or trans-
alveolar blood volume. 𝑁𝑜𝑠𝑐 is the number of alveolar compartments 
that are affected by the cardiogenic oscillations. The function φ is the 




𝑝𝑖 = 𝑆𝑖((10 ∙ 𝑣𝑖 − 300)
3/6600) − 𝑃𝑒𝑥𝑡,𝑖 −  𝑃𝑜𝑠𝑐,𝑖   𝑣𝑖 > 0 𝑓𝑜𝑟 𝑖 =
0, … , 𝑁𝑎𝑙𝑣 
𝑝𝑖 = 0   𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
4.2.1.2 Anatomical deadspace gas-mixing module 
The anatomical deadspace gas mixing was represented by a 
newly developed parameter (𝜎) to enable various degrees of gas 
mixing. 𝜎 has a value that ranges between 1 to 0. A value of 1 indicates 
complete gas mixing between the laminas as a result of immense 
turbulent flow, where 0 reflects no gas mixing is occurring. Thus: 
Equation 4.4 
fSD,j
x = ((1 − σ) ∗ fSD,j
x ) + σ ∗ fSD,j+1
x  where j < Nlam 
where 𝑓𝑆𝐷,𝑗
𝑥  is the fraction of gas 𝑥 in lamina 𝑗 and 𝑓𝑆𝐷,𝑗+1
𝑥 is the 
fraction of gas 𝑥 in the next lamina.  
4.2.1.3 Tracheal insufflation module 
Regarding tracheal insufflation, two parameters were 
configured, 𝑟𝑖𝑛𝑠𝑢𝑓𝑓 and 𝑙𝑖𝑛𝑠𝑢𝑓𝑓.  𝑟𝑖𝑛𝑠𝑢𝑓𝑓 is the amount of insufflated air 
flow L·min-1. 𝑙𝑖𝑛𝑠𝑢𝑓𝑓 represents the location of the insufflation. It can 
have a value from 1 to 5. Where 𝑙𝑖𝑛𝑠𝑢𝑓𝑓 of 1 indicate that the 
insufflation location is at the glottis, while 𝑙𝑖𝑛𝑠𝑢𝑓𝑓 of 5 represents the 
insufflation site at the carina. During the O2 insufflation, 𝑓𝑆𝐷,𝑘
𝑂2  at 





O2 ) +  (Fnew ∗ finsuff)
vk + Fnew
 
𝐹𝑛𝑒𝑤 = 𝑓𝑖𝑛𝑠𝑢𝑓𝑓 ∗ 𝑟𝑖𝑛𝑠𝑢𝑓𝑓 
where 𝑓𝑖𝑛𝑠𝑢𝑓𝑓 is the concentration of O2 in the insufflated air 
(accounting for humidified air) and 𝑣𝑘 is the volume of air in lamina 𝑘. 
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Following this, the fractions of the gases in all the layers are adjusted, 
taking into account the proportion of gas mixing between the laminas 
of the series deadspace. 
4.2.1.4 Pharyngeal pressure 
The delivery of high-flow nasal oxygen (HFNO) has been shown 
to generate positive pressure at the pharyngeal space [193, 194]. The 
oscillatory pharyngeal pressure (𝑃𝑝ℎ𝑎𝑟) has been added to the 
tracheal pressure (equal to the atmospheric pressure): 
Equation 4.6 






Where, 𝐴 is the amplitude of the pressure in cmH2O (values 0-2 
cm H2O) [195], and 𝑓 is the frequency in Hz equal to 70. Currently, our 
modelling and simulation are performed using Matlab software 
version R2018a (MathWorks Inc., MA, USA). Initially, the ICSM’s user 
configures in-silico subjects with particular pathophysiological 
characteristics to match the targeted condition/population that is 
intended to be investigated. The values used for configuring the 
subjects are based on human data that are published in the literature. 
Examples of the entered data include weight, height, FRC, cardiac 
output, venous admixture, O2 consumption and some parameters of 
the mechanical ventilator such as the mode, Pinsp or VT, RR, inspiratory 
to expiratory ratio, FiO2 and PEEP. 
Example of protocols that have been used for the thesis includes 
pre-oxygenation, apnoeic oxygenation using various oxygenation 
strategies, and mechanical ventilation at the atmospheric and 
hyperbaric environment. Examples of simulations’ endpoints include 
the duration of the simulation and/or when a certain level of 
hypoxaemia or hypercapnia is reached. The simulations output may 
64 
 
be exported as a spreadsheet or as plots of two or even three-axis 
graphs to observe certain behaviours. Then, a thorough analysis of 
the output is conducted. 
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Chapter 5:  The impact of airway patency, oxygen 
concentration, and high-flow nasal oxygen on gas 
exchange during apnoea in obesity: a computational 
modelling investigation  
5.1 Abstract 
The prevalence of obesity is increasing worldwide. In the UK, 
almost a third of the adult population is obese. Obesity predisposes to 
rapid hypoxaemia during apnoea due to reduced functional residual 
capacity (FRC) and increased O2 consumption. Using computational 
modelling, I configured eight in-silico subjects with body mass index 
(BMI) of 24 to 57 kg·m-2. Five conditions were simulated, which are: (i) 
complete obstruction of the upper airway, (ii) patent upper airway 
without supplemental O2, (iii) patent upper airway with 0.25 L·min-1 of 
100% O2, (iv) patent upper airway with 5 L·min-1 100% O2 provided 
nasally, (v) patent upper airway with 70 L·min-1 humidified 100% O2 
delivered via the nose (HFNO). Apnoea continued for 30 minutes, and 
arterial O2 saturation (SaO2) and arterial carbon dioxide partial 
pressure (PaCO2) were recorded at 5 milliseconds intervals. Relieving 
the upper airway obstruction delays hypoxaemia by about one minute. 
HFNO was more effective than the other interventions in delaying the 
onset and progression of hypoxaemia in all obese subjects. HFNO 
delayed the occurrence of hypercapnia (i.e. PaCO2 of 11 kPa) by 5 
minutes and by less than a minute in non-obese and obese subjects, 
respectively. The results suggest that the provision of HFNO during 
apnoea delays the onset and slows the progression of hypoxaemia 
and hypercapnia, though with reduced benefits as BMI increases. 
5.2 Introduction 
Maintenance of adequate alveolar oxygenation is the principal 
task of airway managers. Appropriate pre-oxygenation, as well as 
apnoeic oxygenation (i.e. providing O2 during apnoea), have been 
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demonstrated to be effective in delaying the onset of hypoxaemia [46, 
122]. There are various methods to deliver apnoeic oxygenation, such 
as via a standard nasal cannulae, pharyngeal insufflation, intra-
tracheal catheter and, more invasively, endobronchial insufflation. 
However, in recent years, HFNO appeared to gain considerable 
research and practical interest in the fields of anaesthesia, critical care 
and emergency medicine [130, 196]. Researchers have investigated 
the efficacy of HFNO during pre-oxygenation [197-200], airway 
management [50] and post-extubation [201]. 
5.2.1 What is HFNO? 
HFNO is an O2 therapy system that can independently provide 
an adjustable concentration of inspired O2 up to 100%, airflow rate up 
to 120 L·min-1 and appropriate humidity and temperature of the 
delivered gas. HFNO is typically delivered via a specialised high-flow 
system that consists of a high flowmeter, O2 blender and an active 
heating humidification system. Examples of some specialised and 
commercial HFNO devices are the POINT (Peri-Operative Insufflatory 
Nasal Therapy) system (Armstrong Medical, Coleraine, UK), Precision 
Flow (Vapotherm, Maryland, USA) and Optiflow (Fisher & Paykel, 
Auckland, New Zealand). However, some invasive and non-invasive 
mechanical ventilators have integrated high-flow O2 therapy to deliver 
HFNO like the Drager babylog VN500, Savina 300 and the Philips V60 
plus. 
5.2.2 When did HFNO enter the practice of anaesthesia and 
critical care? 
Although HFNO devices are commercially available since the 
early 2000s, their clinical application during apnoea was not utilised 
until 2013 [202]. As elaborated earlier, Patel and Nouraei [50] 
conducted the first study (in 2015) that investigated the use of HFNO 
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during prolonged apnoea in patients with difficult airways. The authors 
coined the term Transnasal Humidified Rapid-Insufflation Ventilatory 
Exchange (THRIVE). The multicentre PREOXYFLOW trial [197] 
followed suit, examining the use of HFNO, during apnoea, in acute 
hypoxaemic patients requiring emergency intubation. 
5.2.3 What are the outcomes of HFNO in anaesthesia and critical 
care? 
Provision of HFNO during apnoea has been shown to extend the 
period before dangerous hypoxaemia develops as well as decrease 
the PaCO2 rate of increase in non-obese subjects undergoing elective 
procedures [50, 51, 125]. Nevertheless, during emergency intubations 
that take place outside the operating theatres, the literature 
demonstrates contradictory results of the efficiency of THRIVE. For 
instance, these RCTs [131, 197, 203] showed no difference in the 
lowest SpO2 during intubation in the group that received HFNO and 
those who did not receive it. On the other hand, these trials [130, 204] 
found that the lowest SpO2 during intubation was significantly higher 
in the group that received HFNO than those who did not receive it. 
Moreover, the effectiveness of THRIVE in some populations that are 
at risk for developing hypoxaemia, such as obesity, have not been 
quantified yet. 
5.2.4 Why obesity? 
The prevalence of obesity is dangerously rising. A study found 
no reduction in obesity rates in the screened 188 countries over 33 
years, indicating a global crisis [205]. In the United States of America, 
the prevalence of obesity and severe obesity is 42.4% and 9.2%, 
respectively [206]. In the UK, approximately a third of the adult 
population is obese [2]. By 2030, an additional 11 million English 
adults are predicted to become obese [207]. 
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Obesity imposes metabolic and anatomical deleterious 
implications on airway management. Obesity is considered a risk 
factor for diabetes, hiatus hernia and gastro-oesophageal reflux, 
which all increase the likelihood of developing regurgitation and 
aspiration [4]. Pulmonary aspiration is the leading cause of airway–
related anaesthetic deaths [120]. Anatomically, upper body obesity, 
particularly around the neck, is believed to be the dominant risk factor 
for developing obstructive sleep apnoea (OSA) in adults [112]. 
Obesity is an independent risk factor for difficult face-mask ventilation, 
laryngeal-mask failure and difficult emergency surgical airway, while 
OSA is an independent predictor of impossible face-mask ventilation, 
difficult tracheal intubation and serious airway complications [4, 120, 
208]. Furthermore, obesity predisposes an additional important risk 
factor, which is a remarkable short time to develop O2 de-saturation 
after the anaesthesia induction and the subsequent apnoea. 
Obese subjects are at risk to develop rapid hypoxaemia shortly 
after the anaesthesia induction due to the marked reduction of the 
FRC, i.e. O2 reserve, caused by obesity [91] and anaesthesia induction 
(i.e. > 50%) [96], potentially increased closing capacity [95] and 
elevated O2 consumption rate [94]. The concurrent occurrence of 
anatomical and physiological derangements may likely be responsible 
for the rapidly evolving hypoxaemia. The combination of low FRC and 
high closing capacity increases the probability of developing 
atelectasis (i.e. alveolar collapse), leading to pulmonary shunting, 
which may not be responsive to conventional O2 therapy.  
To sum up, obesity imposes airway-related difficulty that may 
increase the required time to secure an airway. On the other hand, 
hypoxaemia is developed much faster in obesity [24]. The combined 
consequences may seriously endanger these patients, especially that 
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severe hypoxia can rapidly cause cardiac arrest and/or irreversible 
brain damage [16]. 
5.3 Aim of the study 
This study aims to investigate and quantify the effects of airway 
obstruction and patency, ambient O2 concentration, and apnoeic 
oxygenation strategies, including HFNO, on gas exchange during 
apnoea in virtual obese subjects using computational modelling. 
5.4 Methods 
The ICSM suite used for this investigation is described in detail 
in Chapter 4. 
5.4.1 Validation 
Two published studies have been selected that investigated 
hypoxaemia and hypercapnia during apnoea. The first study 
conducted by Hardman and co-workers [142] was performed using a 
previous version of the ICSM (i.e. NPS). This study investigated the 
course of hypoxaemia under different conditions such as 
denitrogenation duration, minute ventilation, O2 consumption, FRC, 
provision of O2 during apnoea, and the airway state (patent or 
blocked) in a non-obese virtual subject. The study’s endpoint was 
reaching a SaO2 of 50%. 
The second study was conducted by Heard and co-workers 
[135]. The authors evaluated apnoeic oxygenation using 10 L·min-1 of 
100% O2 in obese subjects. The endpoint of this study was once the 
SpO2 reaches 95%.  
To validate the current version of the model against Hardman 
and co-workers [142], I used values for the configuration of the non-
obese virtual subject which included FRC of 2.5 L·min-1 and VO2 of 
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250 ml·min-1, while FRC of 1.3 L, VO2 of 273 ml·min-1 was used for the 
configuration of the obese virtual subject to validate the model against 
Heard and co-workers [135]. Not all physiological values were 
reported in the study, so values were estimated according to the mean 
BMI. They were input based on other research studies [96, 118]. A 
two minutes pre-oxygenation was performed for both simulations.  
Moreover, as described in Chapter 4, the anatomical deadspace 
gas mixing was represented by a newly developed parameter (𝜎) to 
enable various degrees of gas mixing. The parameter 𝜎 has a value 
that ranges between 1 to 0. A value of 1 indicates complete gas mixing 
between the laminas as a result of turbulent flow, where 0 reflects no 
gas mixing is occurring. The parameter 𝜎 was set 0.3 for all 
simulations except HFNO, which had a value of 0.6. Finally, the HFNO 
had an oropharyngeal pressure oscillation of 2 cmH2O at 70 Hz, while 
all the other simulations had no pressure oscillation [189].  
5.4.2 Virtual subjects and protocol 
Eight virtual subjects with BMI 24, 27, 32, 37, 42, 47, 52 and 57 
kg·m-2 were configured. The baseline physiological values used for 
their configuration are listed in Table 5.1. These values were extracted 
from previously published studies [31, 96, 101, 118, 209]. All virtual 
subjects received pulmonary denitrogenation (i.e. pre-oxygenation)  
by breathing 100% O2 for two minutes. At simulated induction of 
general anaesthesia, the FRC was reduced by 20% in non-obese [31] 
and by 50% in obese subjects [96]. Subsequently, apnoea 
commenced and persisted for 30 minutes. From the onset of apnoea 
onwards, all virtual subjects underwent five different simulations: 
1. 0 L·min-1 insufflation of 0% O2 with closed glottis (simulating a 
complete blockage of the upper airway) 
2. Patent upper airway, 0.25 L·min-1 of 21% O2 
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3. Patent upper airway, 0.25 L·min-1 of 100% O2 
4. Patent upper airway, 5 L·min-1 of 100% O2 delivered nasally 
(classical apnoeic oxygenation) 
5. Patent upper airway, 70 L·min-1 of 100% O2 delivered nasally 
(HFNO) 
The outcome data collected were: (i) the time from the start of 
apnoea until arterial O2 saturation (SaO2) reaches 90%, (ii) the rate of 
hypoxaemia progression from SaO2 90% to 50%, (iii) the time from 
the start of apnoea until the CO2 partial pressure in arterial blood 
(PaCO2) reach 11 kPa, and (iv) the PaCO2 rate of rise during the 30 
Table 5.1. The physiological characteristics used to configure the 
virtual subjects 
Subjects 
BMI weight VT RR FRC* VO2 VCO2 
kg/m2 kg ml b/min L ml/min ml/min 
1 24 70.0 420 12.0 3.0 241 193 
2 27 76.8 415 12.5 2.8 250 200 
3 32 89.3 410 13.0 2.7 269 215 
4 37 102.0 400 14.0 2.5 288 230 
5 42 113.0 390 15.5 2.0 304 243 
6 47 134.6 385 17.0 1.9 336 267 
7 52 139.7 375 18.0 1.8 343 274 
8 57 152.0 365 19.0 1.8 361 289 
BMI, body mass index; VT, tidal volume; RR, respiratory rate (breath·min-1); FRC, 
functional residual capacity; VO2, oxygen consumption; VCO2, carbon dioxide 
production. 
* FRC value prior to anaesthesia induction 
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minutes of apnoea. These parameters were collected every five 
milliseconds. The modelling and simulations were conducted using 
Matlab software version R2018a (MathWorks Inc., MA, USA). 
5.5 Results 
5.5.1 Validation results 
Numerous simulations with various values of cardiogenic 
oscillations pressure and the number of alveoli affected by this 
pressure have been conducted. A cardiogenic oscillations pressure 
value of 2.5 cmH2O affecting 60% of alveoli was found to best fit the 
oxyhemoglobin desaturation as well as the PaCO2 rate of increase, as 
shown in Table 5.2 and Table 5.3. Therefore, all subsequent 
simulations were performed using a cardiogenic oscillation pressure 
value of 2.5 cmH2O affecting 60% of alveoli. The output data from our 
current model displays notable comparability against the studies used 
for validation. 
Table 5.2. Results of the current version model output in relation 




SaO2 = 50% 
PaCO2 
increase 
 (min) (kPa·min-1) 
Hardman et al 
[142] 
open 66.33 0.43 
close 8.22  
Model output 
open 66.93 0.43* 
close 8.10  
SaO2, arterial oxygen saturation; PaCO2, partial pressure of CO2 in arterial blood 




Table 5.3. Results of the current version model output in relation 
to the study of Heard et al. [135] 
 
FiO2 insufflation 
Time (min) to  
SpO2 = 95% 
Heard et al 
[135] 
0.21 No 4.93 
1.0 10 L·min-1 12.50 
Model output 
0.21 No 4.43 
1.0 10 L·min-1 12.47 
FiO2, the fraction of inspired oxygen; SpO2, pulse oximetry. 
5.5.2 Hypoxaemia 
All the simulated interventions have been shown to influence the 
timing in which the hypoxaemia occurs. The time from the start of 
apnoea until SaO2 drop to 90% is summarised in Table 5.4. 
With respect to airway obstruction, relieving the obstruction of 
the upper airway delays hypoxaemia by about one minute, while the 
airway is exposed to ambient air (i.e. 21% O2). The provision of 100% 
O2 demonstrated a substantial benefit to delaying hypoxaemia, 
especially in the non-obese subjects. Insufflating 5 L·min-1 of pure O2 
(i.e. classical apnoeic oxygenation) did not show to provide an 
additional delay in hypoxaemia onset in obesity, as compared with no 
insufflation. Compared to subjects receiving classical apnoeic 
oxygenation, HFNO provided additional delay to significant 
hypoxaemia (SaO2 90%). 
Although hypoxaemia did not occur in the virtual subject with 
BMI 24 kg·m-2 while receiving (i) 100% O2, (ii) classical apnoeic 
oxygenation and (iii) HFNO within the apnoea period, at the end of 
apnoea (minute 30), his SaO2 was 94%, 96% and 99% while receiving 
these interventions, respectively. In the same way, the virtual subject 
with BMI 27 kg·m-2 did not develop hypoxaemia; similarly, his SaO2 
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was 93% and 99% while receiving classical apnoeic oxygenation and 
HFNO, respectively. 
Table 5.4. The time (in minutes) from the start of apnoea until SaO2 














1 24 6.47 7.98 NR NR NR 
2 27 6.21 7.61 30.00 NR NR 
3 32 4.08 5.11 13.36 13.45 20.36 
4 37 3.67 4.77 12.55 12.50 17.19 
5 42 3.53 4.26 11.76 11.75 13.41 
6 47 3.09 3.88 10.78 10.77 12.02 
7 52 3.01 3.75 10.55 10.55 11.58 
8 57 2.88 3.56 10.03 10.03 10.86 
SaO2, arterial oxygen saturation; HFNO, high-flow nasal oxygen; NR, not reached during 
the 30 minutes of apnoea 
The various interventions have demonstrated to affect also the 
acceleration of the O2 desaturation after hypoxaemia has occurred. 
Table 5.5 summarises the mean rate of hypoxaemia progression 
expressed as a percentage drop from SaO2 90% to 50%. Across all 
simulated interventions, the life-threatening hypoxaemia (i.e. SaO2 
50%) was reached faster as BMI increases. The fastest rate of 
hypoxaemia acceleration was observed during airway obstruction 
ranging approximately from 20 to 30 %·min-1. Compared to airway 
obstruction, opening the airway to room air slowed the hypoxaemia 
acceleration by approximately 7 %·min-1 in all subjects. The provision 
of 100% O2 further slowed hypoxaemia by about 10 %·min-1 in obesity. 
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Classical apnoeic oxygenation did not provide any further reduction 
in the hypoxaemia progression. As compared to classical apnoeic 
oxygenation, HFNO slowed the progression of hypoxaemia. 
Table 5.5. The mean rate of hypoxaemia progression in (%·min-1) 













1 24 20.7 13.1 NR NR NR 
2 27 21.7 13.8 NR NR NR 
3 32 25.3 19.3 7.9 8.2 3.8 
4 37 27.8 21.0 9.2 9.2 6.2 
5 42 28.2 21.6 11.3 11.2 9.8 
6 47 30.5 23.3 12.6 12.4 11.2 
7 52 30.3 23.4 12.9 13.1 11.5 
8 57 30.8 24.0 13.8 13.9 12.5 
HFNO, high-flow nasal oxygen; NR, not reached during the 30 minutes of apnoea 
5.5.3 Hypercapnia 
The PaCO2 mean rate of increase in the eight virtual subjects 
undergoing all simulated interventions is displayed in Table 5.6. The 
PaCO2 rate of increase was observed to be proportionally related to 
BMI. This could be anticipated as the CO2 production is increased as 
O2 consumption increases, which is the case in obesity. 
Compared to room air, the provision of pure O2 increased the 
CO2 mean rate of rise. However, in severe obesity (BMI ≥ 42 kg·m-2), 
the 100% O2 is observed to not increase the CO2 rate of rise. The 
classical apnoeic oxygenation had minimal effect of the CO2 rate of 
76 
 
rise in all subjects. Among all interventions, HFNO achieved the lowest 
PaCO2 rate of increase in all subjects. 
Table 5.6. The PaCO2 mean rate of increase in (kPa·min-1) in the 












1 24 0.76 0.45 0.60 0.56 0.27 
2 27 0.80 0.44 0.63 0.60 0.28 
3 32 1.18 0.66 0.85 0.84 0.80 
4 37 1.55 0.71 0.89 0.88 0.85 
5 42 1.57 0.94 0.93 0.92 0.90 
6 47 1.90 1.06 1.05 1.02 0.94 
7 52 1.93 1.10 1.07 1.07 0.95 
8 57 1.98 1.19 1.14 1.13 0.96 
HFNO, high-flow nasal oxygen 
The time from the start of apnoea until the occurrence of 
significant hypercapnia (i.e. PaCO2 11 kPa) is presented in Table 5.7. 
As compared to classical apnoeic oxygenation, HFNO was observed 
to delay the occurrence of significant hypercapnia by 5.4 min and 4.9 
min in the subjects with BMI 24 and 27 kg·m-2, respectively, while the 
time difference was less than 30 seconds in the obese subjects. 
Interestingly, despite the similar values of CO2 at the end of 
apnoea in obesity, the shape of the PaCO2 curve of the severely obese 
subjects (i.e. BMI 47, 52 and 57 kg·m-2) is observed to behave 
differently. For instance, as compared to 21% O2, the provision of pure 
O2 delayed the sharp increase in the slope of the curve, as highlighted 
by red arrows in Figure 5.1. In the subject with BMI 42 kg·m-2, the 
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administration of pure O2 prevented the appearance of this abrupt rise 
of the slope throughout the allocated apnoea time. 
Table 5.7. The time (in minutes) from the start of apnoea until the 
arterial partial pressure of CO2 (PaCO2) reaches 11 kPa, in the eight 













1 24 8.00 9.79 9.42 9.63 15.04 
2 27 7.63 9.19 8.86 9.04 13.92 
3 32 7.60 7.50 6.85 6.88 7.31 
4 37 7.22 7.03 6.38 6.38 6.68 
5 42 7.08 6.81 5.95 5.95 6.08 
6 47 6.50 6.24 5.37 5.37 5.47 
7 52 6.81 6.15 5.23 5.23 5.31 
8 57 6.15 5.88 4.95 4.96 5.02 






Figure 5.1. Time courses of PaCO2 of all subjects while receiving 21% oxygen (left), 
100% oxygen (right) and HFNO (bottom). The arrows indicate the increase in the slope. 
The vertical dashed line represents the start of apnoea. 
5.6 Discussion 
5.6.1 Main results 
To my knowledge, this is the first study that thoroughly 
investigated apnoeic gas exchange during various interventions such 
as complete obstruction of the upper airway, patent airway that is 
exposed to room air and 100% O2, classical apnoeic oxygenation and 
THRIVE, using computational modelling in virtual subjects with a wide 
spectrum of BMI (i.e. obesity). The results suggest that HFNO offers a 
significant delay before dangerous and life-threatening hypoxaemia 
and hypercapnia occurs, though with reduced benefits as BMI 
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increases. The finding demonstrated that relieving the upper airway 
obstruction delays hypoxaemia by about a minute. The provision of 
pure O2 substantially extends the non-hypoxic apnoea time, especially 
in the non-obese subjects. Classical apnoeic oxygenation seems to 
not provide any additional gas exchange benefit compared to the sole 
provision of 100% O2. 
5.6.2 Relation to previous studies 
Regarding obstructed-airway apnoea, the present study finding 
is in agreement with Cheun and Choi [147]. This study found a 6.5 min 
to reach SaO2 of 90% (in the virtual subject with BMI 24 kg·m-2), while 
Cheun and Choi [147] found a 7.5 min to reach 90% in their subjects 
who had a mean BMI of 20 kg·m-2. 
The safe apnoea time in the virtual subject with BMI 27 kg·m-2 
(while receiving classical apnoeic oxygenation) is not consistent with 
Rajan et al. [124]. They found a 5.8 min to reach SpO2 of 90% while 
the SaO2, in the corresponding virtual subject, did not reach 90% 
throughout the 30 min of apnoea. The discrepancy may be due to the 
removal of the facemask (source of apnoeic oxygen) to evaluate the 
grade of the laryngeal view. 
The clinical studies that examined HFNO in obesity are lacking. 
However, Gustafsson and co-workers [51] examined the effects of 
HFNO on gas exchange during apnoea in 18 subjects with normal 
BMI, eight overweight and four mildly obese subjects in their case 
series study. The findings of the current study are in partial agreement 
with their findings. For instance, all the lean subjects had a SpO2 ≥ 
98% during the entire apnoeic periods, which is consistent with the 
current study’s finding. In the overweight population, two subjects with 
BMI 26 and 28 kg·m-2 had a SpO2 of 99% at the end of their apnoea 
that lasted ≥25 minutes. The in-silico subject with BMI 27 kg·m-2 of this 
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study also had a SaO2 of 99% at the end of the apnoea time. In the 
obese population, the authors reported that a subject with a BMI of 
32.2 kg·m-2 had a SpO2 of 91% after 21 minutes of apnoea. The in-
silico subject with BMI 32 kg·m-2 here had a SaO2 of 88% at the 
corresponding apnoea time (i.e. 21 min). A justification for this 
difference may be due to the longer pre-oxygenation time applied in 
their study (specified as at least 3 min) as compared to 2 minutes in 
the present study. Interestingly, the researchers also reported that 
another subject with identical BMI (i.e. 32.2 kg·m-2) had a longer 
apnoea time of 29 minutes (compared to 21 min) and a higher SpO2 
100% (compared to 91%). 
These differences support the multifactorial causation and or 
association that may exist between obesity and hypoxaemia during 
apnoea. A few potential factors that may explain this discrepancy are 
the variation in the FRC, O2 consumption and the degree of airway 
patency. Regarding the hypercapnia, in the study of Gustafsson and 
co-workers [51], a detailed analysis of their individual data revealed 
that the highest values of CO2 rate of increase were mostly from non-
obese subjects. 
On the contrary, in the four obese subjects, their CO2 rate of rise 
was actually less than the reported mean value (i.e. 0.24 kPa·min-1), 
except for one patient that had a rate of 0.29 kPa·min-1. This suggests 
that the CO2 rate of increase may not be purely explained by the 
bodyweight, but other factors may play a role in the hypercapnia 
development during apnoea. The model data of this investigation for 
the CO2 rate of rise are comparable with the lean and the overweight 
subjects, but not with the obese subjects. 
The data reported by Gustafsson and co-workers [51] show that 
eight out of the eighteen (44%) lean subjects had a PaCO2 rate of rise 
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that is equal to or higher than the overall mean rate (i.e. ≥0.24 kPa·min-
1) of the entire cohort, while only one out of the four (25%) obese 
subjects had that value. Furthermore, four of the lean subjects had a 
PaCO2 rate of rise of ≥0.30 kPa·min-1, where none of the obese 
subjects had a PaCO2 rate of rise of ≥0.30 kPa·min-1. Since the authors 
did not measure the metabolic status (e.g. CO2 production) of the 
subjects, it is difficult to draw conclusions, but at least this observation 
may suggest that predicting the CO2 clearance based on the 
bodyweight is not currently attainable. 
This study’s findings were also comparable to Lyons and 
Callaghan [125] case series. In their study, there was no incidence of 
hypoxaemia in the non-obese subjects with BMI ≤25 kg·m-2, which is 
in agreement with this study’s findings. Regarding obesity, the 
researchers recruited two mildly obese subjects with almost identical 
BMI (32.7 and 32.8 kg·m-2) that had a non-consistent trend. The first 
subject had a SpO2 of 93% at 30 min of apnoea, while the other 
subject had a SpO2 of 87% only at 13 min of apnoea. The 
corresponding in-silico subject here with BMI 32 kg·m-2 had a 20 min 
of apnoea with a SaO2 of 90%. The authors mentioned that O2 de-
saturation was reversed by opening the airway and increasing the flow 
rate from 80 to 120 L·min-1. Therefore, this O2 desaturation might be 
caused by some degree of airway obstruction rather than the 
inefficiency of the HFNO. 
The present study also shows a partial agreement with the 
finding reported by Baraka and co-workers [137]. The authors 
randomised morbidly obese patients to 5 L·min-1 via nasopharyngeal 
insufflation or no insufflation. All the subjects in the study group 
completed the entire allocated apnoea period (i.e. 4 min) with SpO2 of 
100% except one patient whose BMI was 65 kg·m-2, where the control 
group had a 2.4 min mean time to reach SpO2 of 95%. The virtual 
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subject with BMI 42 kg·m-2 that correspond to the study group had 
100% at the fourth minute of apnoea, but the virtual subject with BMI 
42 kg·m-2 that correspond to the control group had 3.9 minutes to 
reach a SpO2 of 95%. 
5.6.3 Additions to the knowledge of the subject 
This work provides a quantification of the time in which 
dangerous and life-threatening hypoxaemia and hypercapnia develop 
in diverse conditions that clinicians may encounter during an airway 
management crisis. Additionally, the effects of HFNO on gas 
exchange during apnoea in several obese populations were examined 
for the first time. 
Furthermore, the finding of this study in which the classical 
apnoeic oxygenation provides no additional gas exchange benefit 
over the sole provision of 100% O2 may support the current 
physiological understanding of the mechanism of apnoeic 
oxygenation. Unlike HFNO, insufflating low-flow O2 would not affect 
the transairway pressure (PTA), thus not influencing the mass inflow. I 
would argue that the superiority (in terms of oxygenation) of HFNO 
over classical apnoeic oxygenation may be due to a few reasons. 
Firstly, HFNO can increase the PTA (the pressure gradient between the 
airway opening and the alveoli) via increasing the pharyngeal 
pressure [189, 193, 210], thus entraining a higher amount of gas (e.g. 
O2) inflow to the alveoli. Secondly, HFNO may increase lung volume 
[211] hence pulmonary O2 reservoir by the effect of the positive 
pressure associated with the high flow. Finally, HFNO washout the 
CO2 in the anatomical deadspace [212] and replace it with 100% O2 
in which the mass inflow will carry and replenish continuously. 
Regarding the superiority of HFNO over classical apnoeic 
oxygenation to achieve apnoeic ventilation (i.e. increase CO2 
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clearance), our research group has investigated HFNO and suggested 
a few key responsible mechanisms. These mechanisms include the 
augmentation of gas mixing in the anatomical dead space, the micro-
ventilation induced by cardiogenic oscillations and the pharyngeal 
pressure oscillation. Another research group [213] has shown that 
HFNO produces higher CO2 clearance than classical apnoeic 
oxygenation, approximately from 25 to 55 ml·min-1, that is induced by 
the same stroke volume (i.e. 40 ml) of cardiac oscillations. 
5.6.4 Strengths and weakness of the study 
Using the high-fidelity computational model allowed the 
investigation of gas exchange during fatal conditions (e.g. severe 
hypoxaemia) that maybe not feasible clinically nor ethically. On the 
other hand, a limitation of this study is that the model behaviour and 
outputs may not always be reliable during extreme situations, as it has 
not been validated in some of these scenarios (e.g. airway obstruction 
and obesity). Additionally, the study was limited by the lack of 
sufficient clinical and physiological data of obese subjects undergoing 
HFNO during apnoea. This has prevented the validation of the model 
in this area and warrant caution in generalising the preliminary results. 
Part of the credibility of research findings is based on how 
representative is the sample to the studied population in terms of 
characteristics. Robust samples are large enough to represent the 
population but small enough to be measured easily and economically. 
The sample size of this study is small.  However, it is worth mentioning 
that our model can individually configure the cardiopulmonary system, 
even the micromechanics, at the alveolar and capillary level [183]. It 
is quite reproducible and reliable [188]. Therefore small, yet, carefully-




5.6.5 Future studies 
Hypercapnia and the subsequent acidemia remains a major 
limiting factor for the clinical use of prolonged apnoeic oxygenation. 
Although several mechanisms were suggested to be important [189, 
213], the exact factors that affect the CO2 clearance during apnoea 
are not completely understood. 
Future physiological clinical research studies that examine the 
metabolic and the cardiopulmonary parameters during apnoeic 
oxygenation (e.g. THRIVE) may facilitate a better understanding and 
enable an analysis of the mechanisms involved and potentially 
establishing a relationship. 
5.6.6 Conclusions 
The results suggest that the patency of the upper airway, high 
O2 concentration, and the use of HFNO during apnoea delays the 
onset and the progression rate of hypoxaemia. The HFNO was 
superior to the classical apnoeic oxygenation in terms of extending 
the safe apnoea time and increasing the CO2 clearance, though with 
reduced benefits as BMI increases. 
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Chapter 6: High-flow nasal oxygen delays hypoxaemia 
during apnoea in virtual obese subjects  
6.1 Abstract 
Prolonging safe apnoea time is useful when anaesthetising 
patients at risk of rapid deoxygenation and patients who have 
increased difficulty with airway management. Obesity appears to be 
associated with both of these risk factors. This study quantified the 
effects of three treatments during apnoea (i) no supplemental O2 
(control), (ii) low-flow nasal O2 (low-flow), (iii) high-flow nasal O2 
(HFNO) using a computer simulation of a bank of virtual obese 
subjects (n=90). Both forms of O2 administration delayed hypoxaemia. 
HFNO outperformed low-flow O2 in delaying hypoxaemia. 
6.2 Introduction 
As previously mentioned, the prevalence of obesity is continuing 
to increase worldwide. More than a quarter of the UK adult population 
are obese [2]. The combined effect of obesity [91], general 
anaesthesia [96], and supine position [32] on reducing the functional 
residual capacity (FRC), i.e. O2 reserve in the lungs, is dramatic, 
causing a rapidly progressing hypoxaemia following the induction of 
general anaesthesia. Hypoxaemia can cause organ (e.g. brain) injury. 
Furthermore, obesity is linked with increased O2 consumption [94] and 
is a risk factor for difficult face-mask ventilation, failure of supraglottic 
airways, and difficulty in establishing an emergency surgical airway 
[120]. Thus, obesity is associated with increased complexity in many 
aspects of airway management, while the time available for these 
interventions is shortened. Consequently, extending the non-




As previously stated, the use of HFNO has been shown to extend 
the safe apnoea time in non-obese subjects [50], but its effectiveness 
in obesity remains mostly unquantified. 
In previous computational modelling research (described in 
Chapter 5), the values of physiological parameters of in-silico subjects 
were individually configured based on literature data. To enhance the 
model output, I configured a bank of obese in-silico subjects in which 
their physiological parameters’ values were randomly selected by the 
ICSM model based on values extracted from the literature. This is 
claimed to better represent the variability that exists within the real-
world targeted population. 
6.2.1 Why extending safe apnoea time? 
Prolonged safe apnoea time is not only useful when 
anaesthetising individuals at risk for rapid O2 desaturation (e.g. severe 
obesity) but also during anaesthetising all individuals, as the vast 
majority of difficult airway incidences are unanticipated [214]. The 
difficult airway society 2015 guidelines recommend the use of apnoeic 
oxygenation in high-risk subjects [215]. Additionally, extending the 
safe apnoea time may minimise the repeated tracheal intubation 
attempts and increase the first-attempt intubation success [128]. A 
study collected data of more than 10,000 emergency tracheal 
intubations over ten years period has shown that more than two 
intubation attempts were positively correlated with significantly higher 
rates of complications such as hypoxaemia (70 vs 10.5 %), severe 
hypoxaemia (28 vs 1.9 %), aspiration (13 vs 0.8 %), and cardiac arrest 
(11 vs 0.7 %) [216].  
Another critical reason to extend safe apnoea time is to 
decrease the likelihood of severe hypoxaemia because the incidence 
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of cardiac arrest has been strongly (83%) associated with severe 
hypoxaemia (SpO2 < 70%) [16]. 
6.3 Aim of the study 
This study aims to compare the effects of three O2 treatments 
(HFNO, low-flow nasal O2, and no supplemental O2) during apnoea on 
gas exchange in a bank of obese virtual subjects.  
6.4 Hypothesis 
The delivery of O2 during apnoea is hypothesised to delay safe 
apnoea time in obesity, and the use of HFNO is claimed to further 
increase the safe apnoea time with respect to classical apnoeic 
oxygenation. 
6.5 Methods 
In this study, the Interdisciplinary Collaboration in Systems 
Medicine (ICSM) simulation suite was used, based upon the 
Nottingham Physiology Simulator [217]; it includes high-fidelity, 
integrated, computational models of several organ systems including 
respiratory and cardiovascular. 
The ICSM is described in detail in Chapter 4. The design of this 
study is a crossover computational modelling experiment, where 
every in-silico subject undergoes all the simulated interventions. 
Conducting such a study on the clinical level is difficult and not ethical 
due to exposing real subjects to long durations of apnoea and life-
threatening levels of hypoxaemia. Therefore, I chose to use this 
methodology because it allows a meticulous observation of the 
dynamic behaviour of the pulmonary gas exchange during apnoea. 
88 
 
6.5.1 Obesity data extraction from literature 
Relevant parameters’ values were required in order to configure 
the in-silico subjects appropriately. Therefore, a thorough literature 
search for clinical and physiological studies that examined obese 
individuals was performed. The targeted variables were mainly 
pulmonary and cardiovascular parameters such as respiratory rate, 
tidal volume, functional residual capacity, heart rate, cardiac output, 
O2 consumption, anatomical shunt, and physiological deadspace. The 
search aimed to collect data only from obese subjects that are 
otherwise healthy. 
A coding file has been scripted using Matlab software to create 
a bank of in-silico obese subjects. The values that were used to 
configure the physiological and metabolic parameters of the in-silico 
subjects were selected randomly by the computer simulator. 
However, the selected values are within pre-set ranges of values that 
are based on literature data. 
6.5.2 Simulation of three different protocols 
Part of the protocol used to conduct the study reported in 
Chapter 5 was implemented in this chapter. In particular, the gas-
exchange efficiency of low-flow apnoeic oxygenation and high-flow 
nasal O2 (HFNO) was compared in obesity during apnoea. 
Three groups (i.e. obese I, II and III) of in-silico obese subjects 
were created, and each group consisted of 30 subjects. All groups 
received a pre-oxygenation of 100% O2 for two minutes. The FRC was 
reduced by 50% to simulate the impact of the induction of general 
anaesthesia in obese individuals [96]. However, the baseline FRC 
values were variable. 
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Next, apnoea commenced and persisted until the SaO2 reached 
50%, while the upper airway remained patent. All the subjects (n=90) 
underwent the following interventions: 
1. Control intervention: Ambient gas without supplemental O2; 
2. Low-flow intervention: 5 L·min-1 of cold (22° C) and dry O2 
delivered nasally; 
3. HFNO intervention: 70 L·min-1 of heated (37° C) and 
humidified O2 delivered via the nose with oropharyngeal 
pressure oscillations of 2 cmH2O at 70 Hz. 
In all interventions, the cardiac oscillations generated a pressure 
of 2.5 cmH2O affecting 60% of the alveoli [189]. To predict O2 
consumption (VO2) in obesity, I used White and co-workers [118] 
formula. The equation is 𝑉𝑂2 = 138 + (1.47 ∗ 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡). 
6.5.3 Outcome measures 
The outcome variables were: (i) the time from the start of apnoea 
until SaO2 reaches 90% (i.e. significant hypoxaemia) and 50% (i.e. life-
threatening hypoxaemia), (ii) the rate of decrease of SaO2 from 90% 
to 50%, (iii) the time from the start of apnoea until PaCO2 reach 8 kPa 
(i.e. significant hypercapnia) and 16 kPa (i.e. severe hypercapnia), (iv) 
the rate of increase of PaCO2 during apnoea. Variables such as PaO2, 
SaO2 and PaCO2 were recorded at an interval of 5 milliseconds. Model 
simulations were run using a 64-bit Intel Core i3 3.7 GHz Windows 10 
University of Nottingham computer, running Matlab version 




6.6.1 Data extraction from the literature and configuration 
of the bank 
The consort flow diagram in Figure 6.1. highlight the number of 
subjects that were involved from the screening to the inclusion 
process. Out of 793 subjects, individual data of 115 obese subjects 
were used from eight clinical studies [89, 96, 101, 117-119, 218, 219]. 
The data were pooled all together in an excel spreadsheet then 
arranged according to the body weight. Next, the data were divided 
into three levels of obesity severities termed Obese I, II, and III. The 
bodyweight of Obese I is from 79 to 115 kg, Obese II is from 116 to 
136 kg, and Obese III is from 137 to 205 kg. Table 6.1 summarises the 
actual values of the physiological parameters that were extracted from 




Figure 6.1. Consort flow diagram of the subjects from screening to inclusion.  
Subjects screened 
(n = 793) 
Excluded (n = 128) 
- Not obese subjects, 
BMI < 30 kg·m2 
Obese subjects 




(n = 660) 
 
Excluded (n = 5) 
- Subjects had obesity-
hypoventilation 
syndrome (n=4) 
- A subject had an odd 
value (n=1) 
Subjects included 
(n = 115) 
 
Excluded (n = 545) 
- Individual data of 
the subjects were 
not reported  
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Table 6.1. The baseline characteristics of the three levels of obesity obtained from eight clinical studies [89, 96, 101, 117-119, 218, 219]. 
  




  kg kg·m-2 L breath·min-1 L ml·min-1 beat·min-1 ml L·min-1 % ml 
Obese I 
n=37 
mean (SD) 103 (11) 39 (5) 0.62 (0.17) 15.7 (6.3) 2.24 (0.9) 289 (16) 91 (14) 79 (17) 7 (1) 5.5 (2.0) 148 (73) 




** [101] [101] 
[96, 101, 
218] 
[118] [119] [119] [119] [218] [218, 219] 
Obese II 
n=36 
mean (SD) 125 (6) 44 (5) 0.65 (0.2) 17.6 (4) 2.39 (0.69) 322 (9) 75 (4) 75 (4) 7 (1) 5.2 (4.1) 189 (57) 





** [101, 117] [101, 117] 
[89, 96, 101, 
117, 218] 
[118] [117, 119] [119] [119] [218] [218, 219] 
Obese III 
n=42 
mean (SD) 158 (18) 54 (8) 0.63 (0.2) 19.3 (7) 2.39 (0.72) 375 (28) 80 (12) 110 (10) 9 (1) 4.0 (1.9) 200 (103) 





** [101, 117] [101, 117] 
[89, 96, 101, 
117, 218] 
[118] [117, 119] [119] [119] [218] [218, 219] 
BMI, body mass index; VT, tidal volume; RR, respiratory rate; FRC, functional residual capacity; VO2, oxygen consumption; HR, heart rate; SV, stroke volume; CO, cardiac output; QS/QT Anat, 
anatomical shunt; VDphys, physiological deadspace. 
*values obtained during wakefulness 
** BMI is a calculated variable 
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Due to the variability of the extracted data, the interquartile 
range was implemented as it appeared a better representation of the 
obesity level than the full range. Table 6.2 lists the values’ ranges that 
were entered in the computer simulator to create the bank of the 
obese in-silico subjects.  
Table 6.2. The parameters’ values used to configure the bank  
 Obese I Obese II Obese III 
Parameter (unit) [min-max] [min-max] [min-max] 
weight (kg) [79-115] [116-136] [137-205] 
VT (L) [0.48-0.65] [0.45-0.76] [0.44-0.80] 
RR (breath·min-1) [11.2-15.6] [16.5-19.7] [15.2-20.6] 
FRC (L) [1.1-3.7] [1.3-3.4] [1.3-3.3] 
VO2 (ml·min-1) [254-307] [308-337] [339-439] 
HR (beat·min-1) [85-103] [72-78] [66-88] 
QS/QT Anat (%) [4-6] [1-13] [3-5] 
VDphys (ml) [120-150] [124-216] [108-235] 
VT, tidal volume; RR, respiratory rate; FRC, functional residual capacity; VO2, oxygen 
consumption; HR, heart rate; QS/QT Anat, anatomical shunt; VDphys, physiological 
deadspace. 
The baseline characteristics of the 90 virtual obese subjects that 
were randomly configured by the computer simulator are presented 
in Table 6.3.  
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Table 6.3. The baseline characteristics of the three levels of 
obesity generated by the computer simulator 
 
Obese I Obese II Obese III 
Parameter (unit) n=30 n=30 n=30 
Weight (kg) 97±10 126±5 171±20 
Tallness (m) 1.63±0.1 1.67±0.1 1.63±0.1 
BMI (kg·m-2) 37 45 64 
PaO2 (kPa) 12.5±0.7 12.0±2.0 12.1±1.2 
PaCO2 (kPa) 4.7±0.5 4.1±0.6 4.7±0.9 
SaO2 (%) 98±0.5 97±1.0 97±1.0 
VT (L) 0.59±0.44 0.65±0.08 0.65±0.11 
RR (breath·min-1) 13.3±1.3 18.1±0.9 18.2±1.6 
HR (beat·min-1) 94±6 75±2 76±6 
CO (L·min-1) 7.4±0.9 7.5±0.3 9.1±0.5 
FRC (L) 2.87±0.68 2.57±0.13 2.43±0.19 
VO2 (ml·min-1) 283±14 325±8 390±31 
VDphys (ml) 132±9 160±28 172±31 
QS/QT Anat (%) 5±0.6 7±4 4±0.6 
BMI, body mass index; VT, tidal volume; RR, respiratory rate; FRC, functional residual 
capacity; CO, cardiac output; VO2, oxygen consumption; HR, heart rate; QS/QT Anat, 
anatomical shunt; VDphys, physiological deadspace. 
Reported data is mean±SD 
6.6.2 Simulations results 
A total of 270 simulations have been performed. Their results are 
summarized in two tables, Table 6.4 (results related to hypoxaemia) 
and Table 6.5 (results related to hypercapnia). Compared to the 
control intervention, the provision of supplemental O2 during apnoea 
substantially delayed hypoxaemia, more than tripling the duration of 
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safe apnoea in all groups. HFNO provided a further extension of the 
safe apnoea time. 
Table 6.4. The onset and the progression of hypoxaemia of all the 
in-silico subjects in all the simulated interventions  
  
Time from the start of 
apnoea until SaO2 
reached 
SaO2 rate of 
decrease 
from 90% to 
50% 
  90% 50% 
Group Intervention min min %·min-1 
 Control 4.7 (0.4) 6.9 (0.5) 18.6 (1.6) 
Obese I Low-flow 16.3 (1.8) 21.0 (2.2) 8.6 (0.9) 
 HFNO 19.1 (2.3) 25.3 (3.2) 6.6 (1.0) 
 Control 4.5 (0.3) 6.4 (0.3) 21.3 (1.2) 
Obese II Low-flow 15.4 (2.1) 20.2 (2.2) 8.6 (1.1) 
 HFNO 18.3 (2.6) 24.4 (3.2) 6.7 (1.1) 
 Control 3.7 (0.4) 5.3 (0.5) 25.7 (2.4) 
Obese III Low-flow 13.6 (2.1) 17.4 (2.4) 10.6 (1.3) 
 HFNO 15.2 (2.5) 19.8 (3.0) 9.0 (1.5) 
Reported data is mean (SD). SaO2, oxygen saturation in arterial blood, HFNO, high-flow 
nasal oxygen. 
The control intervention was associated with the lowest PaCO2 
rate of increase, followed by HFNO and low-flow O2, respectively, in 
all obesity severities. However, the time taken for hypercapnia to 




Table 6.5. The onset and the progression of hypercapnia of all the 
in-silico subjects in all the simulated interventions 
  
Time from the start of 




  8 kPa 16 kPa 
Group Intervention min min kPa·min-1 
 Control 4.5 (0.7) - 0.71 (0.07) 
Obese I Low-flow 4.4 (0.5) 12.6 (1.2) 0.99 (0.09) 
 HFNO 4.5 (0.6) 13.1 (1.3) 0.92 (0.09) 
 Control 4.8 (0.8) - 0.75 (0.07) 
Obese II Low-flow 4.6 (0.6) 12.6 (1.1) 1.00 (0.08) 
 HFNO 4.7 (0.7) 13.1 (1.2) 0.94 (0.08) 
 Control 4.3 (0.7) - 0.80 (0.08) 
Obese III Low-flow 4.2 (0.7) 11.4 (1.4) 1.09 (0.11) 
 HFNO 4.2 (0.7) 11.7 (1.5) 1.05 (0.11) 
Reported data is mean (SD). PaCO2, partial pressure of carbon dioxide in arterial blood, 
HFNO, high-flow nasal oxygen. 
- In the control intervention, the apnoea was terminated, and the PaCO2 of 16 kPa was 
not reached due to meeting the study endpoint of SaO2 of 50%. 
6.7 Discussion 
6.7.1 Main results 
HFNO has been shown to be consistently more effective than 
low-flow nasal O2 in terms of delaying significant and life-threatening 
hypoxaemia in all obesity severity levels. However, the impact of 
HFNO on extending the safe apnoea time was noticed to attenuate as 
obesity severity increases. The benefits of HFNO may be attributed to 
(i) higher mass inflow due to higher trans-airway pressure gradient 
induced by the flow-dependent positive pressure in the pharyngeal 
region, (ii)  more lung volume induced by HFNO, and (iii) the 
enhanced CO2 clearance allows O2 to replace CO2 molecules, which 
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may help maintain a positive gradient between PAO2 and PaO2 thus 
enabling longer duration of apnoeic O2 diffusing into the bloodstream. 
Although the time to reach PaCO2 of 8 kPa was similar in all the 
interventions, the PaCO2 rate of increase in the control intervention 
has been observed to be consistently lower relative to the classical 
apnoeic oxygenation and HFNO interventions. Compared to the 
classical apnoeic oxygenation, HFNO was always associated with a 
lower PaCO2 rate of increase, leading to slight (subclinical) delays to 
develop severe hypercapnia (i.e. PaCO2 of 16 kPa). 
A possible explanation for the reduced efficiency of apnoeic 
ventilation during HFNO might be related to the visceral adipose 
tissues in obesity that may reduce the ability of cardiogenic 
oscillations to move gas within the respiratory system, which is a vital 
component of apnoeic ventilation [213]. An additional burden is that 
obesity is associated with noticeably increased CO2 production. 
6.7.2 Relation to previous studies 
The present study’s finding, which revealed that the use of 
HFNO extends the safe apnoea time more than low-flow apnoeic O2 
even in severely obese subjects, is in agreement with the finding’s 
reported by a recent RCT [220]. The trial was conducted on 40 
morbidly obese (BMI ≥ 40 kg·m-2) patients undergoing elective 
surgery. The authors found that the safe apnoea time (i.e. SpO2 ≤ 
95%) was 4.3 and 3.0 minutes in the groups that received HFNO (60 
L·min-1) and the facemask O2 (15 L·min-1), respectively. These values, 
however, are not consistent with the current study’s data. The safe 
apnoea time observed in the current study is considerably higher than 
the cited study. The discrepancy may be related to (i) the efficacy of 
pre-oxygenation may have been suboptimal, (ii) the O2 facemask has 
been removed (i.e. cessation of 100% O2)  to assess airway view, (iii) 
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a decreased degree of airway patency caused by either the reduced 
laryngoscopic force creating a grade III view, or 
nasopharyngeal/retropalatal reduced patency, and finally (iv) the 
development of early intrapulmonary shunt has not been integrated 
into the current study, which may have overestimated the effects of 
both HFNO and low-flow apnoeic O2. 
Another recent double-blinded RCT [221] has revealed that 
apnoeic oxygenation of 15 L·min-1 of O2 resulted in a safe apnoea time 
of 4.4 minutes, which is higher than the safe apnoea time produced 
by the HFNO (60 L·min-1) reported by the previously described RCT 
[220]. This inconsistency could be attributed to methodological 
differences, such as the former trial [220] used a nasal cannulae to 
deliver O2, while the latter [221] used a nasopharyngeal airway, which 
could theoretically guarantee that the O2-rich gas reaches the 
pharynx. Secondly, the subjects who participated in the former study 
[220] are more obese (by about 10 kg·m-2 of BMI) than those who 
participated in the latter [221]. The authors [221] also reported that a 
total of ten obese patients have had reached the alternative endpoint 
of the study (i.e. 8 minutes of apnoea), while their SpO2 values were 
more than 95%, which support the finding of the present study. An 
imperative implication that emerged from these studies confirms the 
crucial importance of maximising the patency of the upper airway, 
especially in obese subjects, as they are at a higher risk to develop 
airway obstruction (due to OSA) than lean subjects. 
6.7.3 Additions to the knowledge of the subject 
The findings of this study offer an in-depth quantitative analysis 
of the effects of three O2 treatments (HFNO, low-flow O2, and no 
supplemental O2) on hypoxaemia and hypercapnia that occur during 
the apnoeic period in a bank of obese virtual subjects. HFNO has been 
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shown to be consistently more effective than low-flow O2 in all obesity 
severity levels. However, the impact of HFNO on extending the safe 
apnoea time was noticed to decrease as obesity severity increases. 
6.7.4 Strengths and weakness of the study 
This study offers a novel and extensive investigation of apnoeic 
oxygenation interventions in a population that are at increased risk for 
rapid desaturation of O2 (i.e. severe obesity). The course of gas 
exchange was tracked and meticulously inspected until the 
occurrence of life-threatening levels of hypoxaemia and hypercapnia 
during a simulated prolonged apnoea, which may not be feasible to 
perform clinically. 
This study was limited by a few issues. First, the extracted data 
from the literature to create the bank did not specify the distribution 
of body fat, which is demonstrated to affect the magnitude of the 
alterations of the pulmonary and thoracic mechanics [97].  
Secondly, although the influence of the induction of general 
anaesthesia on the FRC is assimilated in our model, the arising 
spontaneous development of ‘early’ intrapulmonary shunt as a result 
of the newly-formed atelectasis, that occur shortly post the general 
anaesthesia induction, is not yet incorporated, which may have 
overestimated the benefits of apnoeic oxygenation. Similarly, the 
development of absorption atelectasis due to receiving increased 
levels of inspired oxygen was not incorporated in the model, which 
may, in reality, affect the safe apnoea time. 
6.7.5 Future studies 
I would recommend that future PhD students investigate the role 
of HFNO use during extended apnoea periods in critically ill patients 
suffering from hypoxaemic respiratory failure using computational 
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modelling. The rationale behind this recommendation is because of 
the contradicting findings reported by the ICU and emergency 
department literature [130, 131, 197, 204]. Another reason is to 
evaluate whether HFNO still offers clinical benefits in the presence of 
pulmonary shunting. 
Moreover, another interesting area to research is to determine 
the efficacy of CPAP as an apnoeic strategy. This may be relevant to 
neurocritical care and organ transplantation practice, where apnoea 
testing for the brain death assessment is regularly performed. The 
rationale for this recommendation is that a common method for 
oxygenation during this procedure (intra-tracheal insufflation O2 at 
rates up to 15 L·min-1) has been reported unsafe and led to severe 
complications and fatality [222, 223]. Apnoeic CPAP may be more 
efficacious and safer than this method, though this would need to be 
confirmed by a thorough investigation.  
6.7.6 Conclusions 
The present computational modelling study was designed to 
compare the effects of three O2 treatments (HFNO, low-flow O2, and 
no supplemental O2) on gas exchange in a bank of 90 obese virtual 
subjects. The findings indicate that the use of HFNO during apnoea is 
more effective than non-warmed, non-humidified, low-flow nasal O2 in 
delaying life-threatening hypoxaemia in in-silico patients with all 
severity levels of obesity, though with reduced benefits as the severity 
of obesity increases. HFNO is likely to offer additional safe apnoea 




Chapter 7: High oxygen fraction during airway opening 
is key to effective airway rescue in obese subjects. 
7.1 Disclosure 
This study has been performed during my PhD by our 
multidisciplinary research group and has been published as an 
extended abstract in the IEEE Xplore and indexed in PubMed [224]. I 
was a co-author due to the scientific contribution that I offered, which 
included examining and amending the obese virtual subjects’ 
configuration, as well as reviewing and editing the manuscript. 
7.2 Abstract 
Apnoea is common after induction of anaesthesia and may 
produce dangerous hypoxaemia, particularly in obese subjects. 
Optimal management of airway emergencies in obese, apnoeic 
subjects is complex and controversial, and clinical studies of rescue 
strategies are inherently difficult and ethically-challenging to perform. 
We investigated rescue strategies in various degrees of obesity, using 
a highly-integrated, computational model of the pulmonary and 
cardiovascular systems, configured against data from 8 virtual 
subjects (body mass index [BMI] 24-57 kg·m-2). Each subject received 
pre-oxygenation with 100% O2 for 3 min, and then apnoea with an 
obstructed airway was simulated until SaO2 reached 40%. At that time, 
airway rescue was simulated, opening of the airway with the provision 
of various patterns of tidal ventilation with 100% O2. Rescue using tidal 
ventilation with 100% O2 provided rapid re-oxygenation in all subjects, 
even with small tidal volumes in subjects with large BMI. Overall, 
subjects with larger BMI pre-oxygenated faster and, after airway 
obstruction, developed hypoxaemia more quickly. Our results indicate 
that attempts to achieve substantial tidal volumes during airway 
rescues are probably not worthwhile (and maybe counter-productive); 
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rather, it is the assurance of a high-inspired O2 fraction that will 
prevent critical hypoxaemia. 
7.3 Introduction 
During anaesthesia, patients are often rendered apnoeic; the 
anaesthetist provides a patent airway through airway manipulation, 
facilitating pulmonary ventilation. Failure to manage the airway 
effectively may result in prolonged and potentially lethal apnoea. A 
worst-case scenario results in a “Can’t intubate, can’t oxygenate” 
situation. O2 stores are depleted, and carbon dioxide accumulates 
during apnoea. However, our understanding of the factors affecting 
the progression of these pathophysiological abnormalities in various 
clinical contexts is incomplete.  
Previous clinical investigations have highlighted obesity as an 
important risk factor that may radically change the progression of 
hypoxaemia during apnoea due to reduction of functional residual 
capacity (FRC) in obese patients [96, 225, 226] and higher metabolic 
O2 consumption [227]. Equally, a high body mass index (BMI) and 
associated factors like a short, thick neck and obstructive sleep 
apnoea are recognized predictors for difficult mask ventilation and 
difficult laryngoscopy [228, 229]. However, the optimal management 
of airway emergencies is unclear even in healthy subjects, and the 
optimal management of obese, apnoeic subjects is complex and 
controversial. In vivo studies have been difficult and ethically-
challenging to perform, and thus evidence to inform this issue is 
scarce.  
This paper uses a high-integrated computational modelling of 
cardiovascular and pulmonary systems to evaluate different patterns 
of tidal ventilation achieving re-oxygenation following airway rescue 
(i.e. re-opening). We investigated different degrees of obesity, 
103 
 
examining the rate of progression of hypoxaemia and the impact on 
re-oxygenation following the opening of an obstructed airway and the 
application of various patterns of tidal ventilation. 
7.4 Methods 
7.4.1 Computational Model 
We used the Interdisciplinary Collaboration in Systems Medicine 
(ICSM) suite of physiological simulations that consists of highly-
integrated computational models of the pulmonary and cardiovascular 
systems [217, 230-233]. The model has been widely validated for the 
investigation of pre-oxygenation, apnoea and hypoxaemia in adults, 
[143, 177] parturients [179] and children [234]. 
The model includes a series deadspace volume, 100 
independently-configurable alveolar compartments and 19 in-series 
cardiovascular compartments. The series deadspace (SD) is located 
between the airway and the alveolar compartments, and it is simulated 
as a series of stacked, rigid laminae of equal volume (Nlam). The static 
total volume of the series deadspace is set to 150 ml, and each lamina, 
"𝑗”, has a known fraction ( f  (SD,j)
x
) of gas "𝑥”. The pressure (above 
atmospheric) within each alveolar compartment is described by the 





) − Pext,i             vi>0    for i=0, …, Nalv 
 pi=0          otherwise     Equation 7.1 
In Equation 7.1, p
i
  is the alveolar pressure in cmH2O for the i
th
 
of Nalv alveolar compartments for the given volume of the alveolar 
compartment, v𝑖, in millilitres. Pext,i (per alveolar unit, in cmH2O) 
represents the effective net pressure generated by the sum of the 
effects of factors outside each alveolus. 
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We recently developed and validated additional modules in the 
ICSM simulation suite in order to include: (i) cardiogenic pulsation 
affecting intrathoracic gas spaces, (ii) augmented gas-mixing within 
the conducting respiratory deadspace, (iii) oxygen insufflation into the 
trachea, larynx or supraglottic space and (iv) pharyngeal pressure 
oscillation (e.g. occurring as a result of high-flow nasal oxygen 
administration) [189, 235]. For the purpose of this paper, we used the 
following modules: 
7.4.1.1 Cardiogenic oscillations module 
We described the effect of cardiac oscillations on alveolar 
compartments by the following equation: 
Posc,i=Kosc∙ φ  
for i = 0, .., Nosc          where Nosc ≤ Nalv    
In for i = 0, .., Nosc          where Nosc ≤ Nalv   Equation 7.2 
Posc,i represents the pressure of the heart acting on the alveolar 
compartment 𝑖. This additional pressure, in combination with existing 
pressure values of the alveolar compartments, creates a pressure 
difference between the mouth and the alveolar compartments, across 
which the flow of gas can occur. The parameter Kosc,i is a constant, 
representing the strength of the effect of cardiogenic oscillations on 
alveolar ventilation due to the alveoli being compressed by the heart 
and/or trans-alveolar blood volume. Nosc is the number of alveolar 
compartments that are affected by cardiogenic oscillations and Nalv 
represents the number of alveolar compartments. The function "𝜑” , 
described by a squared half-sine wave, is the ventricular activation 
function, equal to 1 at the peak of systolic contraction and 0 during 
maximal diastolic relaxation. Thus, the final equation (Equation 7.3) 








) − Pext,i − Posc,i  vi>0    for i=0, …, Nalv 
pi=0          otherwise   Equation 7.3 
7.4.1.2 Anatomical deadspace gas-mixing module 
In order to represent the proportion of gas mixing between 
adjacent laminas of the anatomical deadspace, a variable parameter 
("𝜎” ) is introduced to the calculation of f SD,j
x
.  
This new parameter allows various degrees of mixing: "𝜎 “ =1 
would indicate a complete mixing of gases between layers, 
representing the effects of extreme turbulent flow of air, while "𝜎” = 0 
would indicate no mixing of gases. Thus:  
 f  (SD,j)
x = ((1 -σ)∙fSD,j
 x )+  σ ·f  (SD,j+1)
x  where j<Nlam   Equation 7.4 
As it is presented in Equation 7.4,  f  (SD,j)
x
 is the fraction of gas 
"𝑥”  in lamina 𝑗 and  f  (SD,j+1)
x
 is the fraction of gas x in the next lamina. 
7.4.2 Virtual subjects, protocol and data 
For this study, we created eight virtual (in-silico) subjects with 
BMI between 24 and 57 kg·m-2, describing various degrees of obesity. 
Physiological variables relating to tidal ventilation, respiratory rate, 
FRC and oxygen consumption were calculated for each virtual subject 
using data from previously published papers [227, 236-238] and were 
used to configure the ICSM model to create a simulation of each 
patient. The physiological descriptors used are provided in Table 7.1. 
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Table 7.1. Physiological parameters of the virtual subjects 
 BMI weight VT RR FRC VO2 
subject (kg·m-2) (kg) (ml) (breaths·min-1) (l) (ml·min-1) 
BMI 24 24 70.0 420 12.0 3.00 250 
BMI 27 27 76.8 415 12.5 2.87 251 
BMI 32 32 89.3 410 13.0 2.73 269 
BMI 37 37 102.0 400 14.5 2.57 288 
BMI 42 42 113.0 390 15.5 2.06 304 
BMI 47 47 134.6 385 16.5 1.99 336 
BMI 52 52 139.7 375 18.0 1.89 343 
BMI 57 57 152.0 365 19.0 1.80 361 
BMI body mass index; VT tidal volume; RR respiratory rate; VO2 resting oxygen 
consumption; FRC function residual capacity before induction of anaesthesia  
Resting tidal volume was configured as decreased in subjects 
with larger BMI; respiratory rate similarly increased with increasing 
BMI. Resting oxygen consumption (VO2) was configured, as shown in 
Equation 7.5. 
VO2=138 + 1.47 ∙ bodyweight  Equation 7.5 
Where VO2 is expressed in ml min-1, and body weight is 
expressed in kg [227]. During the induction of anaesthesia, the FRC 
was configured as decreasing by 20% in subjects with BMI<30 kg·m-2 
and by 50% in subjects with BMI 32–57 kg·m-2 [237, 238]. 
Each virtual subject underwent pulmonary denitrogenation (i.e. 
pre-oxygenation) during resting, tidal breathing with an inspired 
oxygen fraction (FiO2) of 100% for 3 min. Induction of general 
anaesthesia then occurred, and apnoea commenced. The upper 
airway became obstructed immediately upon loss of consciousness. 
Apnoea continued until the arterial oxygen saturation (SaO2) reached 
40%. At that time, for all virtual subjects, we simulated an airway 
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rescue manoeuvre that consisted of the opening of the airway and 
provision of various patterns of tidal ventilation with 100% oxygen. 
These ventilation patterns simulated varying degrees of success in re-
instituting tidal ventilation; they were: 500 ml min-1 (50 ml x 10 min-1), 
2000 ml min-1 (200 ml x 10 min-1) and 5000 ml min-1 (500 ml x 10 min-
1). 
The following simulation outputs were recorded every 5 msec: 
arterial partial pressure of oxygen (PaO2), the arterial partial pressure 
of carbon dioxide (PaCO2) and SaO2. Model simulations were run 
using a 64-bit Intel Core i7 3.7 GHz Windows 7 personal computer, 
running Matlab version R2018a.v9 (MathWorks Inc. MA, USA). 
7.5 Results 
Figure 7.1 shows the time courses of PaO2 and PaCO2 from the 
start of pre-oxygenation to the end of obstructed-airway apnoea (SaO2 
40%). All subjects showed a rapid increase in PaO2 during pre-
oxygenation; subjects with greater BMI pre-oxygenated more quickly. 
The progression of hypoxaemia during apnoea was consistently 
accelerated by increasing BMI, with the apnoea-time to reach SaO2 
40% in the BMI 57 kg m-2 subject being only 47% of that seen in 
subjects with BMI <30 kg m-2. Carbon dioxide accumulation was 
effectively linear and was slightly slower with increasing BMI.  
Figure 7.2 shows the effect of airway rescue involving airway 
opening and the application of various patterns of tidal ventilation 
using 100% oxygen. Rescuing apnoeic subjects with tidal ventilation 
provided rapid re-oxygenation for all subjects; increasing minute 
volume during rescue provided marginally faster re-oxygenation, but 
even very small volumes of 100% oxygen achieved effective (i.e. life-
preserving) rescue. Post-intervention re-oxygenation was slightly 
slower in subjects with greater BMI. 
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The time from airway rescue to achieving PaO2 8 kPa in the 
various configurations is reported in Table 7.2, representing the 




Figure 7.1. Time-course of PaO2 (upper panel) and PaCO2 (lower panel) during pre-
oxygenation and apnoea with airway obstruction (black curve BMI 24 kg m-2; magenta 
curves: BMI 27–57 kg m-2). All curves end when SaO2 reaches 40%. The vertical, black, 






Figure 7.2. Time-course of PaO2 during pre-oxygenation, apnoea with airway 
obstruction, and rescue with airway opening and tidal ventilation: minute ventilation of 
500 ml min-1 (upper panel), 2000 ml min-1 (middle panel) and 5000 ml min-1 (lower panel) 
(black curve BMI 24 kg m-2; magenta curves: BMI 27–57 kg m-2). The vertical, black, 
dashed line marks airway-opening and rescue tidal ventilation. 
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Table 7.2. Time to reach PaO2 8 kPa following tidal 
ventilation airway rescue 
Subjects 
Minute Ventilation (ml·min-1) 
500 2000 5000 
Time (sec) 
BMI 24 25 25 25 
BMI 27 25 25 25 
BMI 32 35 35 35 
BMI 37 37 36 36 
BMI 42 45 44 44 
BMI 47 47 46 46 
BMI 52 49 48 48 
BMI 57 51 50 49 
BMI, body mass index 
7.6 Discussion 
We have performed a comprehensive modelling investigation 
into apnoea tolerance and rescue strategies in subjects with different 
degrees of obesity. We observed that de-oxygenation during 
obstructed-airway apnoea was significantly accelerated in subjects 
with greater BMI, and for each tidal ventilation pattern used, a degree 
of re-oxygenation was achieved. 
We observed that re-oxygenation was slightly slower with 
increasing obesity, with a maximum delay of 26 sec to reach 8 kPa 
between the subjects with the highest and the lowest BMI. These 
findings are consistent with clinical experience, where it is often noted 
that rapid de-oxygenation may occur during apnoea in the obese 
patient, and that re-oxygenation may be slowed. [225, 238] 
After simulated airway rescue, subjects did not re-oxygenate 
faster when receiving ventilation with larger tidal volumes compared 
to smaller ones. This has clear implications for clinical practice, in that 
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attempts to achieve substantial tidal volumes during airway rescues 
are probably not worthwhile and may be counter-productive. The 
extra effort required to deliver large tidal volumes may result in gastric 
distension, with consequent diaphragmatic splinting and 
regurgitation; rather, it is the assurance of a high-inspired oxygen 
fraction that will prevent critical hypoxaemia. 
We chose to consider tidal ventilation with only one inspired 
oxygen fraction (i.e. 100%). The reason not to consider other inspired 
oxygen fractions was that, during airway rescue, if one can ventilate, 
then it will always be with 100% oxygen. However, in an airway crisis, 
most instances of airway opening are achieved with a local oxygen 
fraction of 21% (i.e. there is no provision of a high concentration of 
oxygen at the airway while it is manipulated). Thus, this study could 
inform clinical consideration for safe airway management in obese 
subjects undergoing anaesthesia. 
Despite extensive validation and very good reproduction of 
normal physiology and pathology [217, 230, 231, 233], the modelled 
scenario must be viewed with a degree of caution since robust model 
validation is difficult due to the sparsity of clinical data describing 
scenarios of extreme physiological derangement. Prior validation of 
the model in less severe environments has been very encouraging, 
however, and given the lack of alternative methodologies to explore 
such crises, we believe that these results provide valuable insights 
into the management of apnoeic de-oxygenation and can usefully 
inform clinical practice and future research in such scenarios. 
The next step will be that to investigate which combinations of 
tidal ventilation modalities assured safe intra-pulmonary pressures for 




Chapter 8: The role of hyperbaric oxygen in rescuing 
severe acute respiratory distress syndrome with 
refractory hypoxaemia: a computational modelling 
investigation 
8.1 Abstract 
Introduction: The occurrence of refractory hypoxaemia in the 
context of acute respiratory distress syndrome (ARDS) is not 
uncommon and is associated with a substantial in-hospital mortality 
rate. Some mechanically-ventilated ARDS patients remain 
hypoxaemic despite the implementation of evidence-based 
techniques that significantly increase survival. Hyperbaric oxygen 
therapy (HBOT) is a powerful tool that increases systemic O2 delivery 
to the tissues. However, the HBOT efficacy to reverse refractory 
hypoxaemia in severe ARDS patients has not been evaluated so far. 
This study aims to determine whether HBOT can achieve acceptable 
O2 availability to the tissues in this population, using robust computer 
simulation. 
Methods: A bank of 12 severe ARDS virtual patients with 
refractory hypoxaemia was configured using a high-fidelity, integrated 
computational simulator. The subjects received lung-protective 
mechanical ventilation at (i) atmospheric pressure, PEEP 18 cm H2O 
and FiO2 of 1.0 (high-PEEP intervention), and (ii) hyperbaric pressure 
(280 kPa), PEEP 5 cm H2O and FiO2, 0.40, 0.70, and 1.0 (HBOT 
intervention). Each simulation lasted for 30 minutes. The primary 
outcome is oxygen delivery (DO2). The secondary outcomes are the 
arterial partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2), 
the arterial haemoglobin oxygen saturation (SaO2), the arterial pH, 
and the Oxygenation Index (OI). 
Results: The baseline characteristics of the 12 severe ARDS 
virtual patients are consistent with the Berlin definition severe 
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classification criteria, with a mean (standard deviation) PaO2/FiO2 ratio 
39 (4) mmHg, SaO2 72 (4) % and shunt fraction 55 (3) %. The DO2 
was 1071 (253), 1090 (255), 1196 (242) and 1221 (234) ml min-1 in 
the high-PEEP intervention and the HBOT intervention with FiO2 of 
0.40, 0.70 and 1.0, respectively. The HBOT significantly improved the 
other oxygenation indexes (i.e. PaO2, SaO2 and OI), while the PaCO2 
and pH values were similar in both interventions. 
Conclusions: Our results suggest that hyperbaric oxygen 
significantly increases the oxygen delivery to tissues, even with a low 
FiO2 in severe ARDS patients. HBOT could be sufficient to rescue 
severely hypoxaemic respiratory failure patients who failed maximal 
lung-protective mechanical ventilation. However, the effectiveness of 
the HBOT needs to be confirmed by an RCT. 
8.2 Introduction 
Acute respiratory distress syndrome (ARDS) is prevalent, 
affecting 10% of all patients admitted to intensive care units (ICU) [57].  
ARDS causes profound hypoxaemia that is usually responsive to 
moderate-to-high levels of positive end-expiratory pressure (PEEP) 
[239]. However, a minority of ARDS patients remain hypoxaemic 
despite the implementation of adequate levels of PEEP, high fractions 
of inspired oxygen (FiO2), restricted tidal-volume and plateau-
pressure, i.e. lung-protective ventilation, and prone-position 
ventilation, as recommended by ARDS management guidelines [240, 
241]. Refractory hypoxaemia causes up to 15% of the ARDS total 
deaths [242]. A multicentre observational study found a 21% 
incidence rate of refractory hypoxaemia (i.e. PaO2/FiO2 < 60 mmHg 
on FiO2 of 1.0) in a moderate-to-severe ARDS cohort and was 
associated with a substantial in-hospital mortality rate of 64% [243]. 
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Although many of the ventilatory and non-ventilatory rescue 
therapies (e.g. recruitment manoeuvres [244], high-frequency 
oscillatory ventilation [245],  inhaled nitric oxide [246], and 
neuromuscular blockade [247]) improve the oxygenation via various 
mechanisms, none of the therapies demonstrated favourable patient-
important outcomes (e.g. mortality), which may contribute to the 
inconsistent frequency to offer these adjunctive therapies [243, 248]. 
Nevertheless, a recent network meta-analysis [249] showed that the 
use of venovenous extracorporeal membrane oxygenation is likely to 
offer a survival benefit for severely hypoxaemic ARDS patients. 
Hyperbaric oxygen therapy (HBOT) has been recommended for 
conditions that cause hypoxia, e.g. carbon monoxide poisoning and 
severe anaemia [250, 251]. 
HBOT is referred to as the breathing of a high concentration of 
oxygen (O2) at an increased ambient pressure environment. HBOT 
substantially increases the amount of O2 diffused into plasma as well 
as fully saturating the haemoglobin, leading to increased systemic O2 
delivery to the tissues. The amount of the O2 dissolved in the plasma 
at 3 atmospheres absolute (ATA) with 100% O2 can theoretically 
exceed the total O2 consumption of a healthy subject at rest, as 
supported by an animal model experiment [67]. 
Despite the powerful capability of the HBOT to increase 
oxygenation, it has not been assessed to reverse the life-threatening 
refractory hypoxaemia in ARDS patients. Conflicting anecdotal views 
exist on the potential benefit of HBOT in patients with significant shunt 
fraction [252, 253]. 
The aim of this study was to determine the efficacy of HBOT, 
with respect to maximal lung-protective mechanical ventilation, to 
achieve and maintain acceptable O2 availability to the tissues in severe 
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ARDS virtual patients with refractory hypoxaemia, using robust 
computer simulation. 
8.3 Research question 
Can hyperbaric oxygen therapy (HBOT) (i.e. increased ambient 
pressure in combination with mechanical ventilation) achieve and 
maintain acceptable O2 availability to tissues in severe ARDS virtual 
patients who remain hypoxaemic despite maximum lung-protective 
mechanical ventilation? 
8.4 Hypothesis 
Hyperbaric oxygen therapy may provide acceptable tissue 
oxygenation hence may serve as an appropriate alternative to ECMO 
in severe ARDS patients that failed mechanical ventilation. 
8.5 Methods 
The Interdisciplinary Collaboration in Systems Medicine (ICSM) 
simulation suite, used in this study, is a rapidly deployed, agile and 
robust computational model of several organ systems, including the 
respiratory and the cardiovascular, originally developed in 1998 [217]. 
The simulator has been validated in numerous pathologies, including 
ARDS [182, 185, 254, 255]. Recently, it has been utilised to investigate 
the Coronavirus disease 2019 (COVID-19) [256] responsible for the 
current pandemic. ICSM simulation suite was used in all my previous 
studies. The ICSM is described in detail in Chapter 4. I chose this 
methodology (computational modelling) because the nature of this 
investigation may be considered as high risk and is likely to be 
challenging to perform clinically. Our high-fidelity model offers a 
suitable, efficient, and ethical-free platform to conduct this study. 
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8.5.1 Virtual subjects and protocol 
A bank of severe ARDS virtual patients with refractory 
hypoxaemia was configured based on values partially extracted from 
Nirmalan and co-workers [257]. The other pulmonary and 
cardiovascular values were obtained from Chikhani and co-workers 
[187]. Table 8.1 shows the ranges of values used to configure the 
ARDS bank. 
 The severe ARDS virtual patients (n=12) received a time-cycled 
pressure-limited controlled mechanical ventilation at: 
1) high-PEEP intervention:  atmospheric pressure (101.3 kPa) 
with PEEP of 18 cm H2O and FiO2 of 1.0; 
2) HBOT intervention: hyperbaric pressure of 280 kPa with 
PEEP of 5 cm H2O and three FiO2, 0.40, 0.70, and 1.0. 
Table 8.1. Parameters’ ranges used to configure the severe 
ARDS bank 
Parameter (unit) Minimum Maximum 
Weight (kg) 60 80 
RR (breath·min-1) 24 30 
VT (ml) 320 560 





 (%) 50 60 
VDphys (ml) 195 235 
VO
2
 (ml·min-1) 200 260 
CO (L·min-1) 6.5 9.4 
Hb (g·L-1) 99 123 
RR, respiratory rate; VT, tidal volume; QS/QT, shunt fraction; CO, cardiac output; Vdphys, 
physiological deadspace; CO, cardiac output, Hb, haemoglobin concentration. 
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The duration of each simulated intervention was 30 minutes. The 
inspiratory pressure (Pinsp) level was initially adjusted to achieve lung-
protective ventilation strategy defined in this study as (i) tidal volume 
≤ 8 ml kg-1 of predicted body weight [155], (ii) inspiratory plateau 
pressure (Pplat) ≤ 30 cm H2O [155], and (iii) driving pressure (∆P) ≤ 15 
cm H2O - i.e. calculated as Pplat minus total PEEP [156]. The virtual 
subjects had variable baseline cardiac output (CO) and shunt fraction, 
but they remained unchanged while undergoing the simulated 
interventions to assess the sole effect of the HBOT. 
8.5.2 Outcome measures 
The primary outcome measure is the oxygen delivery (DO2), 
which was calculated using this formula: DO2 (ml min-1) = CO (L min-
1) * [1.39 * Hb (g L-1) * SaO2] + [PaO2 (kPa) * 0.02]. The secondary 
outcome measures are the arterial partial pressure of oxygen (PaO2) 
and carbon dioxide (PaCO2), the arterial haemoglobin oxygen 
saturation (SaO2), the arterial pH, and the Oxygenation Index (OI) 
corrected for ambient pressure. OI reflects the severity of the 
oxygenation impairment (i.e. PaO2) while considering the intensity of 
the ventilatory support (i.e. FiO2 and mean airway pressure). 
Refractory hypoxaemia was defined as OI > 30 [258]. OI was 
calculated as [ambient pressure (ATA) * FiO2 * mean airway pressure 
(cmH2O) * 100] / PaO2 (mmHg).  
All parameters were recorded at 5 milliseconds interval. Model 
simulations were run using a 64-bit Intel Core i5 3.20 GHz Windows 
10 personal computer, running Matlab version R2018a.v9 
(MathWorks Inc. MA, USA). 
8.6 Results 
Table 8.2 summarises the characteristics of the ARDS virtual 
patients randomly configured by the computer simulator. Their 
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baseline values are consistent with the Berlin definition severe 
classification criteria [55].  
Table 8.3. The baseline characteristics of the ARDS virtual 
patients (n=12) generated randomly by the computer simulator. 
Parameter (unit) Mean (SD) 
Weight (kg) 69 (6) 
HR (beat min-1) 98 (11) 
VF (breath min-1) 28 (1) 
VT (ml) 450 (81) 
VE (L min-1) 12.8 (2.3) 
PaO2 (kPa) 4.6 (0.3) 
FiO2 0.89 (0.07) 
PF ratio (mmHg) 39 (4) 
SaO2 (%) 72 (4) 
PEEP (cm H2O) 6.7 (1.1) 
CO (L min-1) 7.9 (1.1) 
QS/QT (%) 55 (3) 
VO2 (ml) 228 (15) 
VDphys (ml) 215 (9) 
Hb (g L-1) 109 (8) 
HR, heart rate; VF, ventilatory frequency; VT, tidal volume; VE, minute ventilation; PaO2, 
the arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; PF ratio, PaO2 
to FiO2 ratio; SaO2, the arterial oxygen saturation; PEEP, positive end-expiratory 
pressure; CO, cardiac output; QS/QT, shunt fraction, VO2, oxygen consumption; VDphys, 
physiological deadspace; Hb, haemoglobin concentration. 
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Table 8.4 presents the mechanical ventilator settings that 
achieved a lung-protective ventilation strategy and, consequently, 
used in the present investigation. Compared to the HBOT 
intervention, the increased PEEP level used in the high-PEEP 
intervention resulted in a higher functional residual capacity, a lower 
∆P, and, therefore, generated a lower VT and minute ventilation. 
Table 8.4. Settings and parameters of the mechanical ventilator in 






Pinsp (above PEEP) 
(cm H2O) 
13 (0) 18 (0) 
PIP (cm H2O) 31 (0.2) 23 (0.3) 
Pplat (cm H2O) 29 (0.2) 18 (0.3) 
∆P (cm H2O) 9 (0.2) 11 (0.3) 
VT (ml) [ml kg-1 
PBW] 
311 (7) [4.4 (0.1)] 480 (15) [6.9 (0.2)] 
VF (breath min-1) 28 (1) 28 (1) 
VE (L min-1) 8.8 (0.2) 13.6 (0.2) 
FRC (L) 0.85 (0.07) 0.33 (0.06) 
Reported data is mean (SD). Pinsp, inspiratory pressure; PEEP, positive end-expiratory 
pressure; HBOT, hyperbaric oxygen therapy; PIP, peak inspiratory pressure; VT, tidal 
volume; Pplat, inspiratory plateau pressure; ∆P, driving pressure calculated as Pplat minus 
total PEEP; PBW, predicted body weight; VF, ventilatory frequency; VE, minute 
ventilation; FRC, functional residual capacity.  
Table 8.5 shows the primary and secondary outcome measures. 
Compared to the high-PEEP intervention, the HBOT intervention 
provided higher O2 delivery even when using a FiO2 of 0.40. The 
HBOT intervention significantly improved the other oxygenation 
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indexes (i.e. PaO2, SaO2 and OI), while the PaCO2 and pH were similar 
in both interventions. 
Table 8.5. The primary and secondary outcome measures at the end of the 
simulated interventions. 
 High-PEEP  HBOT  
 FiO2 1.0 FiO2 0.40 FiO2 0.70 FiO2 1.0 
DO2 (ml min-1) 1071 (253) 1090 (255) 1196 (242) 1221 (234) 
PaO2 (kPa) 8.4 (1.4) 9.0 (1.6) 35.9 (21.0) 111.0 (30.3) 
SaO2 (%) 88 (5) 90 (5) 99 (2) 100 (0) 
PaCO2 (kPa) 7.1 (0.2) 7.2 (0.2) 7.3 (0.2) 7.3 (0.2) 
pH 7.33 (0.01) 7.32 (0.01) 7.32 (0.01) 7.32 (0.01) 
OI 35.6 18.0 7.9 3.6 
Data is presented as mean (standard deviation). PEEP, positive end-expiratory pressure; HBOT, 
hyperbaric oxygen therapy; DO2, oxygen delivery; PaO2, the arterial partial pressure of oxygen; PF, 
PaO2 to FiO2; SaO2, the arterial oxygen saturation; PaCO2, the arterial partial pressure of CO2, pH, the 
arterial pH; OI, oxygenation index corrected for ambient pressure. 
8.7 Discussion 
8.7.1 Main findings 
In severe ARDS virtual patients, the hyperbaric oxygen 
increased the tissue and arterial oxygenation remarkably with respect 
to the high-PEEP conventional ventilation. The OI was significantly 
lower in the HBOT intervention even after the correction for the 
ambient pressure. OI has been found as an accurate prognostic 
indicator for mortality [259]. No difference was detected in 
hypercapnia and acid-base balance. However, the HBOT had higher 
minute ventilation than the high-PEEP intervention. 
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8.7.2 Relation to previous studies 
Studies that explored the use of HBOT to treat severe ARDS are 
sparse. However, the present study's finding is in agreement with a 
recent unpublished case series [260], which demonstrated that HBOT 
was effective in improving the hypoxaemia of five (two critically ill and 
three severe) patients suffering from COVID-19. The authors showed 
that the oxygenation of all the patients had consistently improved after 
each HBOT session. A six-year prospective observational study [75] 
reported data of 150 mechanically-ventilated (MV) patients, which 
included 35 ARDS patients that underwent a single session of HBOT. 
The most common indication that led these patients to receive MV 
and HBOT was severe carbon monoxide poisoning. The reported 
mortality rate in these moderate-to-severe ARDS cohort was 23%, 
which is substantially lower than the reported 32% and 45% for the 
moderate and severe ARDS, respectively [55]. 
The use of HBOT in critical illness is supported by an animal 
model experiment [261]. The authors showed that, in severe sepsis, 
the early administration of a single HBOT session (98% O2 at 2.4 ATA 
for 60 minutes) significantly increased survival from 13% to 52% (in 
the group that received HBOT after 1 hour from the sepsis induction). 
Additional repeated sessions of HBOT at (1 and 6 hours) and (1, 6, 
and 21 hours) further increased survival to 58% and 60%, 
respectively. The authors suggested that survival benefit is attributed 
to the reduction of the host systemic inflammatory response induced 
by the HBOT. 
8.7.2.1 What are the benefits, risks and challenges of HBOT? 
HBOT presents several benefits, risks and challenges. Firstly, 
HBOT is an effective non-invasive procedure to increase tissue 
oxygenation, even during severe anaemia [67]. This benefit would 
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allow the FiO2 and PEEP to be tapered off. Decreasing the FiO2 
minimises the absorption atelectasis [23], thus gaining more alveolar 
surface area for gas exchange. Decreasing the PEEP level may 
potentially (i) enhance the cardiac output hence tissue oxygenation 
[187], (ii) improve the pulmonary lymphatic circulation, therefore, 
increase the rate of pulmonary oedema elimination, and (iii) minimise 
the risk for the static strain lung injury [262]. Additionally, HBOT offers 
anti-inflammatory [261] and antimicrobial [263] effects. In the context 
of ARDS, both defensive mechanisms would be theoretically helpful 
since ARDS results in an intense inflammatory response, and is most 
commonly caused by infection, e.g. pneumonia and sepsis [264]. 
As discussed earlier, O2 toxicity is a well-recognised risk of 
HBOT. Unit Pulmonary Toxic Dose (UPTD) was established [83] to 
quantify the pulmonary O2 toxicity. One UPTD is equal to breathing 
100% O2 at 1 ATA for 1 minute. The upper cut-off is 1440 UPTD 
(equivalent to breathing pure O2 for 24 hours at sea level). The O2 
toxicity of the central nervous system requires higher PiO2 than the 
pulmonary system. The threshold, however, could not be precisely 
defined due to the wide variation of O2 tolerance even within the same 
subject at different times [76]. Therefore, it is recommended that the 
PiO2 does not exceed 2.8 bar absolute to minimise the occurrence of 
the CNS O2 toxicity, which our methods considered. 
Appropriate oxygenation level should be targeted to avoid 
hypoxaemia and hyperoxia, potential lung injury and O2 toxicity (i.e. 
high PiO2). High-quality evidence indicated that liberal use of O2 
increases mortality in critically ill patients [165]. Girardis and co-
workers [168] found approximately 50% mortality reduction in patients 
who had a lower PaO2 (11.6 vs 13.6 kPa). In our study, the HBOT using 
FiO2 of 0.40 nearly achieved the oxygenation goal, where the other 
interventions resulted in either hyperoxia or hypoxaemia. 
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Interestingly, the incidence rate of seizures was less in ARDS patients 
than non-ARDS patients that underwent HBOT [75]. This may be 
explained by the decreased PaO2, eventually delivered to the brain, 
caused by the ARDS-induced intrapulmonary shunt. 
The use of mechanical ventilation per se has been deemed safe 
in hyperbaric chambers [75]. Critically ill patients should only be 
admitted into a Class 1 chamber, defined as a hyperbaric facility 
capable of supporting ICU patients. However, in the event of an 
emergency, it is likely that rapid decompression will be needed, 
risking decompression sickness, which would be dangerous in this 
vulnerable population.  
If HBOT were to be implemented at a large scale, substantial 
financial expenses are expected for purchasing and installing ICU 
hyperbaric rooms and hyperbaric-compatible devices (e.g. cardiac 
monitors, ventilators, infusion pumps and defibrillators). Additionally, 
medical practitioners involved in this procedure must be well-trained 
in both disciplines (critical care and hyperbaric medicine) [265]. This 
procedure is semi labour-intensive, especially on multi-place 
chambers [265], where close monitoring from various professionals 
(e.g. chamber operator, ICU nurse and doctor) is required. Therefore, 
an adequate number of qualified staff should be available. Depending 
on the duration of the prescribed HBOT session and the available 
staff, the ongoing ICU care (e.g. nursing) is a challenging task. 
However, it may be feasible with sound planning and appropriate 
resources. 
Preparation of environment, equipment, patient and staff are 
paramount. Intensive care monitoring and support can be safely 
provided via mono- and multi-place hyperbaric chambers [266, 267]. 
Each chamber type has its advantages and disadvantages [268]. The 
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decision to prescribe HBO should be based on a deliberate 
risk/benefit evaluation. As fire is considered one of the most significant 
hazards of hyperbaric oxygen, particularly during the mono-place 
chamber [268], the clinicians must be aware of and adhere to the 
safety guidelines meticulously. An additional issue to consider is that 
if the national medical device regulatory system requires that all 
devices be CE-marked, that will impose a limitation for the devices’ 
usage [266]. 
Traditionally, hyperbaric chambers are small, circular and 
located far-away from ICU, which increases transportation risks [265]. 
However, advancements in industry and technology have facilitated 
the utilisation of this modality to critically ill patients. For instance, it 
led to the production of purpose-built large, rectangular, hyperbaric 
rooms located within ICU or in its immediate vicinity. Moreover, the 
availability of a modern closed-loop ventilator (Servo-i HBO, Maquet, 
Bridgewater, NJ), a CE-marked ventilator for hyperbaric use, enabled 
automatic ventilatory adjustments necessary to maintain consistent 
tidal volume delivery irrespective of ambient pressure, which can be 
a challenge when using a ventilator that does not have this feature 
where clinicians rely on manual measurements and adjustments 
[269]. 
Nevertheless, I would claim that HBOT presents a number of 
benefits that may counterbalance the benefits offered by ECMO and 
trades of the known risks. Firstly, unlike ECMO, (i) HBOT is a non-
invasive procedure that does not jeopardises patients to bleeding or 
hematologic disorders. Secondly, (ii) HBOT possesses a higher 
capability than ECMO to increase O2 tissue and does not require an 
adequate amount of haemoglobin to provide sufficient tissue 
oxygenation. Thirdly, (iii) HBOT offers anti-inflammatory [261] and 
anti-microbial [263] effects. 
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8.7.3 Additions to the knowledge of the subject 
This study has added to the body of knowledge that a 30-minute 
session of HBOT at 280 kPa is capable of providing adequate tissue 
oxygenation in severe ARDS (with a mean shunt fraction of 55%) 
virtual patients, which has been previously challenged by Haddon 
[253]. Additionally, it offered a quantitative insight into the impact of 
the FiO2 at hyperbaric pressure on the oxygenation indexes. 
8.7.4 Strengths and weakness of the study 
This is the first study that investigated and quantified the effects 
of HBOT in severe ARDS virtual patients. Our high-fidelity 
computational model allowed the investigation of HBOT in this 
extremely sick population, which is very challenging to conduct 
clinically for ethical, logistical, and medical reasons. 
This study, however, had a number of limitations. Firstly, it is true 
that our model has been validated in ARDS [182] but was not validated 
under increased ambient pressure with a high concentration of O2. 
This environment may cause variations in systemic vascular 
resistance and hemodynamic. Secondly, although the influence of the 
positive end-expiratory pressure (PEEP) on the FRC is integrated into 
our model, the PEEP impact on the degree of the intra-pulmonary 
shunt is not yet incorporated, which may affect the research output 
accuracy. Thirdly, it would have been interesting to study the role of 
the HBOT-induced anti-inflammatory when treating ARDS, especially 
in the hyperinflammatory phenotype. This effect has not been 
integrated into our model, which in reality may expand the HBOT 
benefits beyond the oxygenation advantage to perhaps a survival 
benefit. 
Further, several assumptions were made. First, some 
physiological and anatomical parameters of the virtual subjects 
126 
 
remained constant despite being exposed to influential factors. For 
instance, the response of cardiovascular (e.g. cardiac output and 
systemic vascular resistance) to hypoxia and lung volume (i.e. FRC) 
alteration to FiO2 exposure due to absorption atelectasis. Secondly, 
the virtual subjects were assumed fully sedated and paralysed and 
received controlled ventilation entirely determined by the ventilator. 
Moreover, the physiological ramifications resulting from the ARDS-
induced increased cytokine in the systemic circulation are not 
incorporated in the model. 
8.7.5 Future studies 
It would be helpful to evaluate the HBOT in critical illness (e.g. 
COVID-19) that leads to hypoxia. In particular, sepsis with or without 
ARDS appears as a good choice. Sepsis and septic shock occur 
commonly affecting more than 50 million individuals worldwide, 
leading to more than 5 million deaths annually [270]. 
Considering the beneficial effects of HBOT, sepsis is ideally 
situated due to (i) caused by infection, (ii) produces an aggressive 
inflammatory cascade, and (iii) results in hypotension and 
hypoperfusion. It would be helpful to consider answering the following 
question: will HBOT be effective in terms of providing adequate tissue 
O2 delivery and restoring adequate blood pressure due to the HBOT-
induced systemic vasoconstriction in septic shock despite the 
presence of hypotension and hypoperfusion in virtual patients? 
The present study focussed on evaluating hyperbaric oxygen 
therapy's efficacy from a gas-exchange perspective, mainly on its 
ability to reverse refractory hypoxaemia. However, future research 
should assess other endpoints, such as alveolar stability, especially in 
ARDS, whereas alveolar micromechanics and their response to 
positive-pressure ventilatory strategies (e.g., mode, PEEP level) can 
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be quite variable, at the global and regional level, due to the syndrome 
heterogeneity [271, 272].  
Since the ICSM simulation suite is computational in nature, it 
does not provide any imaging (e.g. microscopy) of alveolar perimeters 
while being under a certain dynamic condition, which is how relevant 
research assess alveolar stability [272]. However, our model can 
record static and dynamic alveolar strains, which dynamic strain has 
been reported as a reliable surrogate for lung injury [273]. Finally, it 
must be recognised that the level of PEEP contributes to the 
prevention or minimisation of lung injury [273, 274], particularly 
atelectrauma, if it is set optimally. Therefore, caution is warranted 
when interpreting this study’s findings. 
8.7.6 Conclusions 
The findings of this study suggest that HBOT can achieve and 
maintain acceptable O2 availability to the tissues in refractory 
hypoxaemic ARDS virtual patients and may be considered as an 
appropriate rescue option. Despite the significant shunt fraction, low 
levels of FiO2 and PEEP at hyperbaric pressure improved oxygenation 
status more than high FiO2 and PEEP settings at atmospheric 
pressure. However, the HBOT effectiveness needs to be confirmed by 




Chapter 9: Thesis summary, contributions, and 
conclusion  
9.1 Summary of the thesis 
The thesis evaluated the efficacy of interventions applied during 
three dangerous situations, namely (i) extended duration of apnoea in 
obesity, (ii) emergency rescue of airway obstruction, and (iii) 
hyperbaric oxygen therapy in severe ARDS virtual patients using 
computer simulation. The thesis aimed to establish and quantify 
credible strategies that improve the oxygenation and ventilation of 
high-risk populations during anaesthesia and critical care settings 
using a series of computational modelling studies. These studies have 
fulfilled their aims and answered their research questions. 
The first modelling study (Chapter 5) aimed to compare the 
effects of airway obstruction and patency, O2 concentration, classical 
apnoeic oxygenation and high-flow nasal O2 on the pulmonary gas 
exchange during apnoea in eight virtual subjects with BMI between 
24 to 57 kg ·m-2. The results revealed that airway patency, high O2 
concentration and HFNO delayed the occurrence of hypoxaemia. 
However, HFNO achieved the longest safe apnoea time as well as the 
lowest PaCO2 rate of increase, though with reduced benefits as 
obesity severity increases. 
Based on the promising findings of the HFNO in obesity obtained 
from Chapter 5, the next study (Chapter 6) expanded the 
investigation on a bank (n=90) of virtual obese subjects. It aimed to 
assess the effects of three different interventions rendered during 
apnoea with an open airway: (i) no supplemental O2, (ii) low-flow nasal 
O2 (classical apnoeic oxygenation), and (iii) high-flow nasal oxygen 
(HFNO). The findings indicated that, in obesity, the use of HFNO 
during apnoea is more effective than classical apnoeic oxygenation in 
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delaying significant and life-threatening hypoxaemia but without 
significant delay to hypercapnia. 
The third modelling study (Chapter 7) explored the role of 
various patterns of tidal ventilation, following the opening of an 
obstructed airway, on the re-oxygenation period to a safe level in 
obese virtual subjects. This study aimed to examine the rate of 
progression of hypoxaemia and the re-oxygenation to a safe level in 
eight virtual subjects with BMI between 24 to 57 kg ·m-2. The results 
showed that during obstructed-airway apnoea, hypoxaemia 
progressed faster in subjects with higher BMI. Also, after the airway 
opening, their re-oxygenation rate was slower than subjects with lower 
BMIs. Moreover, larger tidal volumes compared to smaller ones did 
not produce faster re-oxygenation to a safe level. 
The fourth and final study (Chapter 8) evaluated the use of 
HBOT in virtual patients suffering from severe ARDS who remain 
hypoxaemic despite maximum lung-protective ventilation strategy. 
This study aimed to quantify the O2 delivery to tissues in a bank of 
virtual ARDS patients with refractory hypoxaemia. Subjects 
underwent two interventions: (i) high-PEEP protective lung strategy at 
atmospheric pressure, and (ii) low-PEEP protective lung strategy in a 
simulated hyperbaric environment with three levels of inspired O2 
concentration - FiO2 (i.e. 0.40, 0.70 and 1.0). The results demonstrated 
that hyperbaric oxygen was able to deliver higher O2 delivery to 
tissues even with lower FiO2 in 12 severe ARDS virtual patients. 
9.2 The thesis original contributions to the field  
The results obtained from Chapter 5 and 6 offered a valuable 
quantitative perspective that describes the course in which 
hypoxaemia and hypercapnia evolve during prolonged periods of 
apnoea in obesity. The presented data are unique and are not likely 
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to be obtained from human trials as the nature of these investigations 
is lethal, thus unethical to conduct. The findings of these studies 
featured the impact of the patency of the upper airway, high O2 
concentration and HFNO, during apnoea, on delaying the onset of 
significant and life-threatening hypoxaemia and hypercapnia in the 
obese population. 
The implications of the results attained by these studies highlight 
the effectiveness levels of various apnoeic oxygenation strategies. It 
recommends to healthcare practitioners, who are involved in airway 
management, the use of HFNO during apnoea as it showed to provide 
longer safe apnoea time in obesity, respect to classical apnoeic 
oxygenation. In case of the unavailability of HFNO, it is recommended 
to provide classical apnoeic oxygenation (e.g. via low-flow nasal 
oxygen) during the apnoeic period as it has shown to be significantly 
superior compared to not providing O2. 
The study reported in Chapter 7 contributes to the field by 
demonstrating the unnecessity of providing large tidal ventilation 
following the rescue attempt of airway obstruction, as it was not 
associated with a faster re-oxygenation rate. The implication of this 
research work could inform clinicians to prioritise the provision of a 
high concentration of O2 during this scenario. Additionally, in this 
context, massive tidal ventilation is not recommended as it has shown 
not to be beneficial in terms of oxygenation and might risk patients for 
untoward complications (e.g. pulmonary aspiration and lung injury). 
 Finally, the last study (Chapter 8) added to the body of 
knowledge that HBOT could be sufficient to rescue severely 
hypoxaemic respiratory failure patients who failed maximum lung-
protective mechanical ventilation. However, the effectiveness of the 
HBOT needs to be confirmed by an RCT. The implication of this 
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finding should encourage researchers to consider and utilise this 
powerful modality that we possess within our armamentarium for 
ARDS future trials. 
9.3 Limitations of this research 
There are a few limitations that are related to the methodology 
used, i.e. computational modelling. First, it is impossible to model the 
full aspects of the human organ system due to the incomplete 
knowledge of human physiology during extreme scenarios. Moreover, 
there are physiological compensatory mechanisms to maintain normal 
body homeostasis, and not all compensatory mechanisms are entirely 
understood and applicable, thus not incorporated in the 
computational model. Second, several assumptions were considered. 
For instance, it was assumed that the FRC and O2 consumption were 
constant during apnoea and at different levels of hypoxaemia, which 
may not represent the actual physiology. In the reported modelling 
studies, the autonomic reflex modules were not enabled to minimise 
the effects of confounding factors. 
Additionally, mathematical modelling requires numerical data 
input. So the sparsity of particular literature prevented the calibration 
of the model against human data in specific areas such as in obese 
subjects receiving HFNO during prolonged apnoea and in severe 
ARDS patients receiving mechanical ventilation in a hyperbaric 
environment. Finally, the ICSM model has not incorporated a few 
mechanisms that may play a role in the investigations, such as (i) the 
development of the ‘early’ intrapulmonary shunt occurring after the 
induction of general anaesthesia, (ii) the impact of PEEP on the 
intrapulmonary shunt, (iii) the anti-inflammatory effects and systemic 
vascular constriction induced by the HBOT and hyperoxia. 
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Nevertheless, the latter two mechanisms are not relevant to the 
investigations’ outcome measures. 
9.4 Recommendations for future studies 
It would be encouraging to see more engagement and 
collaborative research work between interdisciplinary professionals 
from the fields of medicine, engineering and computer science. The 
joint efforts would help advance the research by answering multi-
faceted questions in a quality and efficient manner. 
I recommend that future computational modelling studies 
consider examing the following areas: the impact of the early 
implementation of HBOT in COVID-19 patients to decrease the 
intensity of hypoxaemia, thus minimise the need for ICU admission 
and the role of HFNO during apnoea in obstetrics undergoing rapid 
sequence induction since they are considered a high-risk population 
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The appendix presents several tables that summarise the studies that 
investigated apnoeic oxygenation and ventilation while undergoing various 





Table 0.1. Summary of the studies that investigated apnoeic oxygenation during elective procedures. 
 
Author Year # Subjects Type Methods Results 
Frumin et al. 
[46] 
1959 8 Observational 
- Apn-oxy: 100%  O2 via endotracheal tube. 
- Subjects were pre-oxygenated with 100% O2 
for ≥ 30 min. 
- 7 patients had SaO2 ≥ 98% throughout 30-55 
min of apnoea. 
Lee [123] 1998 46 RCT 
- Apn-oxy: 5 L·min-1  O2 via nasal prongs. 
- Control: no Apn-oxy 
- The PaO2 dropped steeply in the control group, 
from 63.8 to 34.1 kPa, as compared to 65.1 to 
45.9 kPa, in the Apn-oxy group. 
Taha et al. 
[275] 
2006 30 RCT 
- Apn-oxy: 5 L·min-1 O2 via a nasal pharyngeal 
catheter. 
- The cut-off either: SpO2 fall to ≤ 95% or 6 
min of apnoea has occurred. 
- SpO2 was 100% throughout the full 6 min of 
apnoea in the Apn-oxy group, while the SAT 




2013 47 Retrospective 
- Apn-oxy: 0.5 L·min-1 O2 via an intratracheal 
catheter placed proximal to the carina. 
- SpO2 was maintained ≥ 93% up to 45 min of 
apnoea except in 3 patients due to O2 
desaturation, which was due to obesity, 
inadequate pre-oxygenation and spontaneous 
breathing. 
Christodoulou 
et al. [276] 
2013 41 RCT 
3 groups: (Apn-oxy via nasal prongs) 
- control no Apn-oxy 
- Apn-oxy 5 L·min-1 
- Apn-oxy 10 L·min-1 O2  
- Apn-oxy of 10 L·min-1 group sustained higher 
PaO2 compared to 5 L·min-1 group and the 
control group, 33.7, 22.3 and 17.8 kPa, 
respectively. 
Rajan et al. 
[124] 
2018 20 RCT 
- 1st group: CPAP of 20 cm H2O, 10 L·min-1 of 
O2. 
- 2ed group: 6 L·min-1 O2 via face mask. 
- The cut-off was either SpO2 ≤90% or 14 min 
of apnoea. 
- CPAP group had significantly longer SAT than 
non-CPAP group (13.6 vs 5.8 min) respectively. 




Table 0.2. Summary of the studies that investigated THRIVE during elective procedures in the adult population 






- Pre-oxy: 10 min, 70 L·min-1, FiO2 1.0 
- Apn-oxy: 70 L·min-1, FiO2 1.0. 
- All patients maintained SpO2 ≥90% throughout the 
apnoea period, ranged from 5-35 min, except 1 
patient had a 65 min of apnoea with O2 saturation of 
95% 
Gustafsson 




- Pre-oxy:  ≥3 min, 40 L·min-1, FiO2 1.0 
- Apn-oxy: 70 L·min-1, FiO2 1.0 
- All patients maintained SpO2 ≥91% throughout 
apnoea period, ranged from 11-30 min, mean 22.5 
min 






- Pre-oxy: 3 min, 80 L·min-1, FiO2 1.0 
- Apn-oxy: 80 L·min-1, FiO2 1.0 
- The median apnoea time was 19 ranged from 9–37 
min 
- All patients maintained SpO2 ≥92% except 4 patients 
who had hypoxaemia with lowest SpO2 of 85% 
Joseph et al. 
[126] 
2018 20 RCT 
HFNO group:   
- Pre-oxy: 3 min, 30 L·min-1, FiO2 1.0 
- Apn-oxy: 60 L·min-1, FiO2 1.0 
CPAP group: 
- Pre-oxy: 3 min, CPAP 15 cmH2O, 6 L·min-1, 
FiO2 1.0 
- Apn-oxy: CPAP 15 cmH2O, 10 L·min-1, FiO2 
1.0 
- Both groups completed the allocated 12 min of 
apnoea without hypoxaemia 
- CPAP group had significantly higher PaO2 (at the end 
of apnoea) 54.6 kPa as compared to 28.1 kPa in the 
HFNO group. 
RCT, randomized control trial; Pre-oxy, pre-oxygenation; Apn-oxy, apnoeic oxygenation; HFNO, high flow nasal oxygen; SpO2, oxygen saturation; CPAP, continuous 
positive airway pressure. 
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Table 0.3. Summary of apnoeic oxygenation studies during emergency intubation. 






RSI, majority trauma 
- Study group: Apn-oxy 
- 15 L·min-1 O2 via NC 
- Control group: no Apn-oxy 
- Hypoxaemia incidence (SpO2< 93%) was 
16.5% and 22.6% in the group that 
received Apn-oxy and not received Apn-
oxy, respectively. 
- Hypoxaemia duration was shorter in the 
Apn-oxy group 92.5 vs 169.8 sec. 






- Study group: Apn-oxy 
- NC 15 L·min-1 (31.7%*) 
- BVM (15.1%*) 
- BVM + NC 15 L·min-1 
(2.2%*) 
- NIV (5.8%*) 
- Control group: no Apn-oxy 
- Hypoxaemia incidence in the non-
respiratory failure patients who received 
Apn-oxy was 0.0% as compared to 16.7% 
who did not receive Apn-oxy. 
- Apn-oxy did not prevent hypoxaemia in 
the respiratory failure patients. 
- Hypoxaemia was the most common 
complication at 17.3%. 
Sakles et al. 
[128] 
2016 635 observational 
emergency intubation 
mainly for airway 
protection (54% 
obese*) 
- Study group: Apn-oxy via 
NC: 
- 5 L·min-1 
- 10 L·min-1 
- 15 L·min-1 
- >15 L·min-1 
- Control group: no Apn-oxy 
- Hypoxaemia incidence was 12.6% and 
20% in the Apn-oxy and no Apn-oxy 
respectively.  
- First-time intubation success without 
hypoxaemia was 82% in Apn-oxy cohort, 
compared to 69% in no Apn-oxy cohort.  
Sakles et al. 
[129] 
2016 127 observational 
intracranial 
hemorrhage mainly 
intubated for airway 
protection 
- Study group: Apn-oxy via 
NC: 
- 5 L·min-1 (14%*) 
- 10 L·min-1 (18%*) 
- 15 L·min-1 (35%*) 
- >15 L·min-1 (33%*) 
- Control group: no Apn-oxy 
- Mild, moderate and severe hypoxaemia 
incidence was significantly lower in the 
Apn-oxy group than the no Apn-oxy: 7% 
vs 29%, 4% vs 18% and 3% vs 9% 
respectively. 
Apn-oxy, apnoeic oxygenation; NC, nasal cannulae; BVM, bag valve mask; NIV, non-invasive ventilation; SpO2, oxygen saturation. *percentage of the group 
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Table 0.4.  Summary of the studies that investigated THRIVE during emergency procedures in the adult population. 









- HFNO group: Pre-oxy, 3 min, 60 L·min-1, 
FiO2 1.0 and remained during apnoea 
- Nasopharyngeal catheter group: Pre-oxy for 
≥3 min via 15 L·min-1 NRM then 6 L·min-1 via 
a nasopharyngeal catheter during apnoea 
- The median SpO2 was 100% in the HFNO group 
while 94% in the NRM group 
- Hypoxaemia incidence (SpO2 < 80%) was 2 % in the 




2015 118 RCT 
- HFNC group: Pre-oxy, 4 min, 60 L·min-1, 
FiO2 1.0 and remained during apnoea 
- Facemask group: Pre-oxy for 4 min with 15 
L·min-1 then no Apn-oxy 
- No difference in the median lowest SpO2 during 
intubation 91.5% in the HFNO group and 89.5% in 
the facemask group 
- Both groups had the same median apnoea duration 
of 1 minute 
Semler et 
al. [131] 
2016 150 RCT 
- HFNC group: 15 L·min-1, FiO2 1.0 during 
apnoea 
- Control group: no Apn-oxy 
- No statistical difference in the median lowest SpO2 
in between the Apn-oxy and the control group. 
Jaber et 
al. [133] 
2016 49 RCT 
- Study group: Pre-oxy, 4 min, HFNO (60 
L·min-1, FiO2 1.0) combined with NIV (PS 10, 
PEEP 5 cm H2O, FiO2 1.0), and HFNO 
remained during apnoea 
- Control group: NIV (same setting) during 4 
min of Pre-oxy, no Apn-oxy 
- The lowest SpO2 values were significantly higher in 
the intervention group than in the control group, 
100 % vs 96 % despite the double median apnoea 
time (120 vs 60 sec) 
- Zero % of patients in the study group and 21 % of 
patients in the control group had SpO2 below 80 % 
Simon et 
al. [203] 
2016 40 RCT 
- Study group: Pre-oxy, 4 min, HFNO 60 
L·min-1, FiO2 1.0 and remained during 
apnoea 
- Control group: Pre-oxy, 4 min, BVM 10 
L·min-1 then no Apn-oxy 
- No difference in the mean lowest SpO2 during 
intubation 89% in the HFNO group and 86% in the 
control group 
- Both groups had similar mean apnoea duration of 
about half a minute 
RCT, randomized control trial; Apn-oxy, apnoeic oxygenation; Pre-oxy, pre-oxygenation; HFNO, high flow nasal oxygen; NRM, non-rebreathing mask; NC, nasal cannulae; 
SpO2, oxygen saturation; NIV, non-invasive ventilation; PS, pressure support; PEEP, positive end-expiratory pressure; BVM, bag valve mask. 
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Table 0.5. Summary of apnoeic oxygenation studies during elective procedures on obese patients. 
Author Year # Subjects Type Population Method Cut-off Results 
Baraka et al. 
[137] 
2007 34 RCT Morbid obesity 
- Study group: 5 L·min-1 O2 
via pharyngeal catheter 
insufflation 
- Control group: no Apn-oxy 
- SpO2≤95 %, 
or 
- 4 min of 
apnoea. 
- All Apn-oxy group completed the 4 
min of apnoea with SpO2 of 100%, 
while the control group had a mean 
SAT of 2.4 min. 
- A significant negative linear 
correlation between SAT and BMI was 
observed. 
Ramachandran 
et al. [134] 
2009 30 RCT Mild obesity 
- Study group: 5 L·min-1 O2 
via NP 
- Control group: no Apn-oxy 
 
- SpO2≤95 %, 
or 
- 6 min of 
apnoea. 
- The Apn-oxy group had a significantly 
longer time to desaturate to 95% (5.29 
min vs 3.49 min). 
Heard et al. 
[135] 
2017 40 RCT 
Mild/moderate 
obesity 
- Study group: 10 L·min-1 O2 
via a 3.5 ETT in the buccal 
area 
- Control group: no Apn-oxy 
- SpO2≤95%, 
or 
- 12.5 min of 
apnoea. 
- The median SAT was 12.5 min in the 
Apn-oxy group compared to 4.9 min 
in the control group. 
Moon et al. 
[221] 
2019 135 RCT 
Moderate/morbid 
obesity 
- O2 group: 15 L·min-1 O2 via 
NP 
- Air group: 15 L·min-1 air via 
NP 
- Control group: no Apn-oxy 
- SpO2≤95%, 
or 
- 8 min of 
apnoea. 
- The median safe apnoea time was 4.4, 
2.5, and 2.7 min in the O2, air, and the 
control group, respectively.  
- 10 subjects in the O2 group completed 
the entire allocated apnoea time with 
SpO2 >95 %. 




Table 0.6. Summary of studies that investigated the CO2 rate of rise during apnoea. 
Author Year # Subjects Measurement Apnoea duration Methods CO2 rate of rise 
    (min) (L·min-1) (kPa·min-1) 
Holmdahl et al. [48] 1956 9 Arterial 6 (total) O2 via ETT 0.68 
Frumin et al. [46] 1959 8 Arterial 41 (mean) O2 via ETT 0.45 
Eger and Severinghaus 
[145] 
1961 5 Alveolar 
-  9.6 (mean) (normoventilation) 
-  16.4 (mean) (hyperventilation) 
O2 via ETT 
- 0.56 (normoventilation) 
- 0.40 (hyperventilation) 
- 0.3 (hypothermia) after 1st 
min of apnoea 
Lee [123] 1998 46 Arterial 3-4 (total) 5 via NP 0.5 
Rudlof and Hohenhorst [29] 2013 47 End-tidal 24.7 (mean) 0.5 via IC 0.24 
Patel and Nouraei [50] 2015 25 End-tidal 14±5 (median) 70 via HFNO  0.15 
Gustafsson et al. [51] 2017 31 
Arterial 
End-tidal 
22.5±4 (mean) 70 via HFNO 
0.24 
0.12 
Joseph et al. [126] 2018 20 Arterial 12 (total) 
15 cm H2O via 
CPAP 
0.3 
Babinski et al. [148] 1985 5 Arterial 30 (total) 24-28 via EI 0.08 
Watson et al. [146] 1992 11 Arterial ~22 (mean) 45 via EI 
- 0.32 (1st 5 min of apnoea) 
then remained relatively 
unchanged 
Stock et al. [150] 1989 14 Arterial ~3.5 (mean) Airway obstruction 
- 1.6 (1st min) 
- 0.45 (thereafter) 
Cheun and Choi [147] 1992 16 Arterial 
- 7.5 (mean) (non-pregnant) 
- 3.6 (mean) (pregnant) 
Airway obstruction 
- 0.37 (non-pregnant) 
- 0.90 (pregnant) 
ETT, endotracheal tube; NP, nasal prongs; IC, intratracheal catheter; EI, endobronchial insufflation. 
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